<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24838515</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1179-1896</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>4</Issue><PubDate><Year>2014</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Applied health economics and health policy</Title><ISOAbbreviation>Appl Health Econ Health Policy</ISOAbbreviation></Journal><ArticleTitle>A systematic and critical review of model-based economic evaluations of pharmacotherapeutics in patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>359-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40258-014-0098-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder (BD) is a chronic and relapsing mental illness with a considerable health-related and economic burden. The primary goal of pharmacotherapeutics for BD is to improve patients' well-being. The use of decision-analytic models is key in assessing the added value of the pharmacotherapeutics aimed at treating the illness, but concerns have been expressed about the appropriateness of different modelling techniques and about the transparency in the reporting of economic evaluations.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This paper aimed to identify and critically appraise published model-based economic evaluations of pharmacotherapeutics in BD patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A systematic review combining common terms for BD and economic evaluation was conducted in MEDLINE, EMBASE, PSYCINFO and ECONLIT. Studies identified were summarised and critically appraised in terms of the use of modelling technique, model structure and data sources. Considering the prognosis and management of BD, the possible benefits and limitations of each modelling technique are discussed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Fourteen studies were identified using model-based economic evaluations of pharmacotherapeutics in BD patients. Of these 14 studies, nine used Markov, three used discrete-event simulation (DES) and two used decision-tree models. Most of the studies (n = 11) did not include the rationale for the choice of modelling technique undertaken. Half of the studies did not include the risk of mortality. Surprisingly, no study considered the risk of having a mixed bipolar episode.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This review identified various modelling issues that could potentially reduce the comparability of one pharmacotherapeutic intervention with another. Better use and reporting of the modelling techniques in the future studies are essential. DES modelling appears to be a flexible and comprehensive technique for evaluating the comparability of BD treatment options because of its greater flexibility of depicting the disease progression over time. However, depending on the research question, modelling techniques other than DES might also be appropriate in some cases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohiuddin</LastName><ForeName>Syed</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Manchester Centre for Health Economics, Institute of Population Health, University of Manchester, Jean McFarlane Building, Oxford Road, Manchester, M13 9PL, UK, syed.mohiuddin@manchester.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Appl Health Econ Health Policy</MedlineTA><NlmUniqueID>101150314</NlmUniqueID><ISSNLinking>1175-5652</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004358" MajorTopicYN="N">Drug Therapy</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018803" MajorTopicYN="Y">Models, Economic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24838515</ArticleId><ArticleId IdType="doi">10.1007/s40258-014-0098-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19922550</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>8</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>The role of dopamine in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>787-806</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2009.00760.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Despite effective pharmacological treatments for bipolar disorder, we still lack a comprehensive pathophysiological model of the illness. Recent neurobiological research has implicated a number of key brain regions and neuronal components in the behavioural and cognitive manifestations of bipolar disorder. Dopamine has previously been investigated in some depth in bipolar disorder, but of late has not been a primary focus of attention. This article examines the role of dopamine in bipolar disorder, incorporating recent advances into established models where possible.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A critical evaluation of the literature was undertaken, including a review of behavioural, neurochemical, receptor, and imaging studies, as well as genetic studies focusing on dopamine receptors and related metabolic pathways. In addition, pharmacologic manipulation of the central dopaminergic pathways and comparisons with other disease states such as schizophrenia were considered, principally as a means of exploring the hypothesised models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Multiple lines of evidence, including data from pharmacological interventions and structural and functional magnetic resonance imaging studies, suggest that the dopaminergic system may play a central role in bipolar disorder.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Future research into the pathophysiological mechanisms of bipolar disorder and the development of new treatments for bipolar disorder should focus on the dopaminergic system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cousins</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Newcastle Magnetic Resonance Centre, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK. d.a.cousins@ncl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butts</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Allan H</ForeName><Initials>AH</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G0501779</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>258</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19922550</ArticleId><ArticleId IdType="pii">BDI760</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2009.00760.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20531126</PMID><DateCompleted><Year>2010</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-736X</ISSN><JournalIssue CitedMedium="Internet"><Volume>198</Volume><Issue>6</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Overdiagnosis of bipolar disorder and disability payments.</ArticleTitle><Pagination><MedlinePgn>452-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NMD.0b013e3181e084e1</ELocationID><Abstract><AbstractText>The diagnosis of bipolar disorder has received increasing attention during the past decade. Several research reports have suggested that bipolar disorder is under-recognized, and that many patients, particularly those with major depressive disorder, have, in fact, bipolar disorder. More recently, some reports have suggested that bipolar disorder is also overdiagnosed at times. There are several possible reasons for bipolar disorder overdiagnosis. In the present study, we examined whether secondary gain associated with receiving disability payments might be partially responsible for bipolar disorder overdiagnosis. A total of 82 psychiatric outpatients reported having been previously diagnosed with bipolar disorder, which was not confirmed when interviewed with the Structured Clinical Interview for DSM-IV. The percentage of patients receiving disability payments and the duration of disability payments were compared in these 82 patients and 528 patients who were not diagnosed with bipolar disorder. Compared with the patients who had never been diagnosed with bipolar disorder, the patients overdiagnosed with bipolar disorder were significantly more likely to have received disability payments at some point during the past 5 years, and were receiving disability payments for significantly more weeks. We conducted a regression analysis controlling for the number of lifetime diagnoses, and overdiagnosis of bipolar disorder was a significant predictor of disability status (OR = 3.8; 95% CI, 1.6-8.8). Thus, an unconfirmed diagnosis of bipolar disorder was significantly associated with receiving disability benefits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Human Behavior, Brown Medical School, Providence, RI 02905, USA. mzimmerman@lifespan.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Galione</LastName><ForeName>Janine N</ForeName><Initials>JN</Initials></Author><Author ValidYN="Y"><LastName>Ruggero</LastName><ForeName>Camilo J</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Chelminski</LastName><ForeName>Iwona</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Dalrymple</LastName><ForeName>Kristy</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Diane</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 MH085730</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="Y">Diagnostic Errors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004185" MajorTopicYN="N">Disability Evaluation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007342" MajorTopicYN="N">Insurance Benefits</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018868" MajorTopicYN="N">Insurance, Disability</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>6</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20531126</ArticleId><ArticleId IdType="doi">10.1097/NMD.0b013e3181e084e1</ArticleId><ArticleId IdType="pii">00005053-201006000-00012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8080501</PMID><DateCompleted><Year>1994</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>38</Volume><Issue>9</Issue><PubDate><Year>1993</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Misdiagnosis of bipolar affective disorder as personality disorder.</ArticleTitle><Pagination><MedlinePgn>587-9</MedlinePgn></Pagination><Abstract><AbstractText>Patients with longstanding recurrent behavioural disturbance, unstable interpersonal relationships and periodic affective symptoms are often diagnosed as having a cluster B personality disturbance using DSM-III-R criteria. Two women are described who were diagnosed as having a personality disorder on several admissions to hospital, but in whom closer inquiry revealed evidence of bipolar affective disorder. Since treatment with lithium and adjunctive mood-stabilizing drugs neither patient has required further admissions to hospital within the past five years.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tyrer</LastName><ForeName>S P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Queen's University, Kingston, Ontario.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brittlebank</LastName><ForeName>A D</ForeName><Initials>AD</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>1806D8D52K</RegistryNumber><NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Can J Psychiatry. 1994 Jun;39(5):315</RefSource><PMID Version="1">8044751</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000639" MajorTopicYN="N">Amitriptyline</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="N">Diagnostic Errors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>11</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8080501</ArticleId><ArticleId IdType="doi">10.1177/070674379303800903</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18977035</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>161</Volume><Issue>3</Issue><PubDate><Year>2008</Year><Month>Dec</Month><Day>15</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Executive and verbal working memory dysfunction in first-degree relatives of patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>318-24</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2007.09.002</ELocationID><Abstract><AbstractText>The authors aimed to investigate cognitive performance of first-degree relatives of probands with bipolar disorder (BD). They hypothesized that the relatives of BD patients would have impaired performance on cognitive tests of frontal-executive functions. A neuropsychological battery was administered to 34 first-degree relatives of BD probands and 25 control subjects. Relatives showed significant impairment in verbal working memory and executive function. Verbal memory and psychomotor performances of relatives were not different from control subjects. One particular component of executive function, cognitive flexibility, was associated with family history of mood episodes with psychotic features. Verbal working memory and executive function deficits may be useful endophenotypic markers of genetic vulnerability to BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bora</LastName><ForeName>Emre</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Affective Disorders Unit, Ege University School of Medicine, Izmir, Turkey. boremre@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahip</LastName><ForeName>Simavi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Akdeniz</LastName><ForeName>Fisun</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Ilerisoy</LastName><ForeName>Hatice</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Aldemir</LastName><ForeName>Ebru</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Alkan</LastName><ForeName>Müge</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004193" MajorTopicYN="Y">Discrimination Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008570" MajorTopicYN="Y">Memory, Short-Term</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011340" MajorTopicYN="Y">Problem Solving</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012718" MajorTopicYN="Y">Set, Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="Y">Verbal Learning</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>01</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2007</Year><Month>08</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>09</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18977035</ArticleId><ArticleId IdType="pii">S0165-1781(07)00327-7</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2007.09.002</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">32327632</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>18</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>18</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>04</Month><Day>23</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>On the diagnostic and neurobiological origins of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>118</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41398-020-0796-8</ELocationID><Abstract><AbstractText>Psychiatry is constructed around a taxonomy of several hundred diagnoses differentiated by nuances in the timing, co-occurrence, and severity of symptoms. Bipolar disorder (BD) is notable among these diagnoses for manic, depressive, and psychotic symptoms all being core features. Here, we trace current understanding of the neurobiological origins of BD and related diagnoses. To provide context, we begin by exploring the historical origins of psychiatric taxonomy. We then illustrate how key discoveries in pharmacology and neuroscience gave rise to a generation of neurobiological hypotheses about the origins of these disorders that facilitated therapeutic innovation but failed to explain disease pathogenesis. Lastly, we examine the extent to which genetics has succeeded in filling this void and contributing to the construction of an objective classification of psychiatric disturbance.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Charney</LastName><ForeName>Alexander W</ForeName><Initials>AW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. alexander.charney@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. alexander.charney@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. alexander.charney@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA. alexander.charney@mssm.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Illness Research, Education, and Clinical Center (VISN 2 South), James J. Peters Veterans Affairs Medical Center, Bronx, NY, 10468, USA. alexander.charney@mssm.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mullins</LastName><ForeName>Niamh</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>You Jeong</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, New York, NY, 10029, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009446" MajorTopicYN="N">Neurobiology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>04</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>03</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32327632</ArticleId><ArticleId IdType="doi">10.1038/s41398-020-0796-8</ArticleId><ArticleId IdType="pii">10.1038/s41398-020-0796-8</ArticleId><ArticleId IdType="pmc">PMC7181677</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fifth edition (American Psychiatric Pub., 2013) https://doi.org/10.1176/appi.books.9780890425596.744053 .</Citation></Reference><Reference><Citation>World Health Organization. The ICD-10 classification of mental and behavioural disorders. Int. Classif. 10, 1–267 (1992).</Citation></Reference><Reference><Citation>Baca-Garcia, E. et al. Diagnostic stability of psychiatric disorders in clinical practice. Br. J. Psychiatry 190, 210–216 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17329740</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, third edition (American Psychiatric Association, 1980).</Citation></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, fourth edition, Text Revision (American Psychiatric Association, Washington, DC, 1994/2000) https://search.library.wisc.edu/catalog/999733358502121 .</Citation></Reference><Reference><Citation>Kendler, K. S. The nature of psychiatric disorders. World Psychiatry 15, 5–12 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26833596</ArticleId><ArticleId IdType="pmcid">4780286</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunayevich, E. &amp; Keck, P. E. Prevalence and description of psychotic features in bipolar mania. Curr. Psychiatry Rep. 2, 286–290 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">11122970</ArticleId></ArticleIdList></Reference><Reference><Citation>Burdick, K. E., Ketter, T. A., Goldberg, J. F. &amp; Calabrese, J. R. Assessing cognitive function in bipolar disorder: challenges and recommendations for clinical trial design. J. Clin. Psychiatry 76, e342–e350 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25830456</ArticleId><ArticleId IdType="pmcid">4472380</ArticleId></ArticleIdList></Reference><Reference><Citation>Merikangas, K. R. et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry 64, 543–552 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId><ArticleId IdType="pmcid">1931566</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis, R. H. et al. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder (STEP-BD). Am. J. Psychiatry 163, 217–224 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>Østergaard, S. D., Jensen, S. O. W. &amp; Bech, P. The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatr. Scand. 124, 495–496 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21838736</ArticleId></ArticleIdList></Reference><Reference><Citation>Galatzer-Levy, I. R. &amp; Bryant, R. A. 636,120 ways to have posttraumatic stress disorder. Perspect. Psychol. Sci. 8, 651–662 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">26173229</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds, E. H. &amp; Kinnier Wilson, J. V. Neurology and psychiatry in Babylon. Brain 137, 2611–2619 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">25037816</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasser, M. Psychiatry in Ancient Egypt. Psychiatr. Bull. 11, 420–422 (1987).</Citation></Reference><Reference><Citation>Bou Khalil, R. &amp; Richa, S. When affective disorders were considered to emanate from the heart: the ebers papyrus. Am. J. Psychiatry 171, 275–275 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24585330</ArticleId></ArticleIdList></Reference><Reference><Citation>Veith, I. Psychiatric thought in Chinese medicine. J. Hist. Med Allied Sci. X, 261–268 (1955).</Citation></Reference><Reference><Citation>Haldipur, C. V. Psychiatric nosology and taxonomy in ancient India. Acta Psychiatr. Scand. 80, 148–150 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2678900</ArticleId></ArticleIdList></Reference><Reference><Citation>Dube, K. C. Nosology and therapy of mental illness in Ayurveda. Comp. Med. East West 6, 209–228 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">383394</ArticleId></ArticleIdList></Reference><Reference><Citation>Eghigian G. The Routledge History of Madness and Mental Health. https://books.google.com/books/about/The_Routledge_History_of_Madness_and_Men.html?id=W-mfDgAAQBAJ Accessed 20 Aug 2017.</Citation></Reference><Reference><Citation>Aretaeus. The Extant Works of Aretaeus, The Cappadocian (Boston Milford House Inc, 1972) http://www.chlt.org/hippocrates/aretaeusEnglish/ . Accessed 20 Aug 2017.</Citation></Reference><Reference><Citation>MORA, G. Paracelsus’ psychiatry: on the occasion of the 400th anniversary of his book “Diseases That Deprive Man of His Reason” (1567). Am. J. Psychiatry 124, 803–814 (1967).</Citation><ArticleIdList><ArticleId IdType="pubmed">4862954</ArticleId></ArticleIdList></Reference><Reference><Citation>Sydenham T. The Works of Thomas Sydenham, M.D. (trans: Latham R. G.) (Sydenham Society, London, 1848). https://books.google.com/books?id=8qYEAAAAYAAJ&amp;pg=PP1#v=onepage&amp;q&amp;f=false Accessed 21 Aug 2017.</Citation></Reference><Reference><Citation>Veith, I. Psychiatric nosology: from hippocrates to Kraepelin. Am. J. Psychiatry 114, 385–391 (1957).</Citation><ArticleIdList><ArticleId IdType="pubmed">13470105</ArticleId></ArticleIdList></Reference><Reference><Citation>de Sauvages F. Nosologia Methodica (Amstelodami: sumptibus fratrum de Tournes, 1768) https://archive.org/details/nosologiamethodi01bois .</Citation></Reference><Reference><Citation>Cullen W. Nosology (C. Stewart and Company, 1800) https://books.google.com/books?id=3IgUAAAAQAAJ .</Citation></Reference><Reference><Citation>Pinel P. A Treatise on Insanity (Sheffield, London, 1806) https://books.google.com/books?id=4snWNO1lETAC&amp;pg=PA7&amp;source=gbs_toc_r&amp;cad=3#v=onepage&amp;q&amp;f=false Accessed 21 Aug 2017.</Citation></Reference><Reference><Citation>Battie W. A Treatise on Madness (J. Whiston and B. White, 1758) https://books.google.com/books?id=F6JbAAAAQAAJ .</Citation></Reference><Reference><Citation>Esquirol E., Hunt E. K. Mental Maladies: A Treatise on Insanity (Lea and Blanchard, 1845) https://books.google.com/books?id=h21s1O4AaJkC .</Citation></Reference><Reference><Citation>Georget É. De la folie (Crevot, 1820) https://books.google.com/books?id=GdpEAAAAcAAJ .</Citation></Reference><Reference><Citation>Griesinger W., Robertson C. A. L., Rutherford J. Mental Pathology and Therapeutics (W. Wood &amp; Company, 1882) https://books.google.com/books?id=OGoSAAAAYAAJ .</Citation></Reference><Reference><Citation>Bayle A. Traité des maladies du cerveau et de ses membranes (Gabon, 1826) https://books.google.com/books?id=oFBAAAAAcAAJ .</Citation></Reference><Reference><Citation>Lepoutre, T. &amp; Dening, T. ‘De la non-existence de la monomanie’, by Jean-Pierre Falret. Hist. Psychiatry 2012, 356–370 (1854).</Citation></Reference><Reference><Citation>Baillarger, J. &amp; Berrios, G. E. Essay on a classification of different genera of insanity. Hist. Psychiatry 19, 358–373 (1853).</Citation></Reference><Reference><Citation>Morel B. -A. Traité des maladies mentales (Victor Masson, Paris, 1860) https://gallica.bnf.fr/ark:/12148/bpt6k76604w/f6.image . Accessed 18 Jun 2019.</Citation></Reference><Reference><Citation>Kahlbaum K. Die Katatonie (Hirschwald, Berlin, 1874).</Citation></Reference><Reference><Citation>Pichot, P., Clayton, P. J. &amp; Reich, T. Tracing the origins of bipolar disorder: from Falret to DSM-IV and ICD-10. J. Affect Disord. 96, 145–148 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16859751</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendler K. S., Parnas J. Philosophical Issues in Psychiatry II: Nosology (Oxford University Press, 2012).</Citation></Reference><Reference><Citation>Decker, H. S., Robins, E., Guze, S., Winokur, G. &amp; Spitzer, R. How Kraepelinian was Kraepelin? How Kraepelinian are the neo-Kraepelinians?-from Emil Kraepelin to DSM-III. Hist. Psychiatry 18, 337–360 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18175636</ArticleId></ArticleIdList></Reference><Reference><Citation>Berrios, G. E. &amp; Hauser, R. The early development of Kraepelin’s ideas on classification: a conceptual history. Psychol. Med. 16, 813–821 (1988).</Citation></Reference><Reference><Citation>Kraepelin E., Diefendorf A. R. Clinical Psychiatry: A Text-book for Students and Physicians (Macmillan, 1915) https://books.google.com/books?id=9QtLAAAAYAAJ .</Citation></Reference><Reference><Citation>Kraepelin, E. &amp; Beer, D. The manifestations of insanity. Hist. Psychiatry 3, 504–508 (1992).</Citation></Reference><Reference><Citation>American Psychiatric Association for Mental Hygiene, Bureau of Statistics NC. Statistical Manual for the Use of Institutions for the Insane (National Committee for Mental Hygiene, 1918) https://books.google.com/books?id=AjFNAAAAMAAJ .</Citation></Reference><Reference><Citation>Grob, G. N. Origins of DSM-!: A Study in Appearance and Reality. Am. J. Psychiatry 148, 421–431 (1991).</Citation><ArticleIdList><ArticleId IdType="pubmed">2006685</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, first edition (Amer. Psychiatric Pub. Inc, 1952).</Citation></Reference><Reference><Citation>Feighner, J. P. et al. Diagnostic criteria for use in psychiatric research. Arch. Gen. Psychiatry 26, 57–63 (1972).</Citation><ArticleIdList><ArticleId IdType="pubmed">5009428</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhard, K. Pathogenesis of manic-depressive disease. Nervenarzt. 6, 271–272 (1957).</Citation></Reference><Reference><Citation>Bleuler E. Dementia Praecox or the Group of Schizophrenias (1911) https://doi.org/10.1037/h0053126 .</Citation></Reference><Reference><Citation>Hoenig J. The concept of schizophrenia. Kraepelin-Bleuler-Schneider. Br. J. Psychiatry 142. http://bjp.rcpsych.org/content/142/6/547 (1983).</Citation></Reference><Reference><Citation>Mayes, R. &amp; Horwitz, A. V. DSM-III and the revolution in the classification of mental illness. J. Hist. Behav. Sci. 41, 249–267 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15981242</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasanin, J. The acute schizoaffective psychoses. Am. J. Psychiatry 90, 97–126 (1933).</Citation></Reference><Reference><Citation>Wilson, J. E., Nian, H. &amp; Heckers, S. The schizoaffective disorder diagnosis: a conundrum in the clinical setting. Eur. Arch. Psychiatry Clin. Neurosci. 264, 29–34 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">23625467</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendler, K. The transformation of American psychiatric nosology at the dawn of the twentieth century. Mol. Psychiatry 21, 152–158 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26692416</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassidy, W. L., Flanagan, N. B., Spellman, M. &amp; Cohen, M. E. Clinical observations in manic-depressive disease. J. Am. Med. Assoc. 164, 1535 (1957).</Citation><ArticleIdList><ArticleId IdType="pubmed">13448904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendler, K. S., Muñoz, R. A. &amp; Murphy, G. The development of the feighner criteria: a historical perspective. Am. J. Psychiatry 167, 134–142 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20008944</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippocrates. On the Sacred Disease (Library of Alexandria, 2007) https://books.google.com/books?id=-vTZuukAkXUC .</Citation></Reference><Reference><Citation>Mora, G. On the 400th anniversary of Johann Weyer’s De Praestigiis Daemonum—its significance for today’s psychiatry. Am. J. Psychiatry 120, 417–428 (1963).</Citation><ArticleIdList><ArticleId IdType="pubmed">14051232</ArticleId></ArticleIdList></Reference><Reference><Citation>Vulpian, E. F. A. Note sur quelques reactions propres a la substance des capsules surrenales. Comptes rendus l’Académie des. Sci. 43, 663–665 (1856).</Citation></Reference><Reference><Citation>Oliver, G. &amp; Schäfer, E. A. The physiological effects of extracts of the suprarenal capsules. J. Physiol. 18, 230–276 (1895).</Citation><ArticleIdList><ArticleId IdType="pubmed">16992252</ArticleId><ArticleId IdType="pmcid">1514629</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldrich T. B. A preliminary report on the active principle of the suprarenal gland. Am. J. Physiol. 5. http://ajplegacy.physiology.org/content/5/7/457.full.pdf+html (1901).</Citation></Reference><Reference><Citation>Barger, G. &amp; Dale, H. H. Chemical structure and sympathomimetic action of amines. J. Physiol. 41, 19–59 (1910).</Citation><ArticleIdList><ArticleId IdType="pubmed">16993040</ArticleId><ArticleId IdType="pmcid">1513032</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker-Azmitia, P. The discovery of serotonin and its role in neuroscience. Neuropsychopharmacology 21, 2S–8S (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10432482</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenstein, E. S. The discovery of chemical neurotransmitters. Brain Cogn. 49, 73–95 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12027394</ArticleId></ArticleIdList></Reference><Reference><Citation>Cade J. F. J. Lithium salts in the treatment of psychotic excitement. http://psycnet.apa.org/psycinfo/1951-03900-001 (1949).</Citation></Reference><Reference><Citation>Hamon, J., Paraire, J. &amp; Velluz, J. VELLUZ. Effect of R. P. 4560 on maniacal agitation. Ann. Med Psychol. 110, 331–335 (1952).</Citation></Reference><Reference><Citation>Ayd, F. J. A preliminary report on marsalid. Am. J. Psychiatry 114, 459–459 (1957).</Citation><ArticleIdList><ArticleId IdType="pubmed">13470120</ArticleId></ArticleIdList></Reference><Reference><Citation>Paton, W. &amp; Rang, H. The uptake of atropine and related drugs by intestinal smooth muscle of the guinea-pig in relation to acetylcholine receptors. Proc R Soc Lond B Biol Sci. 163, 1–44 (1965).</Citation><ArticleIdList><ArticleId IdType="pubmed">14338492</ArticleId></ArticleIdList></Reference><Reference><Citation>Bylund D. B., Toews M. L. Radioligand binding methods: practical guide and tips. Am. J. Physiol. 265. http://ajplung.physiology.org/content/265/5/L421 (1993).</Citation></Reference><Reference><Citation>Schildkraut, J. J. The catecholamine hypothesis of affective disorders: a review of supporting evidence. Am. J. Psychiatry 122, 509–522 (1965).</Citation><ArticleIdList><ArticleId IdType="pubmed">5319766</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rossum, J. M. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs. Arch. Int. Pharmacodyn. Thér. 160, 492 (1966).</Citation><ArticleIdList><ArticleId IdType="pubmed">5954044</ArticleId></ArticleIdList></Reference><Reference><Citation>Battaglia, M. Beyond the usual suspects: a cholinergic route for panic attacks. Mol. Psychiatry 7, 239–246 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">11920151</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumeister, A. A. &amp; Hawkins, M. F. The serotonin hypothesis of schizophrenia: a historical case study on the heuristic value of theory in clinical neuroscience. J. Hist. Neurosci. 13, 277–291 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15370312</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergink, V. Glutamate and anxiety. Eur. Neuropsychopharmacol. 14, 175–183 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15056476</ArticleId></ArticleIdList></Reference><Reference><Citation>Previc, F. H. Prenatal influences on brain dopamine and their relevance to the rising incidence of autism. Med. Hypotheses 68, 46–60 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">16959433</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo, J. H., Valdovinos, M. G. &amp; Williams, D. C. Relevance of donepezil in enhancing learning and memory in special populations: a review of the literature. J. Autism Dev. Disord. 37, 1883–1901 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17221321</ArticleId></ArticleIdList></Reference><Reference><Citation>Luscher, B., Shen, Q. &amp; Sahir, N. The GABAergic deficit hypothesis of major depressive disorder. Mol. Psychiatry 16, 383–406 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21079608</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury, P. R., Lahiri, S. &amp; Rajamma, U. Glutamate mediated signaling in the pathophysiology of autism spectrum disorders. Pharm. Biochem. Behav. 100, 841–849 (2012).</Citation></Reference><Reference><Citation>Egerton, A. &amp; Stone, J. M. The glutamate hypothesis of schizophrenia: neuroimaging and drug development. Curr. Pharm. Biotechnol. 13, 1500–1512 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22283750</ArticleId></ArticleIdList></Reference><Reference><Citation>Möhler, H. The GABA system in anxiety and depression and its therapeutic potential. Neuropharmacology 62, 42–53 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21889518</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanacora, G., Treccani, G. &amp; Popoli, M. Towards a glutamate hypothesis of depression. Neuropharmacology 62, 63–77 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21827775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardila, A. Toward a cholinergic theory of schizophrenia. Gac. Neuro-Psiquiatrica 2, 46–60 (1978).</Citation></Reference><Reference><Citation>Harrington, R. A., Lee, L.-C., Crum, R. M., Zimmerman, A. W. &amp; Hertz-Picciotto, I. Serotonin hypothesis of autism: implications for selective serotonin reuptake inhibitor use during pregnancy. Autism Res. 6, 149–168 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23495208</ArticleId></ArticleIdList></Reference><Reference><Citation>Fakhoury, M. Revisiting the serotonin hypothesis: implications for major depressive disorders. Mol Neurobiol. 5, 2778–2786 (2016).</Citation></Reference><Reference><Citation>Pålsson, E. et al. Markers of glutamate signaling in cerebrospinal fluid and serum from patients with bipolar disorder and healthy controls. Eur. Neuropsychopharmacol. 25, 133–140 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25482684</ArticleId></ArticleIdList></Reference><Reference><Citation>Emrich, H. M., Zerssen, D. V., Kissling, W., Möller, H.-J. &amp; Windorfer, A. Effect of sodium valproate on mania. Arch. Psychiatr. Nervenkr. 229, 1–16 (1970).</Citation></Reference><Reference><Citation>Charney, D. S. &amp; Redmond, D. E. Neurobiological mechanisms in human anxiety. Evidence supporting central noradrenergic hyperactivity. Neuropharmacology 22, 1531–1536 (1983).</Citation><ArticleIdList><ArticleId IdType="pubmed">6142428</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahn, R. S. &amp; Van Praag, H. M. A serotonin hypothesis of panic disorder. Hum. Psychopharmacol. Clin. Exp. 3, 285–288 (1988).</Citation></Reference><Reference><Citation>Dilsaver, S. C. &amp; Coffman, J. A. Cholinergic hypothesis of depression: a reappraisal. J. Clin. Psychopharmacol. 9, 173–179 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2661605</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiva, D. B. The neurochemistry of mania: a hypothesis of etiology and rationale for treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 14, 423–429 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2193316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussman, J. P. Suppressed GABAergic inhibition as a common factor in suspected etiologies of autism. J. Autism Dev. Disord. 31, 247–248 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11450824</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahmood, T. &amp; Silverstone, T. Serotonin and bipolar disorder. J. Affect. Disord. 66, 1–11 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11532527</ArticleId></ArticleIdList></Reference><Reference><Citation>Charney A. W., Sayed S., Charney D. S. An assessment of the catecholamine hypothesis of bipolar disorder. In: Bipolar Disorders: Basic Mechanisms and Therapeutic Implications (eds Soares J. C. and Young A. H.) 21–42 (Cambridge University Press, Cambridge, 2016).</Citation></Reference><Reference><Citation>Rosenblatt, S., Chanley, J. D., Sobotka, H. &amp; Kaufman, M. R. Interrelationships between electroshock, the blood brain barrier, and catecholamines. J. Neurochem. 5, 172–176 (1960).</Citation><ArticleIdList><ArticleId IdType="pubmed">14438966</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunney, W. E. &amp; Davis, J. M. Norepinephrine in Depressive Reactions. Arch. Gen. Psychiatry 13, 483 (1965).</Citation><ArticleIdList><ArticleId IdType="pubmed">5320621</ArticleId></ArticleIdList></Reference><Reference><Citation>Randrup, A. et al. Mania, depression and brain dopamine. Curr. Dev. Psychopharmacol. 2, 206–248 (1975).</Citation></Reference><Reference><Citation>Serra, G., Argiolas, A., Klimek, V., Fadda, F. &amp; Gessa, G. L. Chronic treatment with antidepressants prevents the inhibitory effect of small doses of apomorphine on dopamine synthesis and motor activity. Life Sci. 25, 415–423 (1979).</Citation><ArticleIdList><ArticleId IdType="pubmed">481130</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunney, W. E. Jr., Garland, B. L., Bunney, W. E. J. &amp; Garland, B. L. A second generation catecholamine hypothesis. Pharmacopsychiatria 15, 111–115 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">6292964</ArticleId></ArticleIdList></Reference><Reference><Citation>Berk, M. et al. Dopamine dysregulation syndrome: Implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. 116, 41–49 (2007).</Citation></Reference><Reference><Citation>Schaffner, K. F. K. F., Kendler, K. S. &amp; Schaffner, K. F. K. F. The dopamine hypothesis of schizophrenia: an historical and philosophical analysis. Philos. Psychiatry Psychol. 18, 41–63 (2011).</Citation></Reference><Reference><Citation>Kendler, K. S. &amp; Schaffner, K. F. Further Thoughts on the Dopamine Hypothesis of Schizophrenia. Philos. Psychiatry Psychol. 18, 73–75 (2011).</Citation></Reference><Reference><Citation>Barnett, J. H. &amp; Smoller, J. W. The genetics of bipolar disorder. Neuroscience 164, 331–343 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">3637882</ArticleId><ArticleId IdType="pmcid">3637882</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenstein, P. et al. Recurrence risks for schizophrenia in a Swedish national cohort. Psychol. Med. 36, 1417–1425 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16863597</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendler, K. S., Pedersen, N. L., Neale, M. C. &amp; Mathe, A. A. A pilot Swedish twin study of affective illness including hospital- and population-ascertained subsamples: results of model fitting. Behav. Genet. 25, 217–232 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7598665</ArticleId></ArticleIdList></Reference><Reference><Citation>McGuffin, P. et al. The heritability of bipolar affective disorder and the genetic relationship to unipolar depression. Arch. Gen. Psychiatry. 5, 497–502 (2003).</Citation></Reference><Reference><Citation>Kieseppa, T., Partonen, T., Haukka, J., Kaprio, J. &amp; Lonnqvist, J. High concordance of bipolar I disorder in a nationwide sample of twins. Am. J. Psychiatry 2004, 161 (1814).</Citation></Reference><Reference><Citation>Merikangas, K. R. et al. Independence of familial transmission of mania and depression: results of the NIMH family study of affective spectrum disorders. Mol. Psychiatry 19, 214–219 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24126930</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandeleur, C. L., Merikangas, K. R., Strippoli, M. P. F., Castelao, E. &amp; Preisig, M. Specificity of psychosis, mania and major depression in a contemporary family study. Mol. Psychiatry https://doi.org/10.1038/mp.2013.132 (2013).</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2013.132</ArticleId><ArticleId IdType="pubmed">24126925</ArticleId></ArticleIdList></Reference><Reference><Citation>Smoller, J. W. &amp; Finn, C. T. Family, twin, and adoption studies of bipolar disorder. Am. J. Med. Genet. C Semin. Med. Genet. 123C, 48–58 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">14601036</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtenstein, P. et al. Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study. Lancet 373, 234–239 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19150704</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruderfer, D. M. et al. Polygenic dissection of diagnosis and clinical dimensions of bipolar disorder and schizophrenia. Mol. Psychiatry 19, 1017–1024 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24280982</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, J. et al. Specificity in etiology of subtypes of bipolar disorder: evidence from a Swedish population-based family study. Biol. Psychiatry 84, 810–816 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29331354</ArticleId></ArticleIdList></Reference><Reference><Citation>Gershon, E. S. et al. A family study of schizoaffective, bipolar I, bipolar II, unipolar, and normal control probands. Arch. Gen. Psychiatry. 10, 1157–1167 (1982).</Citation></Reference><Reference><Citation>Heun, R. &amp; Maier, W. The distinction of bipolar II disorder from bipolar I and recurrent unipolar depression: results of a controlled family study. Acta Psychiatr. Scand. 87, 279–284 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8488750</ArticleId></ArticleIdList></Reference><Reference><Citation>Laursen, T. M. et al. Family history of psychiatric illness as a risk factor for schizoaffective disorder: a Danish register-based cohort study. Arch. Gen. Psychiatry 62, 841–848 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">16061761</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertelsen, A. &amp; Gottesman, I. Schizoaffective psychoses: genetical clues to classification. Am. J. Med. Genet. 60, 7–11 (1995).</Citation><ArticleIdList><ArticleId IdType="pubmed">7485238</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng, M. Y. et al. Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol. Psychiatry 14, 774–785 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19349958</ArticleId></ArticleIdList></Reference><Reference><Citation>Segurado, R. et al. Genome scan meta-analysis of schizophrenia and bipolar disorder, part III: bipolar disorder. Am. J. Hum. Genet. 73, 49–62 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12802785</ArticleId><ArticleId IdType="pmcid">1180589</ArticleId></ArticleIdList></Reference><Reference><Citation>Badner, J. A. et al. Genome-wide linkage analysis of 972 bipolar pedigrees using single-nucleotide polymorphisms. Mol. Psychiatry 17, 818–826 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21769101</ArticleId></ArticleIdList></Reference><Reference><Citation>Sklar, P. et al. Association analysis of NOTCH4 loci in schizophrenia using family and population-based controls. Nat. Genet. 28, 126–128 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11381257</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi, J., Gershon, E. S. &amp; Liu, C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr. Res. 104, 96–107 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18715757</ArticleId><ArticleId IdType="pmcid">2562556</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrell, M. S. et al. Evaluating historical candidate genes for schizophrenia. Mol. Psychiatry 20, 555–562 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25754081</ArticleId><ArticleId IdType="pmcid">25754081</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins, A. L., Kim, Y., Sklar, P., O’Donovan, M. C. &amp; Sullivan, P. F. Hypothesis-driven candidate genes for schizophrenia compared to genome-wide association results. Psychol. Med. 42, 607–616 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">21854684</ArticleId></ArticleIdList></Reference><Reference><Citation>Seifuddin, F. et al. Meta-analysis of genetic association studies on bipolar disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 159B, 508–518 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22573399</ArticleId><ArticleId IdType="pmcid">3582382</ArticleId></ArticleIdList></Reference><Reference><Citation>Pe’er, I. et al. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet. Epidemiol. 32, 381 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18348202</ArticleId></ArticleIdList></Reference><Reference><Citation>Riglin, L. et al. Schizophrenia risk alleles and neurodevelopmental outcomes in childhood: a population-based cohort study. Lancet Psychiatry 4, 57–62 (2017).</Citation></Reference><Reference><Citation>Sklar, P. et al. Whole-genome association study of bipolar disorder. Mol. Psychiatry 13, 558–569 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18317468</ArticleId><ArticleId IdType="pmcid">3777816</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott, L. J. et al. Genome-wide association and meta-analysis of bipolar disorder in individuals of European ancestry. Proc. Natl Acad. Sci. USA 106, 7501–7506 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19416921</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, E. N. et al. Genome-wide association study of bipolar disorder in European American and African American individuals. Mol. Psychiatry 14, 755–763 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19488044</ArticleId><ArticleId IdType="pmcid">3035981</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith, E. N. et al. Genome-wide association of bipolar disorder suggests an enrichment of replicable associations in regions near genes. PLoS Genet. 7, e1002134 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21738484</ArticleId><ArticleId IdType="pmcid">3128104</ArticleId></ArticleIdList></Reference><Reference><Citation>Charney, A. W. et al. Evidence for genetic heterogeneity between clinical subtypes of bipolar disorder. Transl. Psychiatry 7, e993 (2016).</Citation></Reference><Reference><Citation>Pardiñas, A. F. et al. Common schizophrenia alleles are enriched in mutation-intolerant genes and in regions under strong background selection. Nat. Genet. 50, 381–389 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29483656</ArticleId><ArticleId IdType="pmcid">29483656</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray, N. R. et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat. Genet. 50, 668–681 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29700475</ArticleId><ArticleId IdType="pmcid">29700475</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, X., Li, Y. I. &amp; Pritchard, J. K. Trans effects on gene expression can drive omnigenic inheritance. Cell 177, 1022–1034.e6 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31051098</ArticleId><ArticleId IdType="pmcid">6553491</ArticleId></ArticleIdList></Reference><Reference><Citation>Wray, N. R., Wijmenga, C., Sullivan, P. F., Yang, J. &amp; Visscher, P. M. Common disease is more complex than implied by the core gene omnigenic model. Cell 173, 1573–1580 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29906445</ArticleId><ArticleId IdType="pmcid">29906445</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyle, E. A., Li, Y. I. &amp; Pritchard, J. K. An expanded view of complex traits: from polygenic to omnigenic. Cell 169, 1177–1186 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28622505</ArticleId><ArticleId IdType="pmcid">28622505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disorder and Schizophrenia Working Group of the Psychiatric Genomics Consortium. Genomic dissection of bipolar disorder and schizophrenia, including 28 subphenotypes. Cell 173, 1705–1715.e16 (2018).</Citation></Reference><Reference><Citation>Cross-Disorder Group of the Psychiatric Genomics Consortium et al. Genome wide meta-analysis identifies genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. bioRxiv. https://doi.org/10.1101/528117 (2019).</Citation></Reference><Reference><Citation>Coleman J. R. I. et al. The genetics of the mood disorder spectrum: genome-wide association analyses of over 185,000 cases and 439,000 controls. bioRxiv. https://doi.org/10.1101/383331 (2018).</Citation></Reference><Reference><Citation>Stahl, E. A. et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat. Genet. 51, 793–803 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31043756</ArticleId><ArticleId IdType="pmcid">6956732</ArticleId></ArticleIdList></Reference><Reference><Citation>Wainschtein P. et al. Recovery of trait heritability from whole genome sequence data. bioRxiv. https://doi.org/10.1101/588020 (2019).</Citation></Reference><Reference><Citation>Yang, J., Lee, S. H., Goddard, M. E. &amp; Visscher, P. M. GCTA: a tool for genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21167468</ArticleId><ArticleId IdType="pmcid">21167468</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulik-Sullivan, B. et al. An atlas of genetic correlations across human diseases and traits. Nat. Genet. 47, 1236–1241 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26414676</ArticleId><ArticleId IdType="pmcid">26414676</ArticleId></ArticleIdList></Reference><Reference><Citation>International Schizophrenia Consortium. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460, 748 (2009).</Citation><ArticleIdList><ArticleId IdType="pmcid">3912837</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross-Disorder Group of the Psychiatric Genomics Consortium. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371–1379 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">3714010</ArticleId><ArticleId IdType="pmcid">3714010</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. H. et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat. Genet. 45, 984–994 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23933821</ArticleId></ArticleIdList></Reference><Reference><Citation>Rees, E. et al. Analysis of intellectual disability copy number variants for association with schizophrenia. JAMA Psychiatry 13, 1–7 (2016).</Citation></Reference><Reference><Citation>Charney A. W. et al. Contribution of rare copy number variants to bipolar disorder risk is limited to schizoaffective cases. Biol. Psychiatry https://doi.org/10.1016/j.biopsych.2018.12.009 (2018).</Citation></Reference><Reference><Citation>Allardyce, J. et al. Association between schizophrenia-related polygenic liability and the occurrence and level of mood-incongruent psychotic symptoms in bipolar disorder. JAMA Psychiatry 75, 28 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29167880</ArticleId></ArticleIdList></Reference><Reference><Citation>Markota, M. et al. Association of schizophrenia polygenic risk score with manic and depressive psychosis in bipolar disorder. Transl. Psychiatry 8, 188 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30201969</ArticleId><ArticleId IdType="pmcid">6131184</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruderfer, D. M. et al. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach. lancet Psychiatry 3, 350–357 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26915512</ArticleId><ArticleId IdType="pmcid">4982509</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaspar H. A., Breen G. Drug enrichment and discovery from schizophrenia genome-wide association results: an analysis and visualisation approach. Sci Rep. 7. https://doi.org/10.1038/s41598-017-12325-3 (2017).</Citation></Reference><Reference><Citation>Fuller Torrey E. et al. Why NIMH should not stop new drug trials for schizophrenia. http://www.treatmentadvocacycenter.org/storage/documents/why-nimh-should-not-stop-new-drug-trials-for-schizophrenia.pdf . Accessed 3 Oct 2018.</Citation></Reference><Reference><Citation>Kendler, K. S. &amp; Jablensky, A Kraepelin’s concept of psychiatric illness. Psychol. Med. 41, 1119–1126 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">20809997</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32215771</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1535-1645</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>03</Month><Day>26</Day></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>A Review of Antidepressant-Associated Hypomania in Those Diagnosed with Unipolar Depression-Risk Factors, Conceptual Models, and Management.</ArticleTitle><Pagination><MedlinePgn>20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11920-020-01143-6</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW">The nosology and management of antidepressant-associated hypomania (AAH) in the treatment of unipolar depression requires clarification. We sought to review recent studies examining AAH, focusing on risk factors, differing explanatory models, and management strategies.</AbstractText><AbstractText Label="RECENT FINDINGS">AAH occurs more frequently in those of female gender, younger age, and with a bipolar disorder (BP) family history. Depressive features (e.g., suicidal ideation, psychotic symptoms) in those with AAH were similar to those with established BPs. Explanatory models for AAH describe it as (i) a transient iatrogenic event, (ii) a specific "bipolar III" disorder, (iii) indicative of "conversion" to BP, (iv) acceleration of BP, and (v) coincidental and unrelated to antidepressant medication. Management recommendations include antidepressant cessation, atypical antipsychotic medications, or switching to a mood stabilizer. Determinants and management of AAH in the treatment of unipolar depression requires considerable clarification, likely to be achieved by close clinical review and refined research studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gill</LastName><ForeName>Nav</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Prince of Wales Hospital, Randwick, NSW, 2031, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bayes</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales (UNSW), Sydney, 2052, Australia. a.bayes@unsw.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Black Dog Institute, Sydney, NSW, 2031, Australia. a.bayes@unsw.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parker</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Prince of Wales Hospital, Randwick, NSW, 2031, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales (UNSW), Sydney, 2052, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Black Dog Institute, Sydney, NSW, 2031, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Antidepressant</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Hypomania</Keyword><Keyword MajorTopicYN="Y">Management</Keyword><Keyword MajorTopicYN="Y">Nosology</Keyword><Keyword MajorTopicYN="Y">Risk factors</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32215771</ArticleId><ArticleId IdType="doi">10.1007/s11920-020-01143-6</ArticleId><ArticleId IdType="pii">10.1007/s11920-020-01143-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2008 Sep;10(6):726-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18837867</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 1996 Mar;6(1):9-11</Citation><ArticleIdList><ArticleId IdType="pubmed">8866932</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Aug;164:14-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24856547</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):65-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12507739</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 1998 Apr;136(3):243-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9566809</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Feb;155:59-64</Citation><ArticleIdList><ArticleId IdType="pubmed">24252168</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2007;(433):50-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17280571</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2001 Sep;104(3):236-8; discusiion 238-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11531662</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Sep;59 Suppl 1:S5-S30</Citation><ArticleIdList><ArticleId IdType="pubmed">11121824</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1980 Nov;137(11):1457-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7435690</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Dec 15;46(12):1707-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10624554</ArticleId></ArticleIdList></Reference><Reference><Citation>Br Med J. 1959 Nov 21;2(5159):1052-5</Citation><ArticleIdList><ArticleId IdType="pubmed">13796229</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1997 Oct;46(1):73-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9387089</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Nov;134(1-3):85-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21632117</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Jul;87(1):115-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15967235</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2007 Jul;13(4):233-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17667735</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1995 Feb;52(2):114-23</Citation><ArticleIdList><ArticleId IdType="pubmed">7848047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1999 Aug;38(8):952-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10434486</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2013 Sep;45(9):984-94</Citation><ArticleIdList><ArticleId IdType="pubmed">23933821</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1996 Dec;16(6):425-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8959466</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Geriatr Psychiatry. 2013 Jun;28(6):654-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23649859</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1994 Apr;164(4):549-50</Citation><ArticleIdList><ArticleId IdType="pubmed">8038948</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2004 Nov;28(7):1201-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15610935</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2017 Sep;219:187-192</Citation><ArticleIdList><ArticleId IdType="pubmed">28558366</ArticleId></ArticleIdList></Reference><Reference><Citation>Turk Psikiyatri Derg. 2008 Fall;19(3):329-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18791886</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2018 Aug 17;14:2099-2104</Citation><ArticleIdList><ArticleId IdType="pubmed">30147322</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2007 Oct;68(10):1472-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17960960</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2008 Feb 27;299(8):901-913</Citation><ArticleIdList><ArticleId IdType="pubmed">18314433</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Aug;152(8):1130-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7625459</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry Clin Pract. 2013 Aug;17(3):219-22</Citation><ArticleIdList><ArticleId IdType="pubmed">23560620</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1988 Jul;145(7):804-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3381922</ArticleId></ArticleIdList></Reference><Reference><Citation>Indian J Psychiatry. 2012 Apr;54(2):194-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22988331</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 1998;12(3 Suppl B):S5-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9808077</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 May 15;148(1):129-35</Citation><ArticleIdList><ArticleId IdType="pubmed">23219059</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Dec;5(6):407-20</Citation><ArticleIdList><ArticleId IdType="pubmed">14636364</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2008;25(12):1014-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18781664</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2003 Jul;108(1):70-4</Citation><ArticleIdList><ArticleId IdType="pubmed">12807380</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Jan;78(1):81-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14672801</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2016 Jun;30(6):495-553</Citation><ArticleIdList><ArticleId IdType="pubmed">26979387</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1985 Feb;5(1):2-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3973068</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Nov;134(1-3):91-101</Citation><ArticleIdList><ArticleId IdType="pubmed">21742381</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2010 Jun;121(6):404-14</Citation><ArticleIdList><ArticleId IdType="pubmed">19958306</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1981 Jan-Feb;22(1):11-20</Citation><ArticleIdList><ArticleId IdType="pubmed">7460559</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1999 Jan;38(1):6-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9893408</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2011 Mar;25(3):306-13</Citation><ArticleIdList><ArticleId IdType="pubmed">20156925</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2017 Apr;62(4):247-258</Citation><ArticleIdList><ArticleId IdType="pubmed">27462036</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1992 Jul-Aug;33(4):253-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1643866</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Jul;57(7):715-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10891045</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Clin Psychopharmacol. 2000 Jan;15(1):53-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10836288</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Mar;152(3):385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">7864264</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Sep;149(9):1282-3</Citation><ArticleIdList><ArticleId IdType="pubmed">1503154</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Feb;6(1):32-42</Citation><ArticleIdList><ArticleId IdType="pubmed">14996139</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1983 May;5(2):115-28</Citation><ArticleIdList><ArticleId IdType="pubmed">6222091</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2006 Oct;26(5):512-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16974195</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 1998;12(4):348-55</Citation><ArticleIdList><ArticleId IdType="pubmed">10065908</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2015 Dec 14;5(12):e008341</Citation><ArticleIdList><ArticleId IdType="pubmed">26667012</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Sep;50(2-3):203-13</Citation><ArticleIdList><ArticleId IdType="pubmed">9858079</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2014 Jan;129(1):4-16</Citation><ArticleIdList><ArticleId IdType="pubmed">23600771</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 1999 Jan-Feb;33(1):23-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10094236</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Investig. 2018 Nov;15(11):1009-1010</Citation><ArticleIdList><ArticleId IdType="pubmed">30481991</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25563517</PMID><DateCompleted><Year>2015</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2015</Year><Month>01</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>61</Volume><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Subclinical hypothyroidism and neurocognitive functioning in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>166-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2014.12.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(14)00357-4</ELocationID><Abstract><AbstractText>The aim of this study was to compare neurocognitive functioning between euthymic bipolar disorder (BD) patients with and without subclinical hypothyroidism (SCH). Patients with SCH had poorer performance than patients without SCH in measures of verbal memory, attention, language, and executive functions. These preliminary results suggest that SCH could have some impact on the neurocognitive performance of euthymic patients with BD and warrant further research in this field. </AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Diego J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Neurosciences, Favaloro University, Buenos Aires, Argentina; National Council of Scientific and Technical Research (CONICET), Argentina. Electronic address: diejmartino@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strejilevich</LastName><ForeName>Sergio A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program, Institute of Neurosciences, Favaloro University, Buenos Aires, Argentina; Institute of Cognitive Neurology (INECO), Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="Y">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="Y">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014706" MajorTopicYN="N">Verbal Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Attention</Keyword><Keyword MajorTopicYN="N">Executive functions</Keyword><Keyword MajorTopicYN="N">Memory</Keyword><Keyword MajorTopicYN="N">Thyroid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>12</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25563517</ArticleId><ArticleId IdType="pii">S0022-3956(14)00357-4</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2014.12.016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">28691361</PMID><DateCompleted><Year>2018</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>5</Issue><PubDate><Year>2017</Year><Month>08</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Impact of childhood trauma on cognitive profile in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>363-374</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12514</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Bipolar Disorder (BD) is associated with cognitive impairment even during remission periods. Nonetheless, this impairment seems to adjust to different profiles of severity. Our aim was to examine the potential impact of childhood trauma (CT) on cognitive performance and, more specifically, on neurocognitive profile membership.</AbstractText><AbstractText Label="METHODS">Using a data-driven strategy, 113 euthymic bipolar patients were grouped according to their cognitive performance using a hierarchical clustering technique. Patients from the three resulting clusters, the so-called "low", "average", and "high performance" groups, were then compared in terms of main sociodemographic, clinical and functioning variables, including CT measures. One-way ANOVA, a chi-square test and partial correlations were used for this purpose, as appropriate. A multinomial logistic regression model was used to determine which variables contributed to neurocognitive clustering membership.</AbstractText><AbstractText Label="RESULTS">Patients from the three neurocognitive clusters differed in terms of sociodemographic, clinical, functioning and CT variables. Scores on the Childhood Trauma Questionnaire (CTQ), especially on the physical negligence subscale, were also associated with a poor cognitive performance. The multinomial regression model indicated that CTQ total scores and the estimated intelligence quotient (IQ) significantly contributed to differentiation among the three neurocognitive groups.</AbstractText><AbstractText Label="CONCLUSIONS">Our results confirmed that CT significantly impacts on cognitive performance during adulthood in BD. The data obtained suggest that a history of CT could act as a liability marker for cognitive impairment. A higher estimated IQ may act as a protective factor against cognitive decline in this group of patients.</AbstractText><CopyrightInformation>© 2017 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jiménez</LastName><ForeName>Esther</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solé</LastName><ForeName>Brisa</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arias</LastName><ForeName>Bárbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Departament Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, CIBERSAM, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mitjans</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Departament Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, Institut de Biomedicina de la Universitat de Barcelona (IBUB), Universitat de Barcelona, CIBERSAM, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Neuroscience, Max Planck Institute of Experimental Medicine, Göttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varo</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>María</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnín</LastName><ForeName>Caterina Del Mar</ForeName><Initials>CDM</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruíz</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Institut Clinic de Neurociencies, Hospital Clinic, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saiz</LastName><ForeName>Pilar Alejandra</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Portilla</LastName><ForeName>M Paz</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burón</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bobes</LastName><ForeName>Julio</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, School of Medicine, University of Oviedo, CIBERSAM Instituto de Neurociencias del Principado de Asturias, INEUROPA, Oviedo, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Servicio de Salud del Principado de Asturias (SESPA), Oviedo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amann</LastName><ForeName>Benedikt L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Institut de Neuropsiquiatria i Addiccions, Centre Fòrum Research Unit, Parc de Salut Mar Hospital del Mar, IMIM, Autonomous University of Barcelona, CIBERSAM, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Arán</LastName><ForeName>Anabel</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0623-6263</Identifier><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torrent</LastName><ForeName>Carla</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0548-0053</Identifier><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benabarre</LastName><ForeName>Antoni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Unit, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054523" MajorTopicYN="N">Adult Survivors of Child Abuse</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="Y">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007361" MajorTopicYN="N">Intelligence Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="Y">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">childhood trauma</Keyword><Keyword MajorTopicYN="Y">cluster analysis</Keyword><Keyword MajorTopicYN="Y">cognitive impairment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28691361</ArticleId><ArticleId IdType="doi">10.1111/bdi.12514</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7028797</PMID><DateCompleted><Year>1982</Year><Month>01</Month><Day>09</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-0749</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>2</Issue><PubDate><Year>1981</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Monoamine oxidase inhibitors in bipolar endogenous depressives.</ArticleTitle><Pagination><MedlinePgn>70-4</MedlinePgn></Pagination><Abstract><AbstractText>Clinical lore suggests that monoamine oxidase inhibitors (MAOIs) are not effective in endogenous depression. A review of previous placebo-controlled trials of MAOI in patients with endogenous depression neither refutes nor confirms their utility in this patient group. We present patients in the depressive phase of bipolar illness refractory to treatment with tricyclics who have responded to MAOI. These open trials require confirmation in controlled studies. Bipolar illness may be a heterogeneous disorder. Presence or absence of X-linkage, low platelet MAO, or response to MAOI may indicate different forms of the disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Quitkin</LastName><ForeName>F M</ForeName><Initials>FM</Initials></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Liebowitz</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author><Author ValidYN="Y"><LastName>Stewart</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Howard</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>O408N561GF</RegistryNumber><NameOfSubstance UI="D010624">Phenelzine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004597" MajorTopicYN="N">Electroshock</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010624" MajorTopicYN="N">Phenelzine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7028797</ArticleId><ArticleId IdType="doi">10.1097/00004714-198103000-00005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2906808</PMID><DateCompleted><Year>1989</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>8</Issue><PubDate><Year>1988</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>State-dependent movement disorder.</ArticleTitle><Pagination><MedlinePgn>945</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wessely</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Feinstein</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Trimble</LastName><ForeName>M R</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004409" MajorTopicYN="N">Dyskinesia, Drug-Induced</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2906808</ArticleId><ArticleId IdType="pii">0006-3223(88)90232-6</ArticleId><ArticleId IdType="doi">10.1016/0006-3223(88)90232-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31203140</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-8421</ISSN><JournalIssue CitedMedium="Internet"><Volume>334</Volume><PubDate><Year>2019</Year><Month>09</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of neuroimmunology</Title><ISOAbbreviation>J Neuroimmunol</ISOAbbreviation></Journal><ArticleTitle>Increased plasma levels of high mobility group box 1 protein in patients with bipolar disorder: A pilot study.</ArticleTitle><Pagination><MedlinePgn>576993</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-5728(19)30128-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2019.576993</ELocationID><Abstract><AbstractText>High mobility group box 1 (HMGB1) is a pro-inflammatory cytokine that emerges as a promising peripheral marker of inflammation. HMGB1 and C-reactive protein levels were assessed in plasma of control subjects and remitted patients with bipolar disorder (BD). HMGB1 levels were significantly higher in patients with BD as compared to control subjects whereas C-reactive protein levels did not differ between the two groups. No significant effect of potential covariates was identified. The results of this pilot study suggest that HMGB1 might be a specific peripheral marker of inflammation in BD.</AbstractText><CopyrightInformation>Copyright © 2019 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Marie-Claire</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France. Electronic address: cynthia.marie-claire@parisdescartes.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Courtin</LastName><ForeName>Cindie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curis</LastName><ForeName>Emmanuel</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France; AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Département de biostatistiques et d'informatique médicales, Paris, France; Laboratoire de biomathématiques, plateau iB(2), EA 7537 (BioSTM), Faculté de Pharmacie de Paris, Université Paris Descartes, Paris F-75006, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouaziz-Amar</LastName><ForeName>Elodie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France; GH Saint-Louis - Lariboisière - F. Widal, Département de Biochimie et Biologie moléculaire, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laplanche</LastName><ForeName>Jean-Louis</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France; GH Saint-Louis - Lariboisière - F. Widal, Département de Biochimie et Biologie moléculaire, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacob</LastName><ForeName>Aude</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etain</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France; AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris Cedex 10, France; Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanchard</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>APHP, Hôpital Européen Georges Pompidou, INSERM CIC1418, Université Paris Descartes, 75015 Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>INSERM U1144 Optimisation Thérapeutique en Neuropsychopharmacologie, Université Paris Descartes, Université Paris Diderot, Université Sorbonne Paris Cité, Paris, France; AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris Cedex 10, France; Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>06</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Neuroimmunol</MedlineTA><NlmUniqueID>8109498</NlmUniqueID><ISSNLinking>0165-5728</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D024243">HMGB1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C585491">HMGB1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024243" MajorTopicYN="N">HMGB1 Protein</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">HMGB1</Keyword><Keyword MajorTopicYN="Y">Inflammation</Keyword><Keyword MajorTopicYN="Y">Plasma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>03</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>06</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>6</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31203140</ArticleId><ArticleId IdType="pii">S0165-5728(19)30128-6</ArticleId><ArticleId IdType="doi">10.1016/j.jneuroim.2019.576993</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12188978</PMID><DateCompleted><Year>2003</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1044-5463</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>2</Issue><PubDate><Year>2002</Year><Season>Summer</Season></PubDate></JournalIssue><Title>Journal of child and adolescent psychopharmacology</Title><ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Clozapine in adolescent inpatients with acute mania.</ArticleTitle><Pagination><MedlinePgn>93-9</MedlinePgn></Pagination><Abstract><AbstractText>Some bipolar patients with acute manic episodes can be refractory to conventional treatment with mood stabilizers. Clozapine, an atypical antipsychotic, has been reported to be effective in adults with treatment-resistant bipolar disorder. We describe the therapeutic effect of clozapine in 10 adolescent inpatients (12- to 17-year-olds) with severe acute manic or mixed episodes who did not improve after treatment with conventional drugs (mood stabilizers, antipsychotics). At hospital discharge, 15 to 28 days after clozapine treatment, all patients had responded positively according to the Clinical Global Impression-Improvement Scale scores. The mean changes in Mania Rating Scale, Brief Psychiatric Rating Scale, Children's Global Assessment Scale, and Clinical Global Impression-Severity Scale were significant (p &lt; 0.001). Clozapine dosage was 142.5 +/- 73.6 mg/day (range 75-300 mg/day). Side effects (increased appetite, sedation, enuresis, sialorrhea) were frequent but not severe enough to require reduction of dosage. Mean weight gain after 6 months was 6.96 +/- 3.08 kg (10.7%). Neither decrease of white cells nor epileptic seizures were reported during follow-up (12-24 months). These preliminary findings suggest that clozapine may improve the clinical picture in adolescents with treatment-refractory manic or mixed episodes. Controlled studies on larger samples are warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Masi</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>IRCCS Stella Maris, Division of Child Neurology and Psychiatry, Calambrone, Pisa, Italy. gabriele.masi@inpe.unipi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mucci</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Millepiedi</LastName><ForeName>Stefania</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA><NlmUniqueID>9105358</NlmUniqueID><ISSNLinking>1044-5463</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="Y">Inpatients</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>8</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>1</Month><Day>7</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>8</Month><Day>22</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12188978</ArticleId><ArticleId IdType="doi">10.1089/104454602760219135</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12216008</PMID><DateCompleted><Year>2002</Year><Month>11</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>5</Issue><PubDate><MedlineDate>2002 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Rapid cycling mood disorder: clinical and demographic features.</ArticleTitle><Pagination><MedlinePgn>336-43</MedlinePgn></Pagination><Abstract><AbstractText>Rapid cycling bipolar disorder is defined as four or more illness episodes per year. We compared demographic, clinical, and symptomatological features of subjects with rapid cycling bipolar disorder (RC) and those with non-rapid-cycling bipolar disorder (NR). Five hundred ninety-five subjects (RC = 275, NR = 320), were included in the study. Subjects were assessed using the Operational Criteria for Psychotic Illness checklist (OPCRIT, n = 496), the Hamilton Rating Scale for Depression (HAMD, n = 47), the Social Adjustment Scale (SAS, n = 160), and the Self-Esteem Scale (SES, n = 160). RC were older at the time of assessment and with more medical illnesses. RC showed a lower risk for psychotic and disorganised features, particularly within bipolar I disorder. Finally, bipolar I RC showed a lower risk for violent suicide attempt. Our findings suggest that rapid cycling bipolar disorder is a condition characterized by less severe psychotic and suicidal features, particularly within bipolar I disorder.</AbstractText><CopyrightInformation>Copyright 2002, Elsevier Science (USA). All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Vita-Salute University, San Raffaele Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelli</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lattuada</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Smeraldi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010507" MajorTopicYN="Y">Periodicity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>9</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>11</Month><Day>26</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>9</Month><Day>7</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12216008</ArticleId><ArticleId IdType="pii">S0010440X02000111</ArticleId><ArticleId IdType="doi">10.1053/comp.2002.34630</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7608045</PMID><DateCompleted><Year>1995</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0890-8567</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>6</Issue><PubDate><Year>1995</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title><ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Recovery and relapse in adolescents with bipolar affective illness: a five-year naturalistic, prospective follow-up.</ArticleTitle><Pagination><MedlinePgn>724-31</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study was a 5-year naturalistic prospective follow-up of 54 consecutive admissions of adolescents to a university inpatient service with a diagnosis of bipolar I affective illness.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Subjects received structured clinical evaluations every 6 months after entry to establish time to recovery and subsequent relapse. Regression models were used to identify predictors of differential course.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Rate of recovery varied by polarity of episode at time of entry, with quick recovery observed in subjects with pure mania or mixed states, and a protracted index episode in subjects with pure depression. Multiple relapses were most often seen in subjects with mixed or cycling episodes at intake.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Polarity of illness may have utility in identifying bipolar adolescents with a more recurrent illness. Comparison with adult data suggests that recurrence risks may vary as a function of age at onset or stage of the disease process.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strober</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>UCLA School of Medicine, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt-Lackner</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Freeman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bower</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Lampert</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>DeAntonio</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA><NlmUniqueID>8704565</NlmUniqueID><ISSNLinking>0890-8567</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="Y">Patient Admission</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7608045</ArticleId><ArticleId IdType="pii">S0890-8567(09)63570-X</ArticleId><ArticleId IdType="doi">10.1097/00004583-199506000-00012</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15693748</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>66 Suppl 1</Volume><PubDate><Year>2005</Year></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Recognizing and managing bipolar disorder in children.</ArticleTitle><Pagination><MedlinePgn>18-23</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorder affects people of all ages, including preschool-aged children. Two major difficulties in diagnosing children with bipolar disorder are its overlap with attention-deficit/hyperactivity disorder (ADHD) and its developmentally distinct presentation from that in adults, with high rates of irritability, chronicity, and mixed states. Comorbid conditions are common in bipolar disorder and, in addition to ADHD, include depression, anxiety disorders, oppositional defiant disorder, and conduct disorder. Family studies have helped to confirm the validity of bipolar disorder in children. In terms of treatment, children do not appear to respond well to conventional mood stabilizers alone. However, using an atypical antipsychotic either alone or in addition to another mood stabilizer has shown utility in treating manic symptoms, depression in mixed states, and aggression. Amphetamine salts have been helpful in treating bipolar children with comorbid ADHD, but no data are available on treating comorbid depression in bipolar children. Because childhood-onset mania is commonly chronic rather than episodic, highly comorbid, and characterized by high rates of irritability, future clinical trials should examine the overlap of mania with other disorders in children to determine routes to accurate diagnosis and treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston, MA 02138, USA. jwozniak@partners.org</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>CK833KGX7E</RegistryNumber><NameOfSubstance UI="D000661">Amphetamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000661" MajorTopicYN="N">Amphetamine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>52</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15693748</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7588181</PMID><DateCompleted><Year>1995</Year><Month>12</Month><Day>08</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Print"><Volume>21 Spec No 2</Volume><PubDate><Year>1995</Year><Month>Mar</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[The long-term course of depression (epidemiology and clinical aspects)].</ArticleTitle><Pagination><MedlinePgn>51-9</MedlinePgn></Pagination><Abstract><AbstractText>Depression recurs in three quarters of cases; it is therefore necessary to undertake long-term studies in order to understand the clinical and epidemiological implications. Current classifications schematically distinguish depressive episodes according to their more or less permanent and complete semiological expression (at least five symptoms over at least two weeks for a major depressive episode, versus at least two criteria for the greater part of the time over at least two years) or their time-scale (isolated or recurrent episodes; recurrent brief depressive episodes...). The terminology of therapeutic strategies is based on the temporal definitions of the depressive process. Thus one speaks of curative treatment during the acute phase of the illness (two months), maintenance treatment during recurrence (four to six months), and prophylaxis against later possible recurrences (more than six months). Epidemiological findings emphasize the importance not only of recurrence of depression (50% in the year following an index episode), but also that of becoming chronic (20%), of partial remissions (15 to 20%), and the "bipolarisation" of a unipolar illness (10 to 15%). Finally, certain risk factors for recurrence have been identified. The most important of these is a large number of previous depressive episodes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cardot</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Service de Psychiatrie, Hôpital Louis Mourier, Colombes.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouillon</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Evolution à long terme des dépressions (épidémiologie et clinique).</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005602" MajorTopicYN="N" Type="Geographic">France</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>77</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7588181</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2027912</PMID><DateCompleted><Year>1991</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-4259</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>1</Issue><PubDate><Year>1991</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Psychiatrische Praxis</Title><ISOAbbreviation>Psychiatr Prax</ISOAbbreviation></Journal><ArticleTitle>[Carbamazepine in the treatment of mania and prevention of recurrence of manic-depressive disorders].</ArticleTitle><Pagination><MedlinePgn>1-8</MedlinePgn></Pagination><Abstract><AbstractText>Carbamacepine is an effective drug in the treatment of acute manic states as well as in preventing relapses in the course of manic-depressive illness. Many controlled studies show that carbamacepine is a valuable alternative and an implementation to the existing methods of treatment. Treatment of acute mania can be more rapid, more specific of carbamacepine is used or combined with neuroleptics (or occasionally with lithium). There are less side effects in carbamacepine treatment than in conventional treatment. In relapse prevention carbamacepine is probably as effective as in lithium. The essential progress of using carbamacepine is given, because more patients are eligible for a regime of relapse prevention: Patients that have proven resistant to lithium treatment and patients with contraindications to lithium. Carbamacepine treatment presents an important breakthrough in Rapid Cycling Affective Psychoses. Here it may be superior to all other methods of treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Finzen</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Psychiatrische Universitätsklinik, Basel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Carbamazepin bei der Behandlung der Manie und der Rückfallprophylaxe manisch-depressiven Erkrankungen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Prax</MedlineTA><NlmUniqueID>0423204</NlmUniqueID><ISSNLinking>0303-4259</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>41</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2027912</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11705718</PMID><DateCompleted><Year>2001</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Reaction time measures of sustained attention differentiate bipolar disorder from schizophrenia.</ArticleTitle><Pagination><MedlinePgn>251-9</MedlinePgn></Pagination><Abstract><AbstractText>Although continuous performance tasks (CPTs) are becoming more common in psychiatric research, it remains unclear which performance measures best differentiate psychiatric patient groups and along which psychological dimensions. To address this the authors examined sustained attention decrements in patients with bipolar disorder and schizophrenia using CPT measures of perceptual sensitivity, response bias, and psychomotor processing speed. Patients with bipolar disorder with psychotic features (N=20), schizophrenia (N=20), and healthy controls (N=20) were evaluated using structured clinical interviews. These patients were rated with the Scale for the Assessment of Positive Symptoms and the Young Mania Rating Scale before completing a degraded-stimulus version of the CPT. Psychomotor processing speed was the only measure that reliably differentiated the groups across the entire vigilance period and was the strongest predictor of group membership. These findings suggest that reaction time measures may be sensitive to differences in the sustained attention abilities of patients with bipolar disorder and schizophrenia. By incorporating reaction time measures into CPT assessments, discriminant ability may be enhanced.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fleck</LastName><ForeName>D E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Bipolar and Psychotic Disorders Research Program, Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0559, USA. fleckde@email.uc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sax</LastName><ForeName>K W</ForeName><Initials>KW</Initials></Author><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-54317</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-58330</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="Y">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016002" MajorTopicYN="N">Discriminant Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="Y">Reaction Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>11</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>11</Month><Day>14</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11705718</ArticleId><ArticleId IdType="pii">S0920996401001700</ArticleId><ArticleId IdType="doi">10.1016/s0920-9964(01)00170-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15820266</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>86</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Do social anxiety disorder patients belong to a bipolar spectrum subgroup?</ArticleTitle><Pagination><MedlinePgn>11-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">It has been proposed that all forms of bipolar disorder-perhaps all primary affective disorders-are best conceptualized as a spectrum of related illness, clinically overlapping but not necessarily genetically uniform illnesses. We aim to describe with retrospective methodology the demographic, clinical, and therapeutic response in a group of social anxiety disorder (SA) patients who improves while taking antidepressants and compare them with bipolar II (B-II) patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">57 SA outpatients (DSM-IV) were diagnosed and naturalistic efficacious treated with selective serotonin reuptake inhibitors (SSRI). Their demographic, clinical features and therapeutic response were compared with 41 DSM-IV bipolar II patients in their starting evaluations in our outpatient clinic in the Federal University of Rio de Janeiro, Brazil.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There is a sub-group of SA patients who improves while taking antidepressants and presents a clear hypomanic phase. Their improvement is identical to a mild/moderate hypomanic state. Without the antidepressant, the symptoms of SA return. The SA and B-II patients have a similar number of previous depressive episodes, alcohol abuse, suicide attempts, and family history for mood disorder.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">It is a retrospective data description based on a naturalist follow-up.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Some SA patients have demographic, clinical and therapeutic features similar to B-II patients and they might just be a Bipolar-III sub-group with a higher level of complains to social situations and without spontaneous hypomania during lifetime.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Valença</LastName><ForeName>Alexandre M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Institute of Psychiatry, Federal University of Rio de Janeiro, R. Visconde de Pirajá, 407/702, Rio de Janeiro-RJ-22410-003, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nardi</LastName><ForeName>Antonio E</ForeName><Initials>AE</Initials></Author><Author ValidYN="Y"><LastName>Nascimento</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Lopes</LastName><ForeName>Fabiana L</ForeName><Initials>FL</Initials></Author><Author ValidYN="Y"><LastName>Freire</LastName><ForeName>Rafael C</ForeName><Initials>RC</Initials></Author><Author ValidYN="Y"><LastName>Mezzasalma</LastName><ForeName>Marco A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Veras</LastName><ForeName>André B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Versiani</LastName><ForeName>Marcio</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000428" MajorTopicYN="N">Alcohol Drinking</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003710" MajorTopicYN="N">Demography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010698" MajorTopicYN="N">Phobic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2004</Year><Month>11</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>12</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>4</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>4</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15820266</ArticleId><ArticleId IdType="pii">S0165-0327(04)00443-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2004.12.007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6696594</PMID><DateCompleted><Year>1984</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>2</Issue><PubDate><Year>1984</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Pursuit eye movement dysfunctions in schizophrenia. Family evidence for specificity.</ArticleTitle><Pagination><MedlinePgn>136-9</MedlinePgn></Pagination><Abstract><AbstractText>In a number of previous investigations, eye tracking dysfunctions had been reliably found in from 50% to 85% of schizophrenic patients, about 40% of manic-depressive patients, and about 8% of the normal population. We report similar smooth pursuit eye movement dysfunctions in 34% of the parents (or 55% of parental pairs) of schizophrenic patients compared with 10% of the parents (or 7% of parental pairs) of manic-depressive patients. Parental eye movement dysfunctions are significantly related to the diagnosis of the patient and not to the patient's eye tracking performance. These data suggest that, in the absence of other CNS disease, these eye tracking dysfunctions represent familial markers of vulnerability to schizophrenia.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Holzman</LastName><ForeName>P S</ForeName><Initials>PS</Initials></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>C M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Levin</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Waternaux</LastName><ForeName>C S</ForeName><Initials>CS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 31154</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 31340</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004585" MajorTopicYN="N">Electrooculography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005133" MajorTopicYN="Y">Eye Movements</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="N">Parents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6696594</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1984.01790130030004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3381929</PMID><DateCompleted><Year>1988</Year><Month>07</Month><Day>26</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>145</Volume><Issue>7</Issue><PubDate><Year>1988</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Graphic representation of the life course of illness in patients with affective disorder.</ArticleTitle><Pagination><MedlinePgn>844-8</MedlinePgn></Pagination><Abstract><AbstractText>The authors illustrate methods for the graphic depiction of the course of unipolar and bipolar affective illness. The utility and advantages of such an approach include 1) accurate assessment of episode patterns, 2) elucidation of relationships to environmental events, endocrine and seasonal factors, and psychosocial stressors, 3) better delineation of treatment response, 4) a greater understanding of the longitudinal and characteristic patterns of illness, and 5) the associated better patient management with psychotherapeutic and pharmacological interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Post</LastName><ForeName>R M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Biological Psychiatry Branch, National Institute of Mental Health, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roy-Byrne</LastName><ForeName>P P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Uhde</LastName><ForeName>T W</ForeName><Initials>TW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="Y">Medical Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010347" MajorTopicYN="N">Patient Care Planning</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3381929</ArticleId><ArticleId IdType="doi">10.1176/ajp.145.7.844</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5732734</PMID><DateCompleted><Year>1969</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2739</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>12</Issue><PubDate><Year>1968</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Psychiatrie, Neurologie, und medizinische Psychologie</Title><ISOAbbreviation>Psychiatr Neurol Med Psychol (Leipz)</ISOAbbreviation></Journal><ArticleTitle>[On the dependence of puerperal psychoses on the beginning of the disease and the treatment method].</ArticleTitle><Pagination><MedlinePgn>454-7</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pogády</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hudáková</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Rybanská</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Uber die Abhängigkeit der Puerperalpsychosen vom Krankheitsbegium und von der Behandlungsart.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Neurol Med Psychol (Leipz)</MedlineTA><NlmUniqueID>0376467</NlmUniqueID><ISSNLinking>0033-2739</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011644" MajorTopicYN="Y">Puerperal Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1968</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1968</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1968</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5732734</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">33656816</PMID><DateCompleted><Year>2021</Year><Month>09</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>09</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1538-1145</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>03</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of psychiatric practice</Title><ISOAbbreviation>J Psychiatr Pract</ISOAbbreviation></Journal><ArticleTitle>Pilot Study of a Brief Sleep Intervention for Suicidal Ideation in Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>109-114</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PRA.0000000000000528</ELocationID><Abstract><AbstractText Label="OBJECTIVE">We investigated the feasibility and acceptability of a brief sleep intervention and sleep monitoring device in bipolar disorder (BD), as well as the intervention's effectiveness in reducing suicidal ideation through improved sleep quality and duration.</AbstractText><AbstractText Label="METHODS">Participants (N=13) with BD received 4 sessions of cognitive-behavioral therapy for sleep disturbance and completed assessments of the intervention and sleep device acceptability, mood, suicidal ideation, and sleep at pretreatment and posttreatment.</AbstractText><AbstractText Label="RESULTS">Feasibility and acceptability of the intervention were high at both pretreatment and posttreatment and did not significantly change by the intervention's conclusion, although participants reported being significantly more likely to recommend the intervention to others at posttreatment. The sleep device was easy to understand, wear, and did not interfere with participants' sleep. Suicidal ideation and depressive symptoms significantly decreased from pretreatment to posttreatment (P&lt;0.05). There were small, but not significant, improvements in the percentage of time spent in stable sleep and total average nightly sleep.</AbstractText><AbstractText Label="CONCLUSION">The potential of this intervention for reducing suicidal ideation and improving sleep is promising, but future research is warranted.</AbstractText><CopyrightInformation>Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sylvia</LastName><ForeName>Louisa G</ForeName><Initials>LG</Initials></Author><Author ValidYN="Y"><LastName>Janos</LastName><ForeName>Jessica A</ForeName><Initials>JA</Initials></Author><Author ValidYN="Y"><LastName>Pegg</LastName><ForeName>Samantha L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Montana</LastName><ForeName>Rebecca E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>Alexandra K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>Andrew A</ForeName><Initials>AA</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F31 MH116557</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 MH091182</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychiatr Pract</MedlineTA><NlmUniqueID>100901141</NlmUniqueID><ISSNLinking>1527-4160</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003419" MajorTopicYN="Y">Crisis Intervention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="Y">Sleep</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059020" MajorTopicYN="Y">Suicidal Ideation</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have no conflicts of interest in direct application to this study or the device to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>3</Day><Hour>14</Hour><Minute>10</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>9</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33656816</ArticleId><ArticleId IdType="doi">10.1097/PRA.0000000000000528</ArticleId><ArticleId IdType="pii">00131746-202103000-00005</ArticleId><ArticleId IdType="pmc">PMC7935402</ArticleId><ArticleId IdType="mid">NIHMS1661225</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pompili M, Innamorati M, Raja M, et al. Suicide risk in depression and bipolar disorder: do impulsiveness-aggressiveness and pharmacotherapy predict suicidal intent? Neuropsychiatr Dis Treat. 2008;4:247–255.</Citation></Reference><Reference><Citation>Fountoulakis KN, Gonda X, Siamouli M, et al. Psychotherapeutic intervention and suicide risk reduction in bipolar disorder: a review of the evidence. J Affect Disord. 2009;113:21–29.</Citation></Reference><Reference><Citation>Goldstein TR, Bridge JA, Brent DA. Sleep disturbance preceding completed suicide in adolescents. J Consult Clin Psychol. 2008;76:84–91.</Citation></Reference><Reference><Citation>Harvey AG, Kaplan KA, Soehner A. Interventions for sleep disturbance in bipolar disorder. Sleep Med Clin. 2015;10:101–105.</Citation></Reference><Reference><Citation>Posner K, Brown GK, Stanley B, et al. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011;168:1266–1277.</Citation></Reference><Reference><Citation>Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389.</Citation></Reference><Reference><Citation>Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20:97–170.</Citation></Reference><Reference><Citation>Beck JS. Cognitive Behavior Therapy: Basics and Beyond, 2nd edition. New York, NY: Guilford Press; 2011.</Citation></Reference><Reference><Citation>Gold AK, Sylvia LG. The role of sleep in bipolar disorder. Nat Sci Sleep. 2016;8:207–214.</Citation></Reference><Reference><Citation>Morin CM, Blais F, Savard J. Are changes in beliefs and attitudes about sleep related to sleep improvements in the treatment of insomnia? Behav Res Ther. 2002;40:741–752.</Citation></Reference><Reference><Citation>Yang CM, Lin SC, Hsu SC, et al. Maladaptive sleep hygiene practices in good sleepers and patients with insomnia. J Health Psychol. 2010;15:147–155.</Citation></Reference><Reference><Citation>Thomas RJ, Mietus JE, Peng CK, et al. An electrocardiogram-based technique to assess cardiopulmonary coupling during sleep. Sleep. 2002;28:1151–1161.</Citation></Reference><Reference><Citation>Miller IW, Norman WH, Bishop SB, et al. The Modified Scale for Suicidal Ideation: reliability and validity. J Consult Clin Psychol. 1986;54:724–725.</Citation></Reference><Reference><Citation>Young RC, Biggs JT, Ziegler VE, et al. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.</Citation></Reference><Reference><Citation>Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep. 1991;14:540–545.</Citation></Reference><Reference><Citation>Kraemer HC. Is it time to ban the P value? JAMA Psychiatry. 2019;76:1219–1220.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31840225</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>11</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>141</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>02</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Three-year longitudinal cognitive functioning in patients recently diagnosed with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>98-109</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.13141</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The longitudinal course of neuropsychological functioning after the first manic episode in bipolar disorder is unknown. The present study evaluated cognitive change in bipolar disorder in the first 3 years after the initial manic episode.</AbstractText><AbstractText Label="METHODS">Ninety-one newly diagnosed patients with bipolar disorder and 61 demographically similar healthy participants received a neuropsychological evaluation assessing multiple cognitive domains at baseline, 1-year, and 3-year time points. Patients also received clinical assessments including mood ratings at all time points.</AbstractText><AbstractText Label="RESULTS">Patients showed deficits in all domains at baseline, but similar longitudinal trajectories across time relative to healthy participants in most cognitive domains. For processing speed, patients showed more gains than controls from baseline to 1 year, but these gains stabilized thereafter. Patients with alcohol/substance abuse showed an initial delay but subsequent recovery in executive functioning. Patients who discontinued antipsychotic treatment showed better cognitive outcomes in verbal memory.</AbstractText><AbstractText Label="CONCLUSION">Appropriately treated patients with bipolar disorder showed favorable cognitive outcome in the first 3 years after experiencing an initial manic episode, arguing against cognitive neuroprogression at this stage of the illness. Discontinuation of antipsychotic treatment may be associated with better cognitive outcomes, but clarification of the role of antipsychotics on cognitive functioning requires further investigation.</AbstractText><CopyrightInformation>© 2019 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>I J</ForeName><Initials>IJ</Initials><Identifier Source="ORCID">0000-0001-5107-3339</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>British Columbia Mental Health and Substance Use Services Research Institute, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qian</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basivireddy</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chakrabarty</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Centre for Health Evaluation and Outcome Sciences, Vancouver, BC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>R W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>L N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>DC9900205</GrantID><Agency>AstraZeneca Canada</Agency><Country>International</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>12</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Acta Psychiatr Scand. 2020 Feb;141(2):95-97</RefSource><PMID Version="1">31953857</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">antipsychotic agents</Keyword><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">cognition</Keyword><Keyword MajorTopicYN="Y">memory</Keyword><Keyword MajorTopicYN="Y">neuropsychological tests</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31840225</ArticleId><ArticleId IdType="doi">10.1111/acps.13141</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>Torres IJ, Defreitas VG, Defreitas CM et al. Neurocognitive functioning in patients with bipolar I disorder recently recovered from a first manic episode. J Clin Psychiatry 2010;71:1234-1242.</Citation></Reference><Reference><Citation>Lee RS, Hermens DF, Scott J et al. A meta-analysis of neuropsychological functioning in first-episode bipolar disorders. J Psychiatr Res 2014;57:1-11.</Citation></Reference><Reference><Citation>Daglas R, Yucel M, Cotton S, Allott K, Hetrick S, Berk M. Cognitive impairment in first-episode mania: a systematic review of the evidence in the acute and remission phases of the illness. Int. J Bipolar Disord 2015;3:9-015-0024-2. eCollection.</Citation></Reference><Reference><Citation>Macneil CA, Hasty MK, Berk M et al. Psychological needs of adolescents in the early phase of bipolar disorder: Implications for early intervention. Early Interv Psychiatry 2011;5:100-107.</Citation></Reference><Reference><Citation>Torres IJ, DeFreitas CM, DeFreitas VG et al. Relationship between cognitive functioning and 6-month clinical and functional outcome in patients with first manic episode bipolar I disorder. Psychol Med 2011;41:971-982.</Citation></Reference><Reference><Citation>Szmulewicz AG, Valerio MP, Lomastro J et al. Neurocognitive functioning in first-episode Bipolar Disorder: Relationship with functional status. J Affect Disord 2018;228:97-100.</Citation></Reference><Reference><Citation>Mackala SA, Torres IJ, Kozicky J, Michalak EE, Yatham LN. Cognitive performance and quality of life early in the course of bipolar disorder. J Affect Disord 2014;168:119-124.</Citation></Reference><Reference><Citation>Sole B, Jimenez E, Torrent C et al. Cognitive impairment in bipolar disorder: treatment and prevention strategies. Int J Neuropsychopharmacol 2017;20:670-680.</Citation></Reference><Reference><Citation>Lewandowski KE, Cohen BM, Ongur D. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder. Psychol Med 2011;41:225-241.</Citation></Reference><Reference><Citation>Kapczinski F, Dias VV, Kauer-Sant'Anna M et al. Clinical implications of a staging model for bipolar disorders. Expert Rev Neurother 2009;9:957-966.</Citation></Reference><Reference><Citation>Post RM. Mechanisms of illness progression in the recurrent affective disorders. Neurotox Res 2010;18:256-271.</Citation></Reference><Reference><Citation>Vieta E, Reinares M, Rosa AR. Staging bipolar disorder. Neurotox Res 2011;19:279-285.</Citation></Reference><Reference><Citation>Berk M, Berk L, Dodd S et al. Stage managing bipolar disorder. Bipolar Disord 2014;16:471-477.</Citation></Reference><Reference><Citation>Berk M, Post R, Ratheesh A et al. Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry 2017;16:236-244.</Citation></Reference><Reference><Citation>Samame C, Martino DJ, Strejilevich SA. Longitudinal course of cognitive deficits in bipolar disorder: a meta-analytic study. J Affect Disord 2014;164:130-138.</Citation></Reference><Reference><Citation>Strejilevich SA, Samame C, Martino DJ. The trajectory of neuropsychological dysfunctions in bipolar disorders: a critical examination of a hypothesis. J Affect Disord 2015;175:396-402.</Citation></Reference><Reference><Citation>Martino DJ, Samame C, Marengo E, Igoa A, Strejilevich SA. A critical overview of the clinical evidence supporting the concept of neuroprogression in bipolar disorder. Psychiatry Res 2016;235:1-6.</Citation></Reference><Reference><Citation>Bora E, Ozerdem A. Meta-analysis of longitudinal studies of cognition in bipolar disorder: comparison with healthy controls and schizophrenia. Psychol Med 2017;47:2753-2766.</Citation></Reference><Reference><Citation>Sanchez-Morla EM, Lopez-Villarreal A, Jimenez-Lopez E et al. Impact of number of episodes on neurocognitive trajectory in bipolar disorder patients: a 5-year follow-up study. Psychol Med 2019;49:1299-1307.</Citation></Reference><Reference><Citation>Torres IJ, Kozicky J, Popuri S et al. 12-Month Longitudinal Cognitive Functioning in Patients Recently Diagnosed with Bipolar Disorder. Bipolar Disord 2014;16:159-171.</Citation></Reference><Reference><Citation>Daglas R, Allott K, Yucel M et al. The trajectory of cognitive functioning following first episode mania: A 12-month follow-up study. Aust N Z J Psychiatry 2016;50:1186-1197.</Citation></Reference><Reference><Citation>Demmo C, Lagerberg TV, Aminoff SR et al. Course of neurocognitive function in first treatment bipolar I disorder: One-year follow-up study. Psychiatry Res 2017;249:286-292.</Citation></Reference><Reference><Citation>Smucny J, Lesh TA, Iosif AM, Niendam TA, Tully LM, Carter CS. Longitudinal stability of cognitive control in early psychosis: Nondegenerative deficits across diagnoses. J Abnorm Psychol 2018;127:781-788.</Citation></Reference><Reference><Citation>Kozicky J, Torres IJ, Silveira LE, Bond DJ, Lam RW, Yatham LN. Cognitive change in the year after a first manic episode: Association between clinical outcome and cognitive performance early in the course of bipolar I disorder. J Clin Psychiatry 2014;75:e587-e593.</Citation></Reference><Reference><Citation>Demmo C, Lagerberg TV, Kvitland LR et al. Neurocognitive functioning, clinical course and functional outcome in first-treatment bipolar I disorder patients with and without clinical relapse: A 1-year follow-up study. Bipolar Disord 2018;20:228-237.</Citation></Reference><Reference><Citation>Kozicky JM, McGirr A, Bond DJ et al. Neuroprogression and episode recurrence in bipolar I disorder: A study of gray matter volume changes in first-episode mania and association with clinical outcome. Bipolar Disord 2016;18:511-519.</Citation></Reference><Reference><Citation>Yatham LN, Kauer-Sant'Anna M, Bond DJ, Lam RW, Torres I. Course and outcome after the first manic episode in patients with bipolar disorder: Prospective 12-month data from the Systematic Treatment Optimization Program For Early Mania project. Can J Psychiatry 2009;54:105-112.</Citation></Reference><Reference><Citation>Sheehan DV, Lecrubier Y, Sheehan KH et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl 20):22-33; quiz 34-57.</Citation></Reference><Reference><Citation>Torres IJ, Boudreau VG, Yatham LN. Neuropsychological functioning in euthymic bipolar disorder: a meta-analysis. Acta Psychiatr Scand Suppl 2007;434:17-26.</Citation></Reference><Reference><Citation>Bora E, Yucel M, Pantelis C. Cognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord 2009;113:1-20.</Citation></Reference><Reference><Citation>Yatham LN, Torres IJ, Malhi GS et al. The international society for bipolar disorders-battery for assessment of neurocognition (ISBD-BANC). Bipolar Disord 2010;12:351-363.</Citation></Reference><Reference><Citation>Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P. Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 1994;5:266-281.</Citation></Reference><Reference><Citation>Nuechterlein KH, Green MF, Kern RS et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 2008;165:203-213.</Citation></Reference><Reference><Citation>Burdick KE, Goldberg TE, Cornblatt BA et al. The MATRICS consensus cognitive battery in patients with bipolar I disorder. Neuropsychopharmacology 2011;36:1587-1592.</Citation></Reference><Reference><Citation>Bo Q, Mao Z, Li X, Wang Z, Wang C, Ma X. Use of the MATRICS consensus cognitive battery (MCCB) to evaluate cognitive deficits in bipolar disorder: A systematic review and meta-analysis. PLoS ONE 2017;12:e0176212.</Citation></Reference><Reference><Citation>Reitan RM, Wolfson D. The Halstead-Reitan neuropsychological test battery. Tucson: Neuropsychology Press; 1985.</Citation></Reference><Reference><Citation>Lezak MD, Lezak MD. Neuropsychological assessment, 4th ed. Oxford: Oxford University Press; 2004.</Citation></Reference><Reference><Citation>Golden CJ, Freshwater SM. Stroop Color and Word Test: A manual for clinical and experimental uses. Chicago: Stoelting; 2002.</Citation></Reference><Reference><Citation>Delis DC, Kramer JH, Kaplan E, Ober BA. California verbal learning test, 2nd ed., Adult Version. San Antonio: The Psychological Corporation; 2000.</Citation></Reference><Reference><Citation>Wechsler D. The Wechsler memory scale. 3rd ed. San Antonio: The Psychological Corporation; 1997.</Citation></Reference><Reference><Citation>Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Consensus and controversies. Bipolar Disord 2005;7(Suppl 3):5-69.</Citation></Reference><Reference><Citation>Yatham LN, Kennedy SH, O'Donovan C et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: Update 2007. Bipolar Disord 2006;8:721-739.</Citation></Reference><Reference><Citation>Yatham LN, Kennedy SH, Schaffer A et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2009. Bipolar Disord 2009;11:225-255.</Citation></Reference><Reference><Citation>Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: Update 2013. Bipolar Disord 2013;15:1-44.</Citation></Reference><Reference><Citation>Yatham LN, Kennedy SH, Parikh SV et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97-170.</Citation></Reference><Reference><Citation>Kaufman AS, Kaufman NL. Kaufman brief intelligence test. 2nd ed. Circle Pines: American Guidance Service; 1990.</Citation></Reference><Reference><Citation>Blair JR, Spreen O. Predicting premorbid IQ: A revision of the National Adult Reading Test. Clin Neuropsychol 1989;3:129-136.</Citation></Reference><Reference><Citation>Martino DJ, Igoa A, Marengo E, Scapola M, Strejilevich SA. Longitudinal relationship between clinical course and neurocognitive impairments in bipolar disorder. J Affect Disord 2018;225:250-255.</Citation></Reference><Reference><Citation>Robinson LJ, Ferrier IN. Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional evidence. Bipolar Disord 2006;8:103-116.</Citation></Reference><Reference><Citation>Levy B, Weiss RD. Cognitive functioning in bipolar and co-occurring substance use disorders: a missing piece of the puzzle. Harv Rev Psychiatry 2009;17:226-230.</Citation></Reference><Reference><Citation>Sanchez-Moreno J, Martinez-Aran A, Colom F et al. Neurocognitive dysfunctions in euthymic bipolar patients with and without prior history of alcohol use. J Clin Psychiatry 2009;70:1120-1127.</Citation></Reference><Reference><Citation>Balanza-Martinez V, Crespo-Facorro B, Gonzalez-Pinto A, Vieta E. Bipolar disorder comorbid with alcohol use disorder: focus on neurocognitive correlates. Front Physiol 2015;6:108.</Citation></Reference><Reference><Citation>Cardoso TA, Bauer IE, Jansen K et al. Effect of alcohol and illicit substance use on verbal memory among individuals with bipolar disorder. Psychiatry Res 2016;243:225-231.</Citation></Reference><Reference><Citation>Torrent C, Martinez-Aran A, Daban C et al. Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry 2011;52:613-622.</Citation></Reference><Reference><Citation>Dias VV, Balanza-Martinez V, Soeiro-de-Souza MG et al. Pharmacological approaches in bipolar disorders and the impact on cognition: a critical overview. Acta Psychiatr Scand 2012;126:315-331.</Citation></Reference><Reference><Citation>Palsson E, Figueras C, Johansson AG et al. Neurocognitive function in bipolar disorder: a comparison between bipolar I and II disorder and matched controls. BMC Psychiatry 2013;13:165-244X-13-165.</Citation></Reference><Reference><Citation>Senturk V, Demirel H, Atbasoglu EC. Cognitive functioning in euthymic bipolar patients on monotherapy with novel antipsychotics or mood stabilizers. Noropsikiyatri Arsivi 2017;54:244-250.</Citation></Reference><Reference><Citation>Jamrozinski K, Gruber O, Kemmer C, Falkai P, Scherk H. Neurocognitive functions in euthymic bipolar patients. Acta Psychiatr Scand 2009;119:365-374.</Citation></Reference><Reference><Citation>Kozicky JM, Torres IJ, Bond DJ, Lam RW, Yatham LN. Comparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder. Int Clin Psychopharmacol 2012;27:91-99.</Citation></Reference><Reference><Citation>Soeiro-DE-Souza MG, Dias VV, Missio G et al. Role of quetiapine beyond its clinical efficacy in bipolar disorder: From neuroprotection to the treatment of psychiatric disorders (Review). Exp Ther Med 2015;9:643-652.</Citation></Reference><Reference><Citation>Arts B, Simons CJ, Drukker M, van Os J. Antipsychotic medications and cognitive functioning in bipolar disorder: moderating effects of COMT Val108/158 Met genotype. BMC Psychiatry 2013;13:63-244X-13-63.</Citation></Reference><Reference><Citation>Flowers SA, Ryan KA, Lai Z, McInnis MG, Ellingrod VL. Interaction between COMT rs5993883 and second generation antipsychotics is linked to decreases in verbal cognition and cognitive control in bipolar disorder. BMC Psychol 2016;4:14-016-0118-3.</Citation></Reference><Reference><Citation>Balanza-Martinez V, Selva G, Martinez-Aran A et al. Neurocognition in bipolar disorders-a closer look at comorbidities and medications. Eur J Pharmacol 2010;626:87-96.</Citation></Reference><Reference><Citation>Omachi Y, Sumiyoshi T. Dose reduction/discontinuation of antipsychotic drugs in psychosis; effect on cognition and functional outcomes. Front Psychiatry 2018;9:447.</Citation></Reference><Reference><Citation>Daglas R, Cotton SM, Allott K et al. A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study. Eur Psychiatry 2016;31:20-28.</Citation></Reference><Reference><Citation>Dandash O, Yucel M, Daglas R et al. Differential effect of quetiapine and lithium on functional connectivity of the striatum in first episode mania. Transl Psychiatry 2018;8:59-018-0108-8.</Citation></Reference><Reference><Citation>Berk M, Dandash O, Daglas R et al. Neuroprotection after a first episode of mania: a randomized controlled maintenance trial comparing the effects of lithium and quetiapine on grey and white matter volume. Transl Psychiatry 2017;7:e1041.</Citation></Reference><Reference><Citation>Torrent C, Reinares M, Martinez-Aran A et al. Affective versus non-affective first episode psychoses: A longitudinal study. J Affect Disord 2018;238:297-304.</Citation></Reference><Reference><Citation>Cotrena C, Branco LD, Ponsoni A, Samame C, Shansis FM, Fonseca RP. Executive functions and memory in bipolar disorders I and II: new insights from meta-analytic results. Acta Psychiatr Scand 2019. https://doi.org/10.1111/acps.13121.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">716530</PMID><DateCompleted><Year>1979</Year><Month>01</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0300-869X</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>1978</Year></PubDate></JournalIssue><Title>Zeitschrift fur klinische Psychologie und Psychotherapie</Title><ISOAbbreviation>Z Klin Psychol Psychother</ISOAbbreviation></Journal><ArticleTitle>[Social behavior and psychosis induction in manic-depressives].</ArticleTitle><Pagination><MedlinePgn>149-60</MedlinePgn></Pagination><Abstract><AbstractText>The social behavior of manic-depressives shows a specific structure of identity, whose consequences for the onset and course of manic-depressive psychosis are investigated. Besides in interactional conduct, group behavior, orientation in values etc. we are mainly interested in the behavior of manic-depressives in social roles. From the point of view of role theory the social behavior especially of monopolar depressives could be described as hypernomic, as it shows an extreme conformity with norms. Situations of opposing or competitive role demands, opposing norms and values therefore are very difficult for manic-depressives to handle. The preponderance of their role identities results in an atrophy of ego-identity and in an increasing dependence on their social roles. This explains why not only the loss but even the endangering of their social roles may result in psychotic states that here are interpreted as crisis of identity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kraus</LastName><ForeName>A</ForeName><Initials>A</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Sozialverhalten und Psychosenauslösung bei Manisch-Depressiven.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Z Klin Psychol Psychother</MedlineTA><NlmUniqueID>1302504</NlmUniqueID><ISSNLinking>0300-869X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004532" MajorTopicYN="N">Ego</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007062" MajorTopicYN="N">Identification, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007063" MajorTopicYN="N">Identity Crisis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012380" MajorTopicYN="Y">Role</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="Y">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1978</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1978</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1978</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">716530</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">696957</PMID><DateCompleted><Year>1978</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-9564</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>1978</Year><Month>Jul</Month></PubDate></JournalIssue><Title>American journal of psychotherapy</Title><ISOAbbreviation>Am J Psychother</ISOAbbreviation></Journal><ArticleTitle>Toward early detection of manic-depressive illness in psychoanalytic patients. I:Patients who later develop a manic illness.</ArticleTitle><Pagination><MedlinePgn>427-39</MedlinePgn></Pagination><Abstract><AbstractText>Patients who eventually display clear signs of bipolar manic-depressive illness may initially be relatively asymptomatic and indistinguishable from classically analyzable cases. Several patients are presented whose subsequent manic decompensation was preceded by a combination of characterological traits (intensity, punning, insensitivity, etc.) whose presence should signal heightened vulnerability to bipolar illness. The family history was often positive for similar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stone</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychother</MedlineTA><NlmUniqueID>0110672</NlmUniqueID><ISSNLinking>0002-9564</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011575" MajorTopicYN="Y">Psychoanalytic Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1978</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1978</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1978</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">696957</ArticleId><ArticleId IdType="doi">10.1176/appi.psychotherapy.1978.32.3.427</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17667735</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2007</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1527-4160</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of psychiatric practice</Title><ISOAbbreviation>J Psychiatr Pract</ISOAbbreviation></Journal><ArticleTitle>Antidepressant-induced hypomania in treatment-resistant depression.</ArticleTitle><Pagination><MedlinePgn>233-7</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors propose that isolated treatment-associated hypomanic episodes in patients with chronic treatment-resistant major depressive disorder are not indicative of true bipolar depression. This proposal is in contrast to most studies that support the notion that antidepressant-induced hypomania reflects an underlying bipolar condition in such depressed patients. However, the patients described in the literature have not had treatment-resistant depression.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Records of 146 patients with treatment-resistant major depression seen at a university-based tertiary referral center were reviewed for evidence of treatment-associated mania or hypomania. Treatment histories, clinical characteristics, and family histories of these patients were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 146 patients, 16 patients had evidenced treatment-induced hypomania or hypomanic-like episodes. The number of antidepressant trials these patients had received ranged from 2 to 13. The hypomanic episodes did not occur with the first antidepressant treatment trial except in one patient. All of the 16 patients had antidepressant treatment trials subsequent to the trial during which they experienced hypomania, but only one of them experienced further episodes of hypomania. In addition, only 1 of the 16 patients had a family history of bipolar disorder, a rate of bipolar family history that is considerably less than we have found among bipolar patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These findings support the concept of antidepressant-induced hypomania presented in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, revised (DSM-IV-TR). However, we argue that this term should be restricted to patients with chronic treatment-resistant major depression who infrequently evidence mania or hypomania.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bader</LastName><ForeName>Cynthia D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dunner</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Psychiatr Pract</MedlineTA><NlmUniqueID>100901141</NlmUniqueID><ISSNLinking>1527-4160</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014861" MajorTopicYN="N" Type="Geographic">Washington</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>10</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>8</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17667735</ArticleId><ArticleId IdType="doi">10.1097/01.pra.0000281483.11946.b5</ArticleId><ArticleId IdType="pii">00131746-200707000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">814073</PMID><DateCompleted><Year>1976</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0015-5721</ISSN><JournalIssue CitedMedium="Print"><Volume>29</Volume><Issue>3</Issue><PubDate><Year>1975</Year></PubDate></JournalIssue><Title>Folia psychiatrica et neurologica japonica</Title><ISOAbbreviation>Folia Psychiatr Neurol Jpn</ISOAbbreviation></Journal><ArticleTitle>Thyroid function levels and thyrotropin responses to TRH administration in manic patients receiving lithium carbonate.</ArticleTitle><Pagination><MedlinePgn>231-7</MedlinePgn></Pagination><Abstract><AbstractText>To determine the pituitary-thyroid dysfunction in the manic patients receiving lithium carbonate, determination of thyroxine concentration, T3 Resin Uptake, thyrotropin concentration in plasma, and thyrotropin responses to administration of TRH, 500 mug i.v., were made. Eight manic patients were examined before and after lithium treatment, 600-1,200 mg daily, for four weeks. Slight reduction in the plasma levels of thyroxine, and slight increase in the plasma thyrotropin levels were seen following lithium treatment. Significantly enhanced thyrotropin responses to TRH administration were found as compared to the results before lithium treatment. It is assumed that lithium salts decrease both output of thyroid hormones and the sensitivity of the thyroid gland to thyrotropin, and that this action of lithium inhibiting the thyroid gland might be related to its anti-manic effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kondo</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Yoshimura</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ochi</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Folia Psychiatr Neurol Jpn</MedlineTA><NlmUniqueID>0372774</NlmUniqueID><ISSNLinking>0015-5721</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5Y5F15120W</RegistryNumber><NameOfSubstance UI="D013973">Thyrotropin-Releasing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-71-5</RegistryNumber><NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013973" MajorTopicYN="Y">Thyrotropin-Releasing Hormone</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1975</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1975</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1975</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">814073</ArticleId><ArticleId IdType="doi">10.1111/j.1440-1819.1975.tb02340.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8543528</PMID><DateCompleted><Year>1996</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0890-8567</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>12</Issue><PubDate><Year>1995</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of the American Academy of Child and Adolescent Psychiatry</Title><ISOAbbreviation>J Am Acad Child Adolesc Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A pilot family study of childhood-onset mania.</ArticleTitle><Pagination><MedlinePgn>1577-83</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To investigate the familial association of attention-deficit hyperactivity disorder (ADHD) and bipolar disorder (BPD) among the first-degree relatives of children with comorbid ADHD and BPD.</AbstractText><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In contrast to a growing body of literature on childhood non-bipolar depression, little is known about childhood BPD. Among the explanations accounting for the lack of recognition and identification of these children is the symptomatic overlap of BPD with ADHD. Family-genetic studies provide information external to the clinical picture and thus are uniquely suited to clarify such issues of diagnostic comorbidity.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Structured diagnostic interviews were used to obtain DSM-III-R psychiatric diagnoses on first-degree relatives (n = 46) of referred children (aged &lt; or = 12 years) satisfying diagnostic criteria for mania using the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Epidemiologic Version (n = 16). For comparison, diagnostic information on the first-degree relatives of non-bipolar ADHD children and control children was examined.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The results show high rates of comorbidity between BPD and ADHD in children and high rates of both BPD and ADHD in the first-degree relatives of these children. Moreover, ADHD and BPD cosegregated among the relatives of children with BPD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These findings, which are consistent with the authors' prior study of children with ADHD, provide family-genetic evidence for the validity of BPD and ADHD when they exist comorbidly in children. Moreover, they suggest that the comorbid condition of ADHD+BPD may be a distinct nosological entity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wozniak</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pediatric Psychopharmacology Unit, Massachusetts General Hospital, Boston 02114, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biederman</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mundy</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Mennin</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Faraone</LastName><ForeName>S V</ForeName><Initials>SV</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH41314-07</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH50657-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Acad Child Adolesc Psychiatry</MedlineTA><NlmUniqueID>8704565</NlmUniqueID><ISSNLinking>0890-8567</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8543528</ArticleId><ArticleId IdType="pii">S0890-8567(09)66346-2</ArticleId><ArticleId IdType="doi">10.1097/00004583-199512000-00007</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23861766</PMID><DateCompleted><Year>2014</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>7</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Cognitive manic symptoms in bipolar disorder associated with polymorphisms in the DAOA and COMT genes.</ArticleTitle><Pagination><MedlinePgn>e67450</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0067450</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Bipolar disorder is characterized by severe mood symptoms including major depressive and manic episodes. During manic episodes, many patients show cognitive dysfunction. Dopamine and glutamate are important for cognitive processing, thus the COMT and DAOA genes that modulate the expression of these neurotransmitters are of interest for studies of cognitive function.</AbstractText><AbstractText Label="METHODOLOGY" NlmCategory="METHODS">Focusing on the most severe episode of mania, a factor was found with the combined symptoms of talkativeness, distractibility, and thought disorder, considered a cognitive manic symptoms (CMS) factor. 488 patients were genotyped, out of which 373 (76%) had talkativeness, 269 (55%) distractibility, and 372 (76%) thought disorder. 215 (44%) patients were positive for all three symptoms, thus showing CMS (Table 1). As population controls, 1,044 anonymous blood donors (ABD) were used. Case-case and case-control design models were used to investigate genetic associations between cognitive manic symptoms in bipolar 1 disorder and SNPs in the COMT and DAOA genes. [Table: see text].</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The finding of this study was that cognitive manic symptoms in patients with bipolar 1 disorder was associated with genetic variants in the DAOA and COMT genes. Nominal association for DAOA SNPs and COMT SNPs to cognitive symptoms factor in bipolar 1 disorder was found in both allelic (Table 2) and haplotypic (Table 3) analyses. Genotypic association analyses also supported our findings. However, only one association, when CMS patients were compared to ABD controls, survived correction for multiple testing by max (T) permutation. Data also suggested interaction between SNPs rs2391191 in DAOA and rs5993883 in COMT in the case-control model. [Table: see text] [Table: see text].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Identifying genes associated with cognitive functioning has clinical implications for assessment of prognosis and progression. Our finding are consistent with other studies showing genetic associations between the COMT and DAOA genes and impaired cognition both in psychiatric disorders and in the general population.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hukic</LastName><ForeName>Dzana Sudic</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Neurogenetics Unit, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. dzana.hukic@ki.se</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frisén</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Backlund</LastName><ForeName>Lena</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lavebratt</LastName><ForeName>Catharina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Landén</LastName><ForeName>Mikael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Träskman-Bendz</LastName><ForeName>Lil</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Edman</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Schalling</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Ösby</LastName><ForeName>Urban</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>07</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C475071">DAOA protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="Y">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015810" MajorTopicYN="N">Linkage Disequilibrium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>02</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>05</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23861766</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0067450</ArticleId><ArticleId IdType="pii">PONE-D-13-06637</ArticleId><ArticleId IdType="pmc">PMC3702534</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2009 Jul 16;361(3):302-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19605837</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Brain Res. 2005 Jun;163(3):352-60</Citation><ArticleIdList><ArticleId IdType="pubmed">15654584</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2012 Apr;125(4):309-17</Citation><ArticleIdList><ArticleId IdType="pubmed">21848702</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 May 15;69(10):1006-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21215384</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):587-92</Citation><ArticleIdList><ArticleId IdType="pubmed">9012828</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Mar 1;73(2-3):257-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15653269</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Feb;9(2):203-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14966479</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2004 Jan;9(1):87-92; image 5</Citation><ArticleIdList><ArticleId IdType="pubmed">14699445</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Aug-Sep;13(5-6):500-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22017219</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2009 Nov 24;164(1):72-87</Citation><ArticleIdList><ArticleId IdType="pubmed">19446012</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Genet. 2007 Feb;120(6):889-906</Citation><ArticleIdList><ArticleId IdType="pubmed">17006672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Mar;13(2):198-207</Citation><ArticleIdList><ArticleId IdType="pubmed">21443574</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Apr;63(4):366-73</Citation><ArticleIdList><ArticleId IdType="pubmed">16585465</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2012 Oct;262(7):549-56</Citation><ArticleIdList><ArticleId IdType="pubmed">22454242</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2010 Dec;122(6):507-15</Citation><ArticleIdList><ArticleId IdType="pubmed">20712826</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2009 Oct 5;150B(7):1007-12</Citation><ArticleIdList><ArticleId IdType="pubmed">19089835</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2011 Apr;41(4):779-88</Citation><ArticleIdList><ArticleId IdType="pubmed">20667170</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Neurobiol. 2002 Apr;25(2):191-212</Citation><ArticleIdList><ArticleId IdType="pubmed">11936559</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1988 Jul;45(7):609-15</Citation><ArticleIdList><ArticleId IdType="pubmed">3382320</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2003 May;72(5):1131-40</Citation><ArticleIdList><ArticleId IdType="pubmed">12647258</ArticleId></ArticleIdList></Reference><Reference><Citation>Cereb Cortex. 1999 Jan-Feb;9(1):20-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10022492</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Pharmacol Toxicol. 2002;42:165-79</Citation><ArticleIdList><ArticleId IdType="pubmed">11807169</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Hum Genet. 2006 Jun;14(6):660-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16721402</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2002 Mar;26(3):368-75</Citation><ArticleIdList><ArticleId IdType="pubmed">11850151</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Psychiatry Clin Pract. 2012 Sep;16(3):170-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22432978</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Nov;162(11):2101-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16263850</ArticleId></ArticleIdList></Reference><Reference><Citation>Afr J Psychiatry (Johannesbg). 2010 Sep;13(4):297-301</Citation><ArticleIdList><ArticleId IdType="pubmed">20957330</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2004 Jul 1;128B(1):61-4</Citation><ArticleIdList><ArticleId IdType="pubmed">15211633</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2010 Sep;15(9):918-27</Citation><ArticleIdList><ArticleId IdType="pubmed">19417742</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2008 Jul;13(7):658-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18560437</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Dec;3(6):284-98</Citation><ArticleIdList><ArticleId IdType="pubmed">11843779</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Sep 1;46(5):650-61</Citation><ArticleIdList><ArticleId IdType="pubmed">10472417</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Sep 1;64(5):438-42</Citation><ArticleIdList><ArticleId IdType="pubmed">18466879</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2010 Jun 5;153B(4):847-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20301110</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Sep;95(1-3):174-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17630258</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6917-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11381111</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Bull. 2001 Jul 15;55(5):631-40</Citation><ArticleIdList><ArticleId IdType="pubmed">11576760</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2005 Jan 15;21(2):263-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15297300</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz J Psychiatry. 2009 Jun;31(2):171-80</Citation><ArticleIdList><ArticleId IdType="pubmed">19578691</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Aug 1;56(3):169-76</Citation><ArticleIdList><ArticleId IdType="pubmed">15271585</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurochem. 2007 Oct;103(2):840-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17897358</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hum Genet. 2007 Sep;81(3):559-75</Citation><ArticleIdList><ArticleId IdType="pubmed">17701901</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2007 Dec;9(6):504-11</Citation><ArticleIdList><ArticleId IdType="pubmed">18221632</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1994;20(1):103-19</Citation><ArticleIdList><ArticleId IdType="pubmed">8197409</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Apr;159(4):652-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11925305</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1998 Jul;3(4):346-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9702745</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2010 Dec;122(6):499-506</Citation><ArticleIdList><ArticleId IdType="pubmed">20637012</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 1996 May;14(5):301-7</Citation><ArticleIdList><ArticleId IdType="pubmed">8703299</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 Jan;155(1):30-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9433335</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neurobiol. 2001 Sep;65(1):1-105</Citation><ArticleIdList><ArticleId IdType="pubmed">11369436</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 1998 Jul;3(4):342-5</Citation><ArticleIdList><ArticleId IdType="pubmed">9702744</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Feb;136(3):370-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22222175</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Sep;60(9):889-96</Citation><ArticleIdList><ArticleId IdType="pubmed">12963670</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21177317</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>27</Day></DateCompleted><DateRevised><Year>2011</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2393</ISSN><JournalIssue CitedMedium="Internet"><Volume>105</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Jan</Month></PubDate></JournalIssue><Title>QJM : monthly journal of the Association of Physicians</Title><ISOAbbreviation>QJM</ISOAbbreviation></Journal><ArticleTitle>Lithium-induced hyperthyroidism, thyrotoxicosis and mania: a case report.</ArticleTitle><Pagination><MedlinePgn>83-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/qjmed/hcq234</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bandyopadhyay</LastName><ForeName>Debabrata</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Cleveland Clinic Foundation, Internal Medicine, NA 10 Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nielsen</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>12</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>QJM</MedlineTA><NlmUniqueID>9438285</NlmUniqueID><ISSNLinking>1460-2393</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006980" MajorTopicYN="N">Hyperthyroidism</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013971" MajorTopicYN="N">Thyrotoxicosis</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21177317</ArticleId><ArticleId IdType="pii">hcq234</ArticleId><ArticleId IdType="doi">10.1093/qjmed/hcq234</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">14533138</PMID><DateCompleted><Year>2003</Year><Month>11</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-6222</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><Issue>7</Issue><PubDate><Year>2003</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Human psychopharmacology</Title><ISOAbbreviation>Hum Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Quetiapine as adjunctive treatment of a case of rapid-cycling bipolar disorder with comorbidity.</ArticleTitle><Pagination><MedlinePgn>559-60</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stratta</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>de Cataldo</LastName><ForeName>Stefano</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mancini</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Gianfelice</LastName><ForeName>Daniela</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Rinaldi</LastName><ForeName>Osvaldo</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Psychopharmacol</MedlineTA><NlmUniqueID>8702539</NlmUniqueID><ISSNLinking>0885-6222</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>12</Month><Day>3</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">14533138</ArticleId><ArticleId IdType="doi">10.1002/hup.523</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">23764381</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>150</Volume><Issue>2</Issue><PubDate><Year>2013</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Verbal episodic memory deficits in remitted bipolar patients: a combined behavioural and fMRI study.</ArticleTitle><Pagination><MedlinePgn>430-40</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2013.04.036</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-0327(13)00337-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Episodic memory deficits affect the majority of patients with bipolar disorder (BD).</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">The study investigates episodic memory performance through different approaches, including behavioural measures, physiological parameters, and the underlying functional activation patterns with functional neuroimaging (fMRI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">26 Remitted BD patients and a matched group of healthy controls underwent a verbal episodic memory test together with monitored autonomic response, psychopathological ratings and functional magnetic resonance imaging (fMRI) during the verbal episodic memory test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared to healthy controls, BD patients performed significantly worse during the episodic memory task. The results further indicate that verbal episodic memory deficits in BD are associated with abnormal functional activity patterns in frontal, occipital and limbic regions, and an increase in stress parameters.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">We aimed to minimise sample heterogeneity by setting clear criteria for remission, based on the scores of a depression (BDI II) and mania scale (BRMAS) and on the DSM IV criteria. However, our patients were not symptom-free and scored higher on BDI II scores than the control group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The results are of interest for the treatment of cognitive symptoms in BD patients, as persistent cognitive impairment may hamper full rehabilitation.</AbstractText><CopyrightInformation>Copyright © 2013 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Oertel-Knöchel</LastName><ForeName>Viola</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Laboratory of Neurophysiology and Neuroimaging, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University, Frankfurt/Main, Germany. viola.Oertel@kgu.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinke</LastName><ForeName>Britta</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Feddern</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Knake</LastName><ForeName>Annika</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Knöchel</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Prvulovic</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Fußer</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Karakaya</LastName><ForeName>Tarik</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Loellgen</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Freitag</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pantel</LastName><ForeName>Johannes</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Linden</LastName><ForeName>David E J</ForeName><Initials>DE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>06</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061212" MajorTopicYN="Y">Memory, Episodic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorders</Keyword><Keyword MajorTopicYN="N">Cognitive performance</Keyword><Keyword MajorTopicYN="N">Episodic memory</Keyword><Keyword MajorTopicYN="N">Neuroimaging</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>01</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>04</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>6</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23764381</ArticleId><ArticleId IdType="pii">S0165-0327(13)00337-6</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2013.04.036</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3147494</PMID><DateCompleted><Year>1989</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0039-9450</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>8</Issue><PubDate><Year>1988</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme</Title><ISOAbbreviation>Tanpakushitsu Kakusan Koso</ISOAbbreviation></Journal><ArticleTitle>[Biochemistry of manic-depressive disorder (II)--neuropeptides and neuroendocrinological research].</ArticleTitle><Pagination><MedlinePgn>1300-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Shibuya</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Tanpakushitsu Kakusan Koso</MedlineTA><NlmUniqueID>0413762</NlmUniqueID><ISSNLinking>0039-9450</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009479">Neuropeptides</NameOfSubstance></Chemical><Chemical><RegistryNumber>5Y5F15120W</RegistryNumber><NameOfSubstance UI="D013973">Thyrotropin-Releasing Hormone</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-71-5</RegistryNumber><NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007030" MajorTopicYN="N">Hypothalamo-Hypophyseal System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009479" MajorTopicYN="N">Neuropeptides</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010913" MajorTopicYN="N">Pituitary-Adrenal System</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013973" MajorTopicYN="N">Thyrotropin-Releasing Hormone</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>36</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3147494</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25446463</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>220</Volume><Issue>3</Issue><PubDate><Year>2014</Year><Month>Dec</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Is research on borderline personality disorder underfunded by the National Institute of Health?</ArticleTitle><Pagination><MedlinePgn>941-4</MedlinePgn></Pagination><Abstract><AbstractText>The relationship between bipolar disorder and borderline personality disorder has generated intense interest. Similar to patients with bipolar disorder, patients with borderline personality disorder are frequently hospitalized, are chronically unemployed, abuse substances, attempt and commit suicide. However, one significant difference between the two disorders is that patients with borderline personality disorder are often viewed negatively by mental health professionals. In the present paper we examined whether this negative bias against borderline personality disorder might be reflected in the level of research funding on the disorder. We searched the National Institute of Health (NIH) Research Portfolio Online Portfolio Reporting Tool (RePORT) for the past 25 years and compared the number of grants funded and the total amount of funding for borderline personality disorder and bipolar disorder. The yearly mean number of grants receiving funding was significantly higher for bipolar disorder than for borderline personality disorder. Results were the same when focusing on newly funded grants. For every year since 1990 more grants were funded for bipolar disorder than borderline personality disorder. Summed across all 25 years, the level of funding for bipolar disorder was more than 10 times greater than the level of funding for borderline personality disorder ($622 million vs. $55 million). These findings suggest that the level of NIH research funding for borderline personality disorder is not commensurate with the level of psychosocial morbidity, mortality, and health expenditures associated with the disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gazarian</LastName><ForeName>Doug</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009316" MajorTopicYN="N">National Institutes of Health (U.S.)</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012109" MajorTopicYN="N">Research Support as Topic</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>09</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>09</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25446463</ArticleId><ArticleId IdType="pii">S0165-1781(14)00819-1</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2014.09.021</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6582772</PMID><DateCompleted><Year>1984</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2008</Year><Month>02</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-1591</ISSN><JournalIssue CitedMedium="Print"><Volume>310</Volume><PubDate><Year>1983</Year></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica. Supplementum</Title><ISOAbbreviation>Acta Psychiatr Scand Suppl</ISOAbbreviation></Journal><ArticleTitle>Multi-axial classification of depression: MULTI-CLAD-2 case record system.</ArticleTitle><Pagination><MedlinePgn>85-102</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rafaelsen</LastName><ForeName>O J</ForeName><Initials>OJ</Initials></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bech</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Clemmesen</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Gjerris</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kastrup</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kramp</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Acta Psychiatr Scand Suppl</MedlineTA><NlmUniqueID>0370365</NlmUniqueID><ISSNLinking>0065-1591</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1983</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1983</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1983</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6582772</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19178948</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>117</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Efficacy of high frequency (rapid) suprathreshold repetitive transcranial magnetic stimulation of right prefrontal cortex in bipolar mania: a randomized sham controlled study.</ArticleTitle><Pagination><MedlinePgn>146-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2008.12.020</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the efficacy of adjunctive right prefrontal high-frequency suprathreshold rTMS treatment in bipolar affective disorder, mania patients as compared to sham stimulation.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">41 right handed bipolar mania patients were randomized to receive daily sessions of active or sham rTMS (20 Hz, 110% of MT, 20 trains, 10 s intertrain interval) over the right dorsolateral prefrontal cortex for 10 days. Mania was rated using Young Mania Rating Scale (YMRS) and Clinical Global Impression (CGI) at baseline, and after 5th and 10th rTMS.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">For YMRS scores, repeated measures ANOVA showed a significant effect of treatment over time as shown by interaction effect (F=12.95, df=1.51/58.94, p&lt;0.001, Greenhouse-Geisser corrected). For CGI-S, repeated measures ANOVA showed a significant interaction effect of treatment over time (F=5.34, df=1.36/53.01, p=0.016, Greenhouse-Geisser corrected).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">High-frequency supra-threshold right prefrontal rTMS in bipolar, mania patients was well tolerated and found to be effective as add-on to standard pharmacotherapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Praharaj</LastName><ForeName>Samir Kumar</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Central Institute of Psychiatry, Kanke, Ranchi, Jharkhand, India, 834006. samirpsyche@yahoo.co.in</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram</LastName><ForeName>Daya</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Arora</LastName><ForeName>Manu</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016037" MajorTopicYN="N">Single-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>09</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>12</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>1</Month><Day>31</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19178948</ArticleId><ArticleId IdType="pii">S0165-0327(09)00004-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2008.12.020</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18849896</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8529</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>Sep</Month></PubDate></JournalIssue><Title>CNS spectrums</Title><ISOAbbreviation>CNS Spectr</ISOAbbreviation></Journal><ArticleTitle>The contemporary face of bipolar illness: complex diagnostic and therapeutic challenges.</ArticleTitle><Pagination><MedlinePgn>763-74, 777-9</MedlinePgn></Pagination><Abstract><AbstractText>Manic depression, or bipolar disorder, is a multifaceted illness with an inevitably complex treatment. The current article summarizes the current status of our knowledge and practice concerning its diagnosis and treatment. While the prototypic clinical picture concerns the "classic" bipolar disorder, today mixed episodes with incomplete recovery and significant psychosocial impairment are more frequent. The clinical picture of these mixed episodes is variable, eludes contemporary classification systems, and possibly includes a constellation of mental syndromes currently classified elsewhere. Treatment includes the careful combination of lithium, antiepileptics, atypical antipsychotics, and antidepressants, but not all of the agents in these broad categories are effective for the treatment of bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fountoulakis</LastName><ForeName>Konstantinos N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Third Department of Psychiatry, Aristotle University of Thessaloniki, Greece. kfount@med.auth.gr</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Spectr</MedlineTA><NlmUniqueID>9702877</NlmUniqueID><ISSNLinking>1092-8529</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018849" MajorTopicYN="N">Controlled Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>240</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>10</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18849896</ArticleId><ArticleId IdType="doi">10.1017/s1092852900013894</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26812917</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1875-5666</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2016</Year></PubDate></JournalIssue><Title>Current molecular medicine</Title><ISOAbbreviation>Curr Mol Med</ISOAbbreviation></Journal><ArticleTitle>The Comorbidity of Bipolar Disorder and Migraine: The Role of Inflammation and Oxidative and Nitrosative Stress.</ArticleTitle><Pagination><MedlinePgn>179-86</MedlinePgn></Pagination><Abstract><AbstractText>Comorbid migraine in the course of bipolar disorder has been reported as highly prevalent and associated with increased morbidity. Patients with bipolar disorder and comorbid migraine tend to present with higher rates of rapid cycling, increased number of depressive episodes, more severe depression, and increased suicidality when compared to subjects with bipolar disorder alone. Both conditions display similar clinical features, such as relapsing-recovering presentation, and vulnerability to psychological and physical stress. Clinical implications of this association have been well established, however the biological underpinnings involved in both conditions remain poorly understood. Inflammation and oxidative and nitrosative stress seem to play a role as mediators in the cross-sensitization between bipolar disorder and migraine. Therefore, the present study aims to review the role of inflammation, oxidative and nitrosative stress as underlying mechanisms in the natural history of bipolar disorder comorbid with migraine. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>da Costa</LastName><ForeName>S C</ForeName><Initials>SC</Initials></Author><Author ValidYN="Y"><LastName>Passos</LastName><ForeName>I C</ForeName><Initials>IC</Initials></Author><Author ValidYN="Y"><LastName>Réus</LastName><ForeName>G Z</ForeName><Initials>GZ</Initials></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>A F</ForeName><Initials>AF</Initials></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Quevedo</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Texas Science Center at Houston, 1941 East Road, Houston, Texas 77054, USA. joao.l.dequevedo@uth.tmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 085667</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Curr Mol Med</MedlineTA><NlmUniqueID>101093076</NlmUniqueID><ISSNLinking>1566-5240</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="Y">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008881" MajorTopicYN="N">Migraine Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015538" MajorTopicYN="N">Nitrosation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018384" MajorTopicYN="Y">Oxidative Stress</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>01</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>01</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26812917</ArticleId><ArticleId IdType="pii">CMM-EPUB-73249</ArticleId><ArticleId IdType="doi">10.2174/1566524016666160126144440</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16511726</PMID><DateCompleted><Year>2006</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0303-4259</ISSN><JournalIssue CitedMedium="Print"><Volume>33 Suppl 1</Volume><PubDate><Year>2006</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Psychiatrische Praxis</Title><ISOAbbreviation>Psychiatr Prax</ISOAbbreviation></Journal><ArticleTitle>[Treatment of bipolar mania with risperidone].</ArticleTitle><Pagination><MedlinePgn>S12-7</MedlinePgn></Pagination><Abstract><AbstractText>In patients with bipolar disorder antipsychotics are frequently used for the treatment of acute manic episodes, either in monotherapy, in addition to a mood stabilizer or in patients refractory to lithium or other mood stabilizers. However, a number of studies demonstrated that the use of conventional neuroleptics is restricted -- particularly for long-term treatment and relapse prevention in bipolar disorder -- due to their side effect profile and their potential to induce or worsen depressive symptoms. In contrast, atypical antipsychotics have a better tolerability profile and fewer extrapyramidal side effects. A number of clinical studies showed that the atypical antipsychotic risperidone was effective and well tolerated in the treatment of bipolar mania. This was reported both for the treatment of acute episodes and for the maintenance therapy. Recent data suggest that risperidone can be used effectively either in addition to or even instead of a mood stabilizer. This review summarizes the available literature on risperidone in the treatment of bipolar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schreiner</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>aschrein@jacde.jnj.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Behandlung manischer Episoden bei bipolaren Störungen mit Risperidon.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychiatr Prax</MedlineTA><NlmUniqueID>0423204</NlmUniqueID><ISSNLinking>0303-4259</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>60</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>7</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16511726</ArticleId><ArticleId IdType="doi">10.1055/s-2005-867024</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24217865</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2044-8341</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Psychology and psychotherapy</Title><ISOAbbreviation>Psychol Psychother</ISOAbbreviation></Journal><ArticleTitle>Impulsivity and risk for mania: towards greater specificity.</ArticleTitle><Pagination><MedlinePgn>401-12</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.2044-8341.2012.02078.x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Impulsivity is elevated among people diagnosed with bipolar disorder, and recent evidence suggests that impulsivity can predict onset among those at risk for the disorder. Impulsivity, though, is a broad construct.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The goal of this study was to examine whether some aspects of impulsivity are more correlated with risk for mania than others. We hypothesized that risk for mania would be related specifically to difficulties controlling impulsive responses to emotions.</AbstractText><AbstractText Label="DESIGN AND METHODS" NlmCategory="METHODS">Undergraduates (N = 257) completed a large battery of measures of emotion-relevant and non-emotional forms of impulsivity, along with a well-validated measure of risk for mania, the Hypomanic Personality Scale (HPS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Analyses examined correlations of impulsivity scales with the HPS, and partial correlations controlling for lifetime tendencies towards depressive symptoms and current symptoms of alcohol abuse, both of which relate to impulsivity and often co-occur with mania. After controlling for these measures, risk for mania remained correlated with measures of impulsive responses to positive emotions, but not with difficulties in following through or with impulsivity in the context of general distress emotions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although impulsivity is a major concern among those at risk for mania and those diagnosed with mania, difficulties may be especially evident during positive affective states, and other forms of impulsivity may be less related to mania risk. Discussion focuses on limitations and future directions.</AbstractText><AbstractText Label="PRACTITIONER POINTS" NlmCategory="CONCLUSIONS">Impulsivity is correlated with risk for mania. Mania risk appears tied to tendencies towards impulsive action, particularly during positive affective states. Mania risk was not significantly correlated with other non-emotional forms of impulsivity. A better understanding of what aspects of impulsivity are problematic in bipolar disorder could guide more refined interventions.</AbstractText><CopyrightInformation>© 2012 The British Psychological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sheri L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of California, Berkeley, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carver</LastName><ForeName>Charles S</ForeName><Initials>CS</Initials></Author><Author ValidYN="Y"><LastName>Mulé</LastName><ForeName>Serena</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Joormann</LastName><ForeName>Jutta</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Psychother</MedlineTA><NlmUniqueID>101135751</NlmUniqueID><ISSNLinking>1476-0835</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="Y">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007175" MajorTopicYN="N">Impulsive Behavior</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>12</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>06</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24217865</ArticleId><ArticleId IdType="doi">10.1111/j.2044-8341.2012.02078.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8038297</PMID><DateCompleted><Year>1994</Year><Month>08</Month><Day>24</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-3223</ISSN><JournalIssue CitedMedium="Print"><Volume>35</Volume><Issue>8</Issue><PubDate><Year>1994</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Biological psychiatry</Title><ISOAbbreviation>Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Elevated cerebrospinal fluid protein in men with unipolar or bipolar depression.</ArticleTitle><Pagination><MedlinePgn>539-44</MedlinePgn></Pagination><Abstract><AbstractText>We studied a large sample of rigorously diagnosed, generally unmedicated patients with major depressive disorder (n = 179), bipolar affective disorder (n = 102), or schizophrenia (n = 125) to determine if increased cerebrospinal fluid (CSF) protein is associated with a particular diagnosis or gender. Men had a higher mean CSF protein level than women across all diagnoses (p &lt; 0.001). There were no differences across diagnosis among the female patients. Men with unipolar depression had a higher mean CSF protein content than other male patients (n = 0.029), but depressed bipolar males had an equivalently elevated mean level. Considered apart from unipolar or bipolar diagnosis, the depressive syndrome was strongly associated with increased CSF protein in men (p = 0.004); again, there was no difference across type of illness (depression versus mania) among women. Elevated CSF protein content seems to be associated with illness syndrome rather than diagnosis, and may represent an important finding among men with depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Samuelson</LastName><ForeName>S D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Kansas City Veterans Administration Medical Center 64128.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Winokur</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Pitts</LastName><ForeName>A F</ForeName><Initials>AF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Psychiatry</MedlineTA><NlmUniqueID>0213264</NlmUniqueID><ISSNLinking>0006-3223</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002556">Cerebrospinal Fluid Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002556" MajorTopicYN="N">Cerebrospinal Fluid Proteins</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>4</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>4</Month><Day>15</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>4</Month><Day>15</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8038297</ArticleId><ArticleId IdType="pii">0006-3223(94)90100-7</ArticleId><ArticleId IdType="doi">10.1016/0006-3223(94)90100-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6722384</PMID><DateCompleted><Year>1984</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0144-6657</ISSN><JournalIssue CitedMedium="Print"><Volume>23 ( Pt 2)</Volume><PubDate><Year>1984</Year><Month>May</Month></PubDate></JournalIssue><Title>The British journal of clinical psychology</Title><ISOAbbreviation>Br J Clin Psychol</ISOAbbreviation></Journal><ArticleTitle>A meta-analytic comparison of the Beck Depression Inventory and the Hamilton Rating Scale for Depression as measures of treatment outcome.</ArticleTitle><Pagination><MedlinePgn>93-9</MedlinePgn></Pagination><Abstract><AbstractText>Some clinicians have considered the Beck Depression Inventory, a self-rating scale, too reactive to patient halo effects and, therefore, a liberal measure of treatment outcome. On the other hand, interviewer-rating scales, like the Hamilton Rating Scale for Depression have been viewed as more conservative measures of treatment gain. Studies which compared the Beck Depression Inventory to the Hamilton Rating Scale, as dependent measures, were reviewed for the purpose of determining if the scales provided comparable data for assessing treatment effects. The use of meta-analysis techniques resulted in a comparison of effect sizes which indicated that the Beck Depression Inventory was significantly less liberal than the Hamilton Rating Scale for Depression. The implications of these results for selecting outcome measures and the application of meta-analysis techniques for comparing dependent measures are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>B C</ForeName><Initials>BC</Initials></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Moran</LastName><ForeName>P W</ForeName><Initials>PW</Initials></Author><Author ValidYN="Y"><LastName>McCully</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>K C</ForeName><Initials>KC</Initials></Author><Author ValidYN="Y"><LastName>Ellingson</LastName><ForeName>A G</ForeName><Initials>AG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Clin Psychol</MedlineTA><NlmUniqueID>8105533</NlmUniqueID><ISSNLinking>0144-6657</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6722384</ArticleId><ArticleId IdType="doi">10.1111/j.2044-8260.1984.tb00632.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2276725</PMID><DateCompleted><Year>1991</Year><Month>03</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-1597</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>12</Issue><PubDate><Year>1990</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Hospital &amp; community psychiatry</Title><ISOAbbreviation>Hosp Community Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A preliminary study of unresolved grief in families of seriously mentally ill patients.</ArticleTitle><Pagination><MedlinePgn>1321-5</MedlinePgn></Pagination><Abstract><AbstractText>Investigations of the grief reactions experienced by families when a relative develops a serious mental illness have been hampered by the lack of an appropriate instrument to measure such reactions. The authors devised the Mental Illness Version of the Texas Inventory of Grief, adapted from the Texas Revised Inventory of Grief, to assess family members' initial and present feelings about their relative's loss of mental health. A test of the instrument with 58 family members of patients with schizophrenia or bipolar disorder revealed a surprisingly low level of initial grief but higher levels of present grief.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>TANDEM Family Services, Department of Psychiatry, University of Chicago Medical Center, IL 60637.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dworkin</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ward</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Barone</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hosp Community Psychiatry</MedlineTA><NlmUniqueID>0040250</NlmUniqueID><ISSNLinking>0022-1597</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="Y">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="Y">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="N">Family Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006117" MajorTopicYN="Y">Grief</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="Y">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2276725</ArticleId><ArticleId IdType="doi">10.1176/ps.41.12.1321</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16697468</PMID><DateCompleted><Year>2006</Year><Month>11</Month><Day>09</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>93</Volume><Issue>1-3</Issue><PubDate><Year>2006</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>The Brief-HAPPI: a questionnaire to assess cognitions that distinguish between individuals with a diagnosis of bipolar disorder and non-clinical controls.</ArticleTitle><Pagination><MedlinePgn>29-34</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite developments in cognitive behavioural therapy for bipolar disorder, little is known about the specific dysfunctional beliefs that may predispose individuals to mania. Therefore a measure was specifically designed for this purpose based on a cognitive approach. The measure is called the Hypomanic Attitudes and Positive Predictions Inventory (HAPPI).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Fifty-six individuals with a diagnosis of bipolar disorder and 39 matched healthy controls completed a brief version of the HAPPI (Brief-HAPPI), the Internal State Scale, and the Hypomanic Interpretations Questionnaire (HIQ).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The bipolar group scored higher on the overall Brief-HAPPI scale, higher on the forward items of the Brief-HAPPI, lower on the reverse items and no different on the filler items. The group differences in overall score remained when controlling for current self-reported symptoms of mania and depression, and recent history of hypomanic symptoms, yet within the bipolar group, Brief-HAPPI score was positively correlated with the level of symptoms. The Brief-HAPPI showed a sizeable correlation with the HIQ, yet each scale showed a significant and independent association with bipolar disorder.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The Brief-HAPPI assesses dysfunctional beliefs that are associated with a diagnosis of bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mansell</LastName><ForeName>Warren</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Psychological Sciences, Coupland I, University of Manchester, Oxford Road, Manchester M13 9PL, UK. warren.mansell@manchester.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Steven H</ForeName><Initials>SH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>05</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003469" MajorTopicYN="Y">Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>09</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>04</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>11</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16697468</ArticleId><ArticleId IdType="pii">S0165-0327(06)00170-4</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2006.04.004</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18199234</PMID><DateCompleted><Year>2008</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1 Pt 2</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Rapid cycling bipolar disorder--diagnostic concepts.</ArticleTitle><Pagination><MedlinePgn>153-62</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2007.00560.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">This paper reviews the literature to examine the DSM-IV diagnostic criteria for rapid cycling in bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Studies on the clinical characteristics of rapid cycling bipolar disorder were reviewed. To identify relevant papers, literature searches using PubMed and MEDLINE were undertaken.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">First observed in the prepharmacologic era, rapid cycling subsequently has been associated with a relatively poor response to pharmacologic treatment. Rapid cycling can be conceptualized as either a high frequency of episodes of any polarity or as a temporal sequence of episodes of opposite polarity. The DSM-IV defines rapid cycling as a course specifier, signifying at least four episodes of major depression, mania, mixed mania, or hypomania in the past year, occurring in any combination or order. It is estimated that rapid cycling is present in about 12-24% of patients at specialized mood disorder clinics. However, apart from episode frequency, studies over the past 30 years have been unable to determine clinical characteristics that define patients with rapid cycling as a specific subgroup. Furthermore, rapid cycling is a transient phenomenon in many patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">While a dimensional approach to episode frequency as a continuum between the extremes of no cycling and continuous cycling may be more appropriate and provide a framework to include ultra-rapid and ultradian cycling, the evidence does not exist today to refine the DSM-IV definition in a less arbitrary manner. Continued use of the DSM-IV definition also enables comparisons between past and future studies, and it should be included in the next release of the ICD. Further scientific investigation into rapid cycling is needed. In addition to improving the diagnostic criteria, insight into neurophysiologic mechanisms of mood switching and episode frequency may have important implications for clinical care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. michael.bauer@uniklinikum-dresden.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beaulieu</LastName><ForeName>Serge</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Dunner</LastName><ForeName>David L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Lafer</LastName><ForeName>Beny</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kupka</LastName><ForeName>Ralph</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>95</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18199234</ArticleId><ArticleId IdType="pii">BDI560</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2007.00560.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8511231</PMID><DateCompleted><Year>1993</Year><Month>07</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-4962</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>1993</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>Cognitive function in the affective disorders: a prospective study.</ArticleTitle><Pagination><MedlinePgn>6-12</MedlinePgn></Pagination><Abstract><AbstractText>A prospective, controlled study of 50 subjects confirmed claims that major depression or mania may cause temporary disorders of attention, memory, visuo-spatial function, and choice reaction time, and cause-independently of medication-the appearance of glabellar tap, positive hand-face test, nuchocephalic reflex, and graphesthesia. On follow-up, all these phenomena either disappeared or markedly improved. Age and age of onset, but not pre-morbid intelligence or history of ECT, seemed to modulate the severity of the cognitive impairment. Presence of delusions predicted poor (but reversible) visuo-spatial function. Cognitive impairment accompanied by reversible soft neurological signs was more marked but patients thus affected surprisingly showed lower depressive scores; this was interpreted as representing a secondary, 'organic' form of affective disorder (i.e. a behavioural phenocopy of depression) characterised by a reduced capacity to experience depressive symptoms and by little improvement at follow-up.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bulbena</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Universidad del Pais Vasco, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berrios</LastName><ForeName>G E</ForeName><Initials>GE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005425" MajorTopicYN="N">Flicker Fusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011939" MajorTopicYN="N">Mental Recall</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009460" MajorTopicYN="N">Neurologic Examination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8511231</ArticleId><ArticleId IdType="doi">10.1159/000284794</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31438925</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2019</Year><Month>08</Month><Day>22</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The effect of a brief mindfulness-based intervention on personal recovery in people with bipolar disorder: a randomized controlled trial (study protocol).</ArticleTitle><Pagination><MedlinePgn>255</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-019-2242-0</ELocationID><Abstract><AbstractText Label="BACKGROUND">With the advent of the recovery movement in mental health, a humanistic paradigm shift has occurred, placing the focus on personal recovery (i.e., hope, identity, and life meaning) instead of functional or clinical recovery only (i.e., symptom reduction or increases in physical function). Along the journey of recovery, people with bipolar disorder (BD) struggle to cope with recurring mood fluctuations between depression and mania. Mindfulness-based interventions (MBIs) have the potential to result in improvements in personal recovery outcomes. Thus, this protocol will evaluate the efficacy and mechanisms of a brief MBI for helping individuals with BD with their personal recovery. It is hypothesized that adults with BD randomly assigned to a brief MBI intervention will report greater improvements in personal recovery than those in a waiting list control condition. In addition, it is hypothesized that such benefits will be mediated by improvements in emotion awareness, emotion regulation, and illness acceptance. Moreover, the specific stage of BD is hypothesized to moderate the beneficial effects of the brief MBI, such that those in the early stage of BD will report more benefits regarding emotion awareness and emotion regulation, whereas those in the late stage of BD will report more advantages concerning illness acceptance.</AbstractText><AbstractText Label="METHOD">One hundred and fifty-four adults with BD will be recruited from hospitals and community settings for this research project. This study will use a mixed methods design. A randomized-controlled trial will be conducted to compare a brief MBI (four sessions in total) group and a waiting list control group. Assessments will be made at baseline, after intervention, and at six-month follow-up. In addition, a qualitative and participatory research method called Photovoice will be employed to further understand the experiences of the participants who receive the brief MBI along their personal recovery journey.</AbstractText><AbstractText Label="DISCUSSION">If the study hypotheses are supported, the findings from this research project will provide empirical support for an alternative treatment. Moreover, by identifying the mechanisms of the beneficial effects of the brief MBI, the findings will highlight process variables that could be specifically targeted to make MBI treatment even more effective in this population.</AbstractText><AbstractText Label="TRIAL REGISTRATION">This study is registered with the Chinese Clinical Trial Registry ( ChiCTR- 1900024658 ). Registered 20th July 2019.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Sunny H W</ForeName><Initials>SHW</Initials><Identifier Source="ORCID">0000-0001-5136-8698</Identifier><AffiliationInfo><Affiliation>Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Hong Kong. sunny.hw.chan@polyu.edu.hk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Samson</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Social Work and Social Administration, The University of Hong Kong, Pok Fu Lam, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>K F</ForeName><Initials>KF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, The University of Hong Kong, Pok Fu Lam, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>C H</ForeName><Initials>CH</Initials><AffiliationInfo><Affiliation>Department of Psychology, The Azusa Pacific University, Azusa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Raymond C K</ForeName><Initials>RCK</Initials><AffiliationInfo><Affiliation>Department of Rehabilitation Sciences, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lo</LastName><ForeName>Herman H M</ForeName><Initials>HHM</Initials><AffiliationInfo><Affiliation>Department of Applied Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ChiCTR</DataBankName><AccessionNumberList><AccessionNumber>ChiCTR-1900024658</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064866" MajorTopicYN="N">Mindfulness</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010549" MajorTopicYN="Y">Personal Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Mindfulness-based intervention</Keyword><Keyword MajorTopicYN="Y">Personal recovery</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>07</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>08</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31438925</ArticleId><ArticleId IdType="doi">10.1186/s12888-019-2242-0</ArticleId><ArticleId IdType="pii">10.1186/s12888-019-2242-0</ArticleId><ArticleId IdType="pmc">PMC6704723</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aust N Z J Psychiatry. 2015 Dec;49(12):1087-206</Citation><ArticleIdList><ArticleId IdType="pubmed">26643054</ArticleId></ArticleIdList></Reference><Reference><Citation>J Womens Health. 1999 Mar;8(2):185-92</Citation><ArticleIdList><ArticleId IdType="pubmed">10100132</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2017 Mar;52:148-163</Citation><ArticleIdList><ArticleId IdType="pubmed">28129636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Jan 1;225:234-245</Citation><ArticleIdList><ArticleId IdType="pubmed">28841486</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2014 Feb;129(2):100-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23600731</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2014 Oct;55(7):1540-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24962450</ArticleId></ArticleIdList></Reference><Reference><Citation>Perspect Psychol Sci. 2011 Nov;6(6):537-59</Citation><ArticleIdList><ArticleId IdType="pubmed">26168376</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment. 2013 Dec;20(6):681-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23794181</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Assess. 2018 May;30(5):e1-e9</Citation><ArticleIdList><ArticleId IdType="pubmed">29756796</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Gen Psychiatry. 2015 Jul 07;14:19</Citation><ArticleIdList><ArticleId IdType="pubmed">26155299</ArticleId></ArticleIdList></Reference><Reference><Citation>Metab Brain Dis. 2014 Jun;29(2):367-75</Citation><ArticleIdList><ArticleId IdType="pubmed">24311196</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Soc Psychiatry. 2016 Dec;62(8):696-707</Citation><ArticleIdList><ArticleId IdType="pubmed">27798049</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Aug;16(5):471-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23782499</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Ther. 2008 Jun;39(2):107-16</Citation><ArticleIdList><ArticleId IdType="pubmed">18502244</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2017 Feb;51:48-59</Citation><ArticleIdList><ArticleId IdType="pubmed">27835764</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Aug;11(5):453-73</Citation><ArticleIdList><ArticleId IdType="pubmed">19624385</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Methods. 2009 Nov;41(4):1149-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19897823</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Oct;77(1):21-30</Citation><ArticleIdList><ArticleId IdType="pubmed">14550932</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1672-82</Citation><ArticleIdList><ArticleId IdType="pubmed">23663953</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Soc Psychol. 2015 Jan;108(1):148-70</Citation><ArticleIdList><ArticleId IdType="pubmed">25347126</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2018 Nov;269:399-407</Citation><ArticleIdList><ArticleId IdType="pubmed">30173047</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2018 Oct 15;239:303-312</Citation><ArticleIdList><ArticleId IdType="pubmed">30031250</ArticleId></ArticleIdList></Reference><Reference><Citation>Value Health. 2005 Mar-Apr;8(2):94-104</Citation><ArticleIdList><ArticleId IdType="pubmed">15804318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2018 Jul;86(7):569-583</Citation><ArticleIdList><ArticleId IdType="pubmed">29939051</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 May;127(5):333-43</Citation><ArticleIdList><ArticleId IdType="pubmed">23216045</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2012 Feb;46(2):92-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22311525</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment. 2014 Jun;21(3):363-71</Citation><ArticleIdList><ArticleId IdType="pubmed">23596271</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Behav Ther. 2013;42(1):21-30</Citation><ArticleIdList><ArticleId IdType="pubmed">22992187</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Endocrinol Lett. 2013;34(4):265-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23803872</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2015 Jan;206(1):58-66</Citation><ArticleIdList><ArticleId IdType="pubmed">25213157</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2017 Oct;16(3):236-244</Citation><ArticleIdList><ArticleId IdType="pubmed">28941093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 May;147(1-3):34-43</Citation><ArticleIdList><ArticleId IdType="pubmed">23182591</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2011 Dec;199(6):445-52</Citation><ArticleIdList><ArticleId IdType="pubmed">22130746</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2012 Nov;46(11):1058-67</Citation><ArticleIdList><ArticleId IdType="pubmed">23015748</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17521513</PMID><DateCompleted><Year>2007</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3812</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>3</Issue><PubDate><Year>2007</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Cycloid psychosis: an examination of the validity of the concept.</ArticleTitle><Pagination><MedlinePgn>184-92</MedlinePgn></Pagination><Abstract><AbstractText>The diagnosis of cycloid psychosis has a long tradition in European psychiatry. However, it has been poorly assimilated within the DSM IV and ICD-10 diagnostic systems. Leonhard set the basis for the current conceptualization of the disorder, and Perris and Brockington developed the first operational diagnostic criteria. However, the two conceptualizations of the disorder are not the same and differ across a number of meaningful variables. Cycloid psychosis is a useful concept in that it possesses both clinical and predictive validity. Despite the high prevalence of mood symptoms and syndromes, cycloid psychosis does not equal schizoaffective disorder. Although a substantial body of evidence suggests that cycloid psychosis differs meaningfully from typical schizophrenia, it is less clear whether it differs from major mood disorders or represents an independent nosological entity. The existence of putative subtypes is also likely, and the differentiation between affective and nonaffective subtypes has received some support.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peralta</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Psychiatric Unit, Virgen del Camino Hospital, Irunlarrea 4, 31008 Pamplona, Spain. victor.peralta.martin@cfnavarra.es</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuesta</LastName><ForeName>Manuel J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Zandio</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>41</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>25</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17521513</ArticleId><ArticleId IdType="doi">10.1007/s11920-007-0017-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Nerv Ment Dis. 1982 Nov;170(11):651-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7119764</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2000 May;30(3):721-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10883726</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1999 Jan-Feb;40(1):4-18</Citation><ArticleIdList><ArticleId IdType="pubmed">9924871</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 1990;23(4-6):212-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2084772</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1986 Aug;74(2):205-16</Citation><ArticleIdList><ArticleId IdType="pubmed">3776667</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2000 Jun;176:576-80</Citation><ArticleIdList><ArticleId IdType="pubmed">10974965</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1982 Nov;39(11):1334-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7138235</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1988 Aug;78(2):182-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3223317</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1974;253:1-77</Citation><ArticleIdList><ArticleId IdType="pubmed">4532463</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1978 Nov;8(4):637-48</Citation><ArticleIdList><ArticleId IdType="pubmed">724876</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 1999 Jun;34(6):328-32</Citation><ArticleIdList><ArticleId IdType="pubmed">10422487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2002 May;109(5-6):907-19</Citation><ArticleIdList><ArticleId IdType="pubmed">12111477</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Dev. 1988 Spring;6(1):37-56</Citation><ArticleIdList><ArticleId IdType="pubmed">3050983</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Nov 15;83(1):11-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15546641</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2005 Oct;255(5):299-307</Citation><ArticleIdList><ArticleId IdType="pubmed">15645162</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Nov 15;79(2-3):217-29</Citation><ArticleIdList><ArticleId IdType="pubmed">15993566</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 1990;23(4-6):196-204</Citation><ArticleIdList><ArticleId IdType="pubmed">2084770</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1964 Jan;138:48-56</Citation><ArticleIdList><ArticleId IdType="pubmed">14106325</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2005 Feb;17(1):53-62</Citation><ArticleIdList><ArticleId IdType="pubmed">16194771</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1982 Aug;12(3):475-92</Citation><ArticleIdList><ArticleId IdType="pubmed">7134308</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2001 Nov-Dec;34(6):305-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11847490</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2006 May;113(5):369-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16603028</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1995 Aug;167(2):216-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7582672</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ment Sci. 1961 Jul;107:633-48</Citation><ArticleIdList><ArticleId IdType="pubmed">13760961</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1982 Feb;12(1):97-105</Citation><ArticleIdList><ArticleId IdType="pubmed">7079434</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Dec;160(12):2108-15</Citation><ArticleIdList><ArticleId IdType="pubmed">14638579</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1992 May;22(2):367-78</Citation><ArticleIdList><ArticleId IdType="pubmed">1615104</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1975;259:1-133</Citation><ArticleIdList><ArticleId IdType="pubmed">1056685</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 1990;23(4-6):205-11</Citation><ArticleIdList><ArticleId IdType="pubmed">2084771</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1986 Oct;149:419-29</Citation><ArticleIdList><ArticleId IdType="pubmed">3814925</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1965;41(3):372-7</Citation><ArticleIdList><ArticleId IdType="pubmed">5858064</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2003 Apr;33(3):443-53</Citation><ArticleIdList><ArticleId IdType="pubmed">12701665</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16566632</PMID><DateCompleted><Year>2006</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychiatric genetics.</ArticleTitle><Pagination><MedlinePgn>324; author reply 324-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feinberg</LastName><ForeName>S Shalom</ForeName><Initials>SS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Clin Psychiatry. 2005 Jul;66(7):821-30</RefSource><PMID Version="1">16013896</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001291" MajorTopicYN="N">Attitude of Health Personnel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005817" MajorTopicYN="N">Genetic Counseling</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="N">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010817" MajorTopicYN="N">Physician-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011361" MajorTopicYN="N">Professional Competence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011368" MajorTopicYN="N">Professional-Family Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011570" MajorTopicYN="N">Psychiatry</DescriptorName><QualifierName UI="Q000193" MajorTopicYN="Y">education</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>3</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16566632</ArticleId><ArticleId IdType="doi">10.4088/jcp.v67n0222a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1901850</PMID><DateCompleted><Year>1991</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>4</Issue><PubDate><Year>1991</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Lithium toxicity in an elderly woman.</ArticleTitle><Pagination><MedlinePgn>181</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bassingthwaighte</LastName><ForeName>M E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Rummans</LastName><ForeName>T A</ForeName><Initials>TA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000506" MajorTopicYN="Y">poisoning</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1901850</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22329469</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Early determinants of four-year clinical outcomes in bipolar disorder with psychosis.</ArticleTitle><Pagination><MedlinePgn>19-30</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2012.00982.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Bipolar disorder with psychosis is common in inpatient settings and is associated with diverse outcomes after hospital discharge, which can range from a return to premorbid functioning with no recurrence, to a chronic or recurring illness. Less is known, however, about factors that can predict a better or worse clinical outcome. The present study sought to assess four-year clinical outcomes and their predictors in patients hospitalized for bipolar I disorder with psychosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Participants from the Suffolk County Mental Health Project (SCMHP) with a baseline diagnosis of bipolar I disorder with psychotic features (N=126) were reassessed using face-to-face interviews at six months, two years, and four years following their first hospitalization. At each time point, clinical status, role functioning, and treatment were assessed by highly trained interviewers using standardized instruments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The majority of participants (73.2%) returned to their premorbid level of role functioning by the four-year follow-up and the median percentage of time ill during the interval was less than 20%. Nevertheless, almost half of the sample (46.9%) was rehospitalized at least once. Psychotic symptoms at baseline (particularly Schneiderian symptoms), depressive phenomenology, childhood psychopathology, and younger age at first hospitalization predicted worse outcome, whereas mood-incongruent psychotic features and age of mood disorder onset did not.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The four-year outcomes of a first-admission cohort with bipolar I disorder with psychosis were generally favorable. Poorer premorbid functioning, Schneiderian delusions, greater depressive symptoms, and a younger age of first hospitalization portend a worse course.</AbstractText><CopyrightInformation>© 2012 John Wiley and Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carlson</LastName><ForeName>Gabrielle A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stony Brook University School of Medicine, Stony Brook, NY, USA. gabrielle.carlson@sbumed.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotov</LastName><ForeName>Roman</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Su-Wei</ForeName><Initials>SW</Initials></Author><Author ValidYN="Y"><LastName>Ruggero</LastName><ForeName>Camilo</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bromet</LastName><ForeName>Evelyn J</ForeName><Initials>EJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH044801</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH044801-17</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH094398</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH44801</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="Y">Delusions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="Y">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22329469</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2012.00982.x</ArticleId><ArticleId IdType="pmc">PMC3281503</ArticleId><ArticleId IdType="mid">NIHMS348110</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Dec;160(12):2099-107</Citation><ArticleIdList><ArticleId IdType="pubmed">14638578</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1996 Feb 12;37(1):23-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8682975</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Nov 1;79(1):45-57</Citation><ArticleIdList><ArticleId IdType="pubmed">16139479</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2006 Nov-Dec;47(6):433-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17067865</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Dec 15;56(12):957-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15601606</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1992 Nov;149(11):1580-4</Citation><ArticleIdList><ArticleId IdType="pubmed">1415828</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1998 Apr;186(4):207-13</Citation><ArticleIdList><ArticleId IdType="pubmed">9569888</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1992;18(2):243-55</Citation><ArticleIdList><ArticleId IdType="pubmed">1621071</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2006 Dec;88(1-3):47-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16904292</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2009;42(2):81-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19225242</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):103-13</Citation><ArticleIdList><ArticleId IdType="pubmed">17391354</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):939-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17064424</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2005 Feb;40(2):106-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15685401</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):13-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16650901</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Oct 1;82(1):21-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15465573</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Dec;62(12):1322-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16330720</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001 Dec;62(12):963-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11780877</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Mar;11(2):205-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19267703</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Jul;47(7):665-71</Citation><ArticleIdList><ArticleId IdType="pubmed">2113802</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Jun;8(3):221-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16696823</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Dec;127(1-3):50-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20557947</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry Suppl. 1989 Nov;(7):49-58</Citation><ArticleIdList><ArticleId IdType="pubmed">2695141</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2003 Jul-Aug;44(4):263-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12923703</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2006 Sep;36(9):1197-211</Citation><ArticleIdList><ArticleId IdType="pubmed">16566850</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):82-91</Citation><ArticleIdList><ArticleId IdType="pubmed">15146337</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2008;9(4):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18949649</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Apr;159(4):592-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11925297</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):240-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16449477</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1977 Oct;34(10):1229-35</Citation><ArticleIdList><ArticleId IdType="pubmed">911222</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Mar;60(3):261-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12622659</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1985 Apr;142(4):479-82</Citation><ArticleIdList><ArticleId IdType="pubmed">3976922</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):79-88</Citation><ArticleIdList><ArticleId IdType="pubmed">11869754</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1982;8(3):470-84</Citation><ArticleIdList><ArticleId IdType="pubmed">7134891</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Apr;8(2):103-16</Citation><ArticleIdList><ArticleId IdType="pubmed">16542180</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1994 Sep-Oct;35(5):341-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7995025</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Feb;11(1):82-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19133970</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2009 Jan;107(1):55-60</Citation><ArticleIdList><ArticleId IdType="pubmed">18793828</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Jun;64(6):680-90; quiz 738-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12823083</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Sep;81(3):259-68</Citation><ArticleIdList><ArticleId IdType="pubmed">15337330</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Dec;47(12):1106-11</Citation><ArticleIdList><ArticleId IdType="pubmed">2244795</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 Aug;49(8):624-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1637252</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 May;12(3):264-70</Citation><ArticleIdList><ArticleId IdType="pubmed">20565433</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Feb;157(2):220-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10671390</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1977 Aug;134(8):919-22</Citation><ArticleIdList><ArticleId IdType="pubmed">879359</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Jul;124(1-2):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19683348</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 2006 Feb;28(2):243-59</Citation><ArticleIdList><ArticleId IdType="pubmed">16484096</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1998 May;155(5):646-52</Citation><ArticleIdList><ArticleId IdType="pubmed">9585716</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Jul;47(7):658-62</Citation><ArticleIdList><ArticleId IdType="pubmed">2360859</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2011 Mar-Apr;52(2):126-31</Citation><ArticleIdList><ArticleId IdType="pubmed">21295217</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2008 Nov;18(11):787-93</Citation><ArticleIdList><ArticleId IdType="pubmed">18725178</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2004 Jun;6(3):168-75</Citation><ArticleIdList><ArticleId IdType="pubmed">15142469</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1986 Mar;143(3):306-11</Citation><ArticleIdList><ArticleId IdType="pubmed">3953863</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1974 Feb;124(579):134-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4825659</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2005 May;111(5):380-3</Citation><ArticleIdList><ArticleId IdType="pubmed">15819732</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1986 Jun;6(3):167-72</Citation><ArticleIdList><ArticleId IdType="pubmed">3711367</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2009 Jul;112(1-3):136-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19410430</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Jun;67(6):925-32</Citation><ArticleIdList><ArticleId IdType="pubmed">16848652</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Jun;13(4):334-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21843273</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Feb;159(2):307-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11823277</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 Apr;109(4):264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15008799</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1979 Nov;36(12):1295-301</Citation><ArticleIdList><ArticleId IdType="pubmed">496548</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2000 Feb;35(2):53-60</Citation><ArticleIdList><ArticleId IdType="pubmed">10784367</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Sep;50(2-3):109-16</Citation><ArticleIdList><ArticleId IdType="pubmed">9858070</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2010 Apr;67(4):339-47</Citation><ArticleIdList><ArticleId IdType="pubmed">20368510</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Apr;107(1-3):45-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17804081</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1983 Nov;140(11):1523-4</Citation><ArticleIdList><ArticleId IdType="pubmed">6625008</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006;67 Suppl 8:21-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16961426</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Mar;152(3):379-84</Citation><ArticleIdList><ArticleId IdType="pubmed">7864263</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Feb;157(2):213-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10671389</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Dec;9(8):851-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18076534</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2000 Nov;177:421-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11059995</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Dec;61(1-2):87-94</Citation><ArticleIdList><ArticleId IdType="pubmed">11099745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2007 Mar;195(3):226-32</Citation><ArticleIdList><ArticleId IdType="pubmed">17468682</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2010 Jan;36(1):173-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18562340</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 1988;24(1):112-7</Citation><ArticleIdList><ArticleId IdType="pubmed">3387514</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 2007 May;150(5):485-90</Citation><ArticleIdList><ArticleId IdType="pubmed">17452221</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2009 Sep;120(3):239-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19426162</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Mar 1;73(2-3):185-91</Citation><ArticleIdList><ArticleId IdType="pubmed">15653261</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2000 Jun;57(6):593-600</Citation><ArticleIdList><ArticleId IdType="pubmed">10839338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Feb;6(1):62-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14996142</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19748130</PMID><DateCompleted><Year>2010</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2009</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>119</Volume><Issue>1-3</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Does a psychoeducational approach reach targeted patients with bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>190-3</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2009.08.016</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The goal of this paper was to determine factors which are related to motivation of bipolar patients to attend a psychoeducation program.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with bipolar disorder which had at least four years of prospective follow-ups were invited to a 6-week psychoeducation program. Patients who accepted and those who refused the participation were compared using several clinical characteristics.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 173 patients who were invited, 84 participated in the program. Participants had significantly more family history of bipolar disorder and suicide, good response to prophylactic treatment, full medication adherence, therapeutic blood levels of mood stabilizers, regular follow-up visits, mixed episodes, and significantly less total number of episodes. Presence of mixed episodes, full medication adherence and therapeutic blood level of mood stabilizers were found predictive for attendance in logistic regression analysis.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results suggest motivation and participation rates of patients who attended a psychoeducation program were constrained. Factors associated with a poor response to psychopharmacologic treatments also seem valid for non-attendance to the psychological interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cakir</LastName><ForeName>Sibel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Istanbul University, Istanbul Medical School, Psychiatry Department, Mood Disorders Unit, 34390 Capa-Istanbul, Turkey. drsibelcakir@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bensusan</LastName><ForeName>Rakel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Akca</LastName><ForeName>Zeynep K</ForeName><Initials>ZK</Initials></Author><Author ValidYN="Y"><LastName>Yazici</LastName><ForeName>Olcay</ForeName><Initials>O</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004522" MajorTopicYN="N">Educational Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009042" MajorTopicYN="N">Motivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="Y">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>05</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>08</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>08</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>1</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19748130</ArticleId><ArticleId IdType="pii">S0165-0327(09)00393-0</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2009.08.016</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25066366</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-8978</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>16</Issue><PubDate><Year>2014</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Psychological medicine</Title><ISOAbbreviation>Psychol Med</ISOAbbreviation></Journal><ArticleTitle>Age at onset, course of illness and response to psychotherapy in bipolar disorder: results from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD).</ArticleTitle><Pagination><MedlinePgn>3455-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S0033291714000804</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The course of bipolar disorder progressively worsens in some patients. Although responses to pharmacotherapy appear to diminish with greater chronicity, less is known about whether patients' prior courses of illness are related to responses to psychotherapy.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Embedded in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) was a randomized controlled trial of psychotherapy for bipolar depression comparing the efficacy of intensive psychotherapy with collaborative care (a three-session psycho-educational intervention). We assessed whether the number of previous mood episodes, age of illness onset, and illness duration predicted or moderated the likelihood of recovery and time until recovery from a depressive episode in patients in the two treatments.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Independently of treatment condition, participants with one to nine prior depressive episodes were more likely to recover and had faster time to recovery than those with 20 or more prior depressive episodes. Participants with fewer than 20 prior manic episodes had faster time to recovery than those with 20 or more episodes. Longer illness duration predicted a longer time to recovery. Participants were more likely to recover in intensive psychotherapy than collaborative care if they had 10-20 prior episodes of depression [number needed to treat (NNT) = 2.0], but equally likely to respond to psychotherapy and collaborative care if they had one to nine (NNT = 32.0) or &gt;20 (NNT = 9.0) depressive episodes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Number of previous mood episodes and illness duration are associated with the likelihood and speed of recovery among bipolar patients receiving psychosocial treatments for depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Illinois at Chicago,Chicago, IL,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sylvia</LastName><ForeName>L G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital,Boston, MA,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Magalhães</LastName><ForeName>P V da Silva</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Universidade Federal de Rio Grande de Sul,Porte Alegre,Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>D J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>UCLA School of Medicine,Los Angeles, CA,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of Pittsburgh,Pittsburgh, PA,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otto</LastName><ForeName>M W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Boston University,Boston, MA,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hansen</LastName><ForeName>N S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital,Boston, MA,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dougherty</LastName><ForeName>D D</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital,Boston, MA,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berk</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Deakin University,Melbourne,Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nierenberg</LastName><ForeName>A A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital,Boston, MA,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deckersbach</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital,Boston, MA,USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH296181</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH029618</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R37 MH029618</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH097007</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH55101</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH093676</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 MH097007</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>N01MH80001</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH43931</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>04</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Med</MedlineTA><NlmUniqueID>1254142</NlmUniqueID><ISSNLinking>0033-2917</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015397" MajorTopicYN="N">Program Evaluation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25066366</ArticleId><ArticleId IdType="pii">S0033291714000804</ArticleId><ArticleId IdType="doi">10.1017/S0033291714000804</ArticleId><ArticleId IdType="pmc">PMC4620042</ArticleId><ArticleId IdType="mid">NIHMS730851</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2012 Sep;51(9):867-78</Citation><ArticleIdList><ArticleId IdType="pubmed">22917200</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1999 Dec 4;319(7223):1492-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10582940</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Nov;165(11):1408-19</Citation><ArticleIdList><ArticleId IdType="pubmed">18794208</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 May;49(2):101-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9609673</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Feb;162(2):324-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15677598</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Aug;11(5):474-82</Citation><ArticleIdList><ArticleId IdType="pubmed">19624386</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2012 Apr;125(4):335-41</Citation><ArticleIdList><ArticleId IdType="pubmed">22283440</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2012 Nov;46(11):1058-67</Citation><ArticleIdList><ArticleId IdType="pubmed">23015748</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Neuropsychiatr. 2010 Apr;22(2):50-3</Citation><ArticleIdList><ArticleId IdType="pubmed">25385029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Sep;62(9):996-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">16143731</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Sep;164(9):1340-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17728418</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med Res Methodol. 2011 Jan 31;11:14</Citation><ArticleIdList><ArticleId IdType="pubmed">21281501</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Apr;64(4):419-26</Citation><ArticleIdList><ArticleId IdType="pubmed">17404119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Dec;14(8):797-808</Citation><ArticleIdList><ArticleId IdType="pubmed">22963164</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Feb;171(2):178-86</Citation><ArticleIdList><ArticleId IdType="pubmed">24077657</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 2008 May 10;27(10):1679-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18008395</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1995 Feb 18;310(6977):452-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7873954</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2011 Feb;41(2):225-41</Citation><ArticleIdList><ArticleId IdType="pubmed">20836900</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):87-98</Citation><ArticleIdList><ArticleId IdType="pubmed">21320256</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 2007;40(4):116-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18227782</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 May;127(5):333-43</Citation><ArticleIdList><ArticleId IdType="pubmed">23216045</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 1998 Apr 30;17(8):873-90</Citation><ArticleIdList><ArticleId IdType="pubmed">9595617</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2012 Feb;46(2):92-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22311525</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1999;249(5):227-30</Citation><ArticleIdList><ArticleId IdType="pubmed">10591987</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):593-604</Citation><ArticleIdList><ArticleId IdType="pubmed">11018230</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 1980 Jan;16(1):47-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7360839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Oct;4(5):323-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12479665</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 Jan;67(1):95-101</Citation><ArticleIdList><ArticleId IdType="pubmed">16426094</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Methods. 2000 Jun;5(2):241-301</Citation><ArticleIdList><ArticleId IdType="pubmed">10937333</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1985;317:1-34</Citation><ArticleIdList><ArticleId IdType="pubmed">3861072</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 Nov;63(11):985-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12444811</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Apr;188:313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16582056</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2012 Apr;125(4):303-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22098628</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2003 Jun 1;53(11):1028-42</Citation><ArticleIdList><ArticleId IdType="pubmed">12788248</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Mar 5;145(3):386-93</Citation><ArticleIdList><ArticleId IdType="pubmed">22858264</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):582-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11018229</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Apr;68(2-3):167-81</Citation><ArticleIdList><ArticleId IdType="pubmed">12063145</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Aug;16(5):471-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23782499</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Health Med. 2013;18(2):155-65</Citation><ArticleIdList><ArticleId IdType="pubmed">22712771</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2012 Nov;6(4):380-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22225628</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Apr;7(2):111-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15762851</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jun 1;59(11):990-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16368078</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10718160</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0095-2990</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2000</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of drug and alcohol abuse</Title><ISOAbbreviation>Am J Drug Alcohol Abuse</ISOAbbreviation></Journal><ArticleTitle>Detecting bipolar disorder among treatment-seeking substance abusers.</ArticleTitle><Pagination><MedlinePgn>13-23</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorder is increasingly recognized to have frequent comorbidity with substance use disorders, but may be difficult to diagnose among patients with active substance use. The purpose of this paper is to describe a brief, self-report form for the efficient detection of bipolar disorder. The 19-item form was piloted in 373 consecutive applicants for substance abuse treatment at an urban Veterans Affairs (VA) medical center. Results show reasonable internal consistency (alpha = .850) and high rates of manic symptomatology (36%), previous bipolar diagnosis (30%, 51% of whom report prior psychiatric hospitalization), and exposure to mood stabilizers (20%, 66% of whom reported therapeutic benefit). Comparison of nine different scoring algorithms with chart diagnosis as the validating criterion found that self-report of bipolar diagnosis was optimally sensitive. Either self-report of bipolar diagnosis with hospitalization or self-report of exposure to mood stabilizers with therapeutic response was optimally specific. Symptom self-report items had significantly poorer sensitivity and specificity (F = 7.60, p &lt; .01). We conclude that questions pertaining to diagnostic and treatment history (especially hospitalization or therapeutic medication response) are considerably superior to symptom-based screening for clinically diagnosed bipolar disorder. Further work using structured interview as the diagnostic criterion is under way to validate this instrument.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>K L</ForeName><Initials>KL</Initials><AffiliationInfo><Affiliation>VA Puget Sound Health Care System-Seattle Division, Washington 98108, USA. klsloan@u.washington.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kivlahan</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Saxon</LastName><ForeName>A J</ForeName><Initials>AJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Am J Drug Alcohol Abuse</MedlineTA><NlmUniqueID>7502510</NlmUniqueID><ISSNLinking>0095-2990</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006787" MajorTopicYN="N">Hospitals, Veterans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000534" MajorTopicYN="Y">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="N">Veterans</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>3</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10718160</ArticleId><ArticleId IdType="doi">10.1081/ada-100100587</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8780440</PMID><DateCompleted><Year>1996</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>153</Volume><Issue>9</Issue><PubDate><Year>1996</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Antidepressant effects of lamotrigine in rapid cycling bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1236</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>J R</ForeName><Initials>JR</Initials></Author><Author ValidYN="Y"><LastName>Fatemi</LastName><ForeName>S H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Woyshville</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014227">Triazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Am J Psychiatry. 1997 Aug;154(8):1171-2</RefSource><PMID Version="1">9247416</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014227" MajorTopicYN="N">Triazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8780440</ArticleId><ArticleId IdType="doi">10.1176/ajp.153.9.1236a</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28574009</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0971-5916</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Indian journal of medical research</Title><ISOAbbreviation>Indian J Med Res</ISOAbbreviation></Journal><ArticleTitle>Potential biomarkers for bipolar disorder: Where do we stand?</ArticleTitle><Pagination><MedlinePgn>7-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4103/ijmr.IJMR_1386_16</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) is a severe, recurrent mood disorder, associated with a significant morbidity and mortality, with high rates of suicides and medical comorbidities. There is a high risk of mood disorders among the first-degree relatives of patients with BD. In the current clinical practice, the diagnosis of BD is made by history taking, interview and behavioural observations, thereby lacking an objective, biological validation. This approach may result in underdiagnosis, misdiagnosis and eventually poorer outcomes. Due to the heterogeneity of BD, the possibility of developing a single, specific biomarker is still remote; however, there is a set of promising biomarkers which may serve as predictive, prognostic or treatment markers in the future. The review presents a critical appraisal and update on some of the most promising candidates for biomarkers, namely, neuroimaging markers, peripheral biomarkers and genetic markers, including a brief discussion on cognitive endophenotypes as indicative of genetic risk. The lessons learnt from other fields and specialties in medicine need to be applied to psychiatry to translate the knowledge from 'bench to bedside' by means of clinically useful biomarkers. Overall, the biomarkers may help in pushing the shift towards personalized medicine for psychiatric patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sagar</LastName><ForeName>Rajesh</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, All Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pattanayak</LastName><ForeName>Raman Deep</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, All Institute of Medical Sciences, New Delhi, India.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>India</Country><MedlineTA>Indian J Med Res</MedlineTA><NlmUniqueID>0374701</NlmUniqueID><ISSNLinking>0971-5916</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>7171WSG8A2</RegistryNumber><NameOfSubstance UI="C579455">BDNF protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059906" MajorTopicYN="N">Neuroimaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28574009</ArticleId><ArticleId IdType="pii">IndianJMedRes_2017_145_1_7_207225</ArticleId><ArticleId IdType="doi">10.4103/ijmr.IJMR_1386_16</ArticleId><ArticleId IdType="pmc">PMC5460576</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clin Pharmacol Ther. 2001 Mar;69(3):89-95</Citation><ArticleIdList><ArticleId IdType="pubmed">11240971</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Investig. 2010 Dec;7(4):243-50</Citation><ArticleIdList><ArticleId IdType="pubmed">21253407</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2014 Dec;16(12):514</Citation><ArticleIdList><ArticleId IdType="pubmed">25308386</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):1-15</Citation><ArticleIdList><ArticleId IdType="pubmed">21320248</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Jul 1;48(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10913502</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Med. 2015 Nov 30;13:289</Citation><ArticleIdList><ArticleId IdType="pubmed">26621529</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2009 May;33(5):699-771</Citation><ArticleIdList><ArticleId IdType="pubmed">19428491</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Psychiatry. 2013 Jan 07;3:114</Citation><ArticleIdList><ArticleId IdType="pubmed">23316174</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Genet. 2011 Sep 18;43(10):977-83</Citation><ArticleIdList><ArticleId IdType="pubmed">21926972</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Dec;104(1-3):91-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17434599</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Dec;111(2-3):135-44</Citation><ArticleIdList><ArticleId IdType="pubmed">18539338</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Jan;45(1):92-5</Citation><ArticleIdList><ArticleId IdType="pubmed">20546789</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Med Genet B Neuropsychiatr Genet. 2010 Jan 5;153B(1):120-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19418510</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Sep 15;64(6):513-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18571627</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Aug;45(8):995-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">21550050</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1017-32</Citation><ArticleIdList><ArticleId IdType="pubmed">18762588</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2012 Dec;66(7):553-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23252921</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Med Res. 2006 Jan;37(1):79-85</Citation><ArticleIdList><ArticleId IdType="pubmed">16314191</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2007;3:137-58</Citation><ArticleIdList><ArticleId IdType="pubmed">17716051</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Feb;45(2):156-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20541770</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Feb;113(1-2):1-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18684514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):589-97</Citation><ArticleIdList><ArticleId IdType="pubmed">16403184</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Sep 15;184:1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">26057335</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009 Apr 21;70(5):699-705</Citation><ArticleIdList><ArticleId IdType="pubmed">19389332</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2013 Apr;47(4):321-32</Citation><ArticleIdList><ArticleId IdType="pubmed">23411094</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2008 Jan 22;19(2):221-4</Citation><ArticleIdList><ArticleId IdType="pubmed">18185112</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 May;170(5):533-41</Citation><ArticleIdList><ArticleId IdType="pubmed">23558337</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2016 Aug;123(8):1001-11</Citation><ArticleIdList><ArticleId IdType="pubmed">27273092</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 May;195:199-214</Citation><ArticleIdList><ArticleId IdType="pubmed">26896814</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Mar 1;67(5):414-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19931855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Sep;12(6):647-56</Citation><ArticleIdList><ArticleId IdType="pubmed">20868463</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Apr;160(4):636-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12668349</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Aug;116(3):214-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19251324</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Nov;159(11):1841-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12411217</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Sep;195(3):194-201</Citation><ArticleIdList><ArticleId IdType="pubmed">19721106</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Sep;128(3):149-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23617548</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2008 Nov;33(6):531-40</Citation><ArticleIdList><ArticleId IdType="pubmed">18982176</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2007 Dec;9(6):512-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18221633</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Feb 15;69(4):326-35</Citation><ArticleIdList><ArticleId IdType="pubmed">21030008</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Dec;45(12):1608-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21889167</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2014 Aug 15;218(1-2):61-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24794031</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Aug;132(3):344-55</Citation><ArticleIdList><ArticleId IdType="pubmed">21470688</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2012 Feb;22(2):100-13</Citation><ArticleIdList><ArticleId IdType="pubmed">21820878</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2009;21(4):394-409</Citation><ArticleIdList><ArticleId IdType="pubmed">20374153</ArticleId></ArticleIdList></Reference><Reference><Citation>Proteomics. 2011 Jan;11(2):261-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21204253</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2008 May;33(6):1229-38</Citation><ArticleIdList><ArticleId IdType="pubmed">17687266</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 May 5;106(18):7501-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19416921</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2015 Sep;17 (9):75</Citation><ArticleIdList><ArticleId IdType="pubmed">26257147</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychiatr Dis Treat. 2014 Dec 09;10:2325-30</Citation><ArticleIdList><ArticleId IdType="pubmed">25525361</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Jun;13(4):414-24</Citation><ArticleIdList><ArticleId IdType="pubmed">21843281</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2014 Oct;57:12-25</Citation><ArticleIdList><ArticleId IdType="pubmed">25015683</ArticleId></ArticleIdList></Reference><Reference><Citation>Proteomics. 2011 Jan;11(1):94-105</Citation><ArticleIdList><ArticleId IdType="pubmed">21182197</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 Nov 9;382(9904):1575-86</Citation><ArticleIdList><ArticleId IdType="pubmed">23993280</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1820-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21624424</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2008 Jun;38(6):771-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17922938</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):185-92</Citation><ArticleIdList><ArticleId IdType="pubmed">16678909</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2008 Nov;47(11):1289-98</Citation><ArticleIdList><ArticleId IdType="pubmed">18827720</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2009 Oct;43(15):1200-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19501841</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Sep;47(9):1119-33</Citation><ArticleIdList><ArticleId IdType="pubmed">23768870</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Aug;171(8):829-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24626773</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neural Transm (Vienna). 2010 May;117(5):639-54</Citation><ArticleIdList><ArticleId IdType="pubmed">20107844</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2009 Dec;120(6):456-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19416126</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2013 Dec;15(12):425</Citation><ArticleIdList><ArticleId IdType="pubmed">24243532</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 May;12(4):447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18771602</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 Feb;12(1):137-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18845016</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Mar 15;174:432-40</Citation><ArticleIdList><ArticleId IdType="pubmed">25553404</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2010 Aug 12;466(7308):827-8</Citation><ArticleIdList><ArticleId IdType="pubmed">20703297</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2009 Mar 13;452(2):111-3</Citation><ArticleIdList><ArticleId IdType="pubmed">19383424</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Neuropsychiatry. 2008 Mar;13(2):135-47</Citation><ArticleIdList><ArticleId IdType="pubmed">18302026</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2014 Jun;71(6):657-64</Citation><ArticleIdList><ArticleId IdType="pubmed">24718920</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Nov 1;68(9):785-94</Citation><ArticleIdList><ArticleId IdType="pubmed">20728076</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):243-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19100808</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2003 Jul;2(7):566-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12838269</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2011 Apr 20;494(1):54-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21362460</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2008 Oct;62(5):515-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18950370</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18657241</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Reporting outcomes in clinical trials for bipolar disorder: a commentary and suggestions for change.</ArticleTitle><Pagination><MedlinePgn>566-79</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2008.00611.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Newer outcome measures and statistical reporting that better translate efficacy data to evidence-based psychiatric care are needed when evaluating clinical trials for bipolar disorder. Using efficacy studies as illustrations, the authors review and recommend changes in the reporting of traditional clinical outcomes both in the acute and maintenance phases of bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Definitions of response, remission, relapse, recovery, and recurrence are reviewed and recommendations for change are made. These suggestions include reporting the numbers needed to treat or harm (NNT or NNH), and a ratio of the two, likelihood of help or harm (LHH), as an important element of the effect size (ES). Moreover, models of prediction that conduct sensitivity or specificity analyses and utilize decision trees to help predict positive and negative outcomes of interest (for instance, excessive weight gain, or time to remission) using positive or negative predictive values (PPV or NPV) are reviewed for potential value to clinicians. Finally, functional and cognitive assessments are recommended for maintenance studies of bipolar disorder.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The examples provided in this manuscript underscore that reporting the NNT or NNH, or alternative effect sizes, or using PPV or NPV may be of particular value to clinicians. Such reports are likely to help translate efficacy-driven clinical data to information that will more readily guide clinicians on the benefits and risks of specific interventions in bipolar disorder.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The authors opine that reporting these newer outcomes, such as NNT or NNH, area under the receiver operating curve (AUC), or PPV or NPV will help translate the results of clinical trials into a language that is more readily understood by clinicians. Moreover, assessing and evaluating functional and cognitive outcomes will not only inform clinicians about potential differences among therapeutic options, but likely will make it easier to communicate such differences to persons with bipolar illness or to their families. Finally, we hope such scientific and research efforts will translate to optimism for recovery-based outcomes in persons with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martinez-Arán</LastName><ForeName>Anabel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, IDIBAPS, CIBER-SAM, Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chengappa</LastName><ForeName>K N Roy</ForeName><Initials>KN</Initials></Author><Author ValidYN="Y"><LastName>Gershon</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mullen</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Paulsson</LastName><ForeName>Björn</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018849" MajorTopicYN="N">Controlled Clinical Trials as Topic</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003663" MajorTopicYN="N">Decision Trees</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017277" MajorTopicYN="N">Drug Approval</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008134" MajorTopicYN="N">Long-Term Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>58</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>7</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18657241</ArticleId><ArticleId IdType="pii">BDI611</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2008.00611.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15677598</PMID><DateCompleted><Year>2005</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>162</Volume><Issue>2</Issue><PubDate><Year>2005</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Relapse prevention in patients with bipolar disorder: cognitive therapy outcome after 2 years.</ArticleTitle><Pagination><MedlinePgn>324-9</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In a previous randomized controlled study, the authors reported significant beneficial effects of cognitive therapy for relapse prevention in bipolar disorder patients up to 1 year. This study reports additional 18-month follow-up data and presents an overview of the effect of therapy over 30 months.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Patients with DSM-IV bipolar I disorder (N=103) suffering from frequent relapses were randomly assigned into a cognitive therapy plus medication group or a control condition of medication only. Independent raters, who were blind to patient group status, assessed patients at 6-month intervals.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over 30 months, the cognitive therapy group had significantly better outcome in terms of time to relapse. However, the effect of relapse prevention was mainly in the first year. The cognitive therapy group also spent 110 fewer days (95% CI=32 to 189) in bipolar episodes out of a total of 900 for the whole 30 months and 54 fewer days (95% CI=3 to 105) in bipolar episodes out of a total of 450 for the last 18 months. Multivariate analyses of variance showed that over the last 18 months, the cognitive therapy group exhibited significantly better mood ratings, social functioning, coping with bipolar prodromes, and dysfunctional goal attainment cognition.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patients in the cognitive therapy group had significantly fewer days in bipolar episodes after the effect of medication compliance was controlled. However, the results showed that cognitive therapy had no significant effect in relapse reduction over the last 18 months of the study period. Further studies should explore the effect of booster sessions or maintenance therapy.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Dominic H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Psychology, Institute of Psychiatry, King's College, London, UK. spjtdhl@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayward</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>Edward R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Sham</LastName><ForeName>Pak</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Evid Based Ment Health. 2005 Nov;8(4):102</RefSource><PMID Version="1">16246878</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>1</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15677598</ArticleId><ArticleId IdType="pii">162/2/324</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.162.2.324</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25282427</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1989-4600</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><MedlineDate>2015 Jan-Mar</MedlineDate></PubDate></JournalIssue><Title>Revista de psiquiatria y salud mental</Title><ISOAbbreviation>Rev Psiquiatr Salud Ment</ISOAbbreviation></Journal><ArticleTitle>[Assessment of individual clinical outcomes: regarding an electroconvulsive therapy case].</ArticleTitle><Pagination><MedlinePgn>11-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rpsm.2014.07.003</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1888-9891(14)00099-8</ELocationID><Abstract><AbstractText>Evaluation of therapeutic results and of the efficacy and effectiveness of treatments is an area of interest both for clinicians and researchers. In general, randomized controlled trial designs have been used as the methodology of choice in which intergroup comparisons are made having a minimum of participants in each arm of treatment. However, these procedures are seldom used in daily clinical practice. Despite this fact, the evaluation of treatment results for a specific patient is important for the clinician in order to address if therapeutic goals have been accomplished both in terms of statistical significance and clinical meaningfulness. The methodology based on the reliable change index (Jacobson y Truax)1 provides an estimate of these two criteria. The goal of this article is to propose a procedure to apply the methodology with a single case study of a woman diagnosed with major depression and treated with electroconvulsive therapy.</AbstractText><CopyrightInformation>Copyright © 2014 SEP y SEPB. Published by Elsevier España. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Iraurgi</LastName><ForeName>Ioseba</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Departamento de Personalidad, Evaluación y Tratamientos Psicológicos, Universidad de Deusto, Bilbao, Vizcaya, España. Electronic address: ioseba.iraurgi@deusto.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gorbeña</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Departamento de Personalidad, Evaluación y Tratamientos Psicológicos, Universidad de Deusto, Bilbao, Vizcaya, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martínez-Cubillos</LastName><ForeName>Miren-Itxaso</ForeName><Initials>MI</Initials><AffiliationInfo><Affiliation>Fundación Eragintza, Bilbao, Vizcaya, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escribano</LastName><ForeName>Margarita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidad de Hospitalización, Avances Médicos (AMSA), Bilbao, Vizcaya, España.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gómez-de-Maintenant</LastName><ForeName>Pablo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Departamento de Personalidad, Evaluación y Tratamientos Psicológicos, Universidad de Deusto, Bilbao, Vizcaya, España.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Evaluación de resultados clínicos individuales: a propósito de un caso tratado con terapia electroconvulsiva.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Psiquiatr Salud Ment</MedlineTA><NlmUniqueID>101528851</NlmUniqueID><ISSNLinking>1888-9891</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="N">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="Y">Electroconvulsive Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063868" MajorTopicYN="Y">Patient Outcome Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063189" MajorTopicYN="N">Symptom Assessment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Case study</Keyword><Keyword MajorTopicYN="N">Clinical assessment</Keyword><Keyword MajorTopicYN="N">Efectividad</Keyword><Keyword MajorTopicYN="N">Effectiveness</Keyword><Keyword MajorTopicYN="N">Estudio de caso</Keyword><Keyword MajorTopicYN="N">Evaluación clínica</Keyword><Keyword MajorTopicYN="N">Reliable change index</Keyword><Keyword MajorTopicYN="N">Índice de cambio fiable</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>07</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25282427</ArticleId><ArticleId IdType="pii">S1888-9891(14)00099-8</ArticleId><ArticleId IdType="doi">10.1016/j.rpsm.2014.07.003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7325488</PMID><DateCompleted><Year>1982</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-4487</ISSN><JournalIssue CitedMedium="Print"><Volume>139</Volume><Issue>3</Issue><PubDate><Year>1981</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annales medico-psychologiques</Title><ISOAbbreviation>Ann Med Psychol (Paris)</ISOAbbreviation></Journal><ArticleTitle>[Unusual ecmnesic condensation during manic attack].</ArticleTitle><Pagination><MedlinePgn>322-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sizaret</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Degiovanni</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Gailard</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Condensation ecmnésique particulière au cours d'un accès maniaque.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Ann Med Psychol (Paris)</MedlineTA><NlmUniqueID>2984692R</NlmUniqueID><ISSNLinking>0003-4487</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008569" MajorTopicYN="N">Memory Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1981</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1981</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1981</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7325488</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21658357</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>16</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>5</Issue><PubDate><Year>2011</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Sleep and circadian rhythm disturbances in bipolar disorder: an urgent need for objective assessment and systematic follow-up.</ArticleTitle><Pagination><MedlinePgn>724</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.11l06850</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>Flavio</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Frey</LastName><ForeName>Benicio N</ForeName><Initials>BN</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>J Clin Psychiatry. 2010 Dec;71(12):1689-95</RefSource><PMID Version="1">21190640</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021081" MajorTopicYN="N">Chronobiology Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21658357</ArticleId><ArticleId IdType="doi">10.4088/JCP.11l06850</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2031465</PMID><DateCompleted><Year>1991</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-690X</ISSN><JournalIssue CitedMedium="Print"><Volume>83</Volume><Issue>3</Issue><PubDate><Year>1991</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Diagnosing personality disorders in psychiatric inpatients.</ArticleTitle><Pagination><MedlinePgn>206-13</MedlinePgn></Pagination><Abstract><AbstractText>This study investigated assumptions made by DSM-III and DSM-III-R regarding Axis I-Axis II associations and sex differences for the 11 personality disorders (PD). A total of 112 patients formed 4 Axis I diagnostic groups: recent-onset schizophrenia (n = 35); recent-onset mania (n = 26); unipolar affective disorder (n = 30); and a mixed diagnostic group (n = 21). The prevalence of PD was determined using the Structured Interview for DSM-III Personality Disorders (SIDP). Schizophrenia was associated with antisocial PD and schizotypal PD; manic disorder was associated with histrionic PD; and unipolar affective disorder was associated with borderline, dependent and avoidant PD. Some of these results were consistent with DSM-III/DSM-III-R postulates. However, there was little support for the DSM-III/DSM-III-R statements on sex differences in the prevalence of PD, except for antisocial PD. The implications of the results for DSM-III/DSM-III-R assumptions are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>H J</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>NH &amp; MRC Schizophrenia Research Unit, University of Melbourne, Victoria, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Whiteside</LastName><ForeName>H L</ForeName><Initials>HL</Initials></Author><Author ValidYN="Y"><LastName>Bates</LastName><ForeName>G W</ForeName><Initials>GW</Initials></Author><Author ValidYN="Y"><LastName>Bell</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Rudd</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Edwards</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005783" MajorTopicYN="N">Gender Identity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2031465</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.1991.tb05526.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19538905</PMID><DateCompleted><Year>2009</Year><Month>11</Month><Day>23</Day></DateCompleted><DateRevised><Year>2009</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>70</Volume><Issue>10</Issue><PubDate><Year>2009</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder, schizoaffective disorder, and schizophrenia overlap: a new comorbidity index.</ArticleTitle><Pagination><MedlinePgn>1432-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.4088/JCP.08m04807</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Growing evidence of an etiologic overlap between schizophrenia, schizoaffective disorder, and bipolar disorder has become increasingly difficult to disregard. We investigated the magnitude of the overlap between the clinical diagnoses of bipolar affective disorder, schizoaffective disorder, and schizophrenia over a 35-year period based on the entire Danish population.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We established a register-based prospective cohort study of more than 2.5 million persons born in Denmark after 1954. Risks for the 3 psychiatric disorders were estimated by survival analysis using the Aalen-Johansen method. Cohort members were followed from 1970 to 2006. We introduced a new comorbidity index measuring the magnitude of the overlap between the 3 disorders.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall, 12,734 patients were admitted with schizophrenia, 4,205 with bipolar disorder, and 1,881 with schizoaffective disorder. A female bipolar patient's risk of also being admitted with a schizoaffective disorder by the age of 45 years was approximately 103 times higher than that of a woman at the same age in the general population. Thus, we defined the comorbidity index between schizoaffective disorder and bipolar disorder at age 45 years to be 103. At age 45 years, the index between schizophrenia and schizoaffective disorder was 80 and between schizophrenia and bipolar disorder was 20. Similar large comorbidity indexes were found for men.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A large comorbidity index between schizophrenia and schizoaffective disorder was found, as well as a large index between bipolar disorder and schizoaffective disorder. But, more surprisingly, it was clear that a substantial comorbidity index between bipolar disorder and schizophrenia was present. This study supports the existence of an overlap between bipolar disorder and schizophrenia and thus challenges the strict categorical approach used in both DSM-IV and ICD-10 classification systems.</AbstractText><CopyrightInformation>Copyright 2009 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laursen</LastName><ForeName>Thomas Munk</ForeName><Initials>TM</Initials><AffiliationInfo><Affiliation>National Centre for Register-Based Research, University of Aarhus, Taasingegade 1, DK-8000 Aarhus C, Denmark. tml@ncrr.dk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agerbo</LastName><ForeName>Esben</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Pedersen</LastName><ForeName>Carsten Bøcker</ForeName><Initials>CB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>02</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19538905</ArticleId><ArticleId IdType="doi">10.4088/JCP.08m04807</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29282470</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>2</Issue><PubDate><Year>2018</Year><Month>02</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of Transcranial Direct Current Stimulation as an Add-on Treatment for Bipolar Depression: A Randomized Clinical Trial.</ArticleTitle><Pagination><MedlinePgn>158-166</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2017.4040</ELocationID><Abstract><AbstractText Label="Importance">More effective, tolerable interventions for bipolar depression treatment are needed. Transcranial direct current stimulation (tDCS) is a novel therapeutic modality with few severe adverse events that showed promising results for unipolar depression.</AbstractText><AbstractText Label="Objective">To determine the efficacy and safety of tDCS as an add-on treatment for bipolar depression.</AbstractText><AbstractText Label="Design, Setting, and Participants">A randomized, sham-controlled, double-blind trial (the Bipolar Depression Electrical Treatment Trial [BETTER]) was conducted from July 1, 2014, to March 30, 2016, at an outpatient, single-center academic setting. Participants included 59 adults with type I or II bipolar disorder in a major depressive episode and receiving a stable pharmacologic regimen with 17-item Hamilton Depression Rating Scale (HDRS-17) scores higher than 17. Data were analyzed in the intention-to-treat sample.</AbstractText><AbstractText Label="Interventions">Ten daily 30-minute, 2-mA, anodal-left and cathodal-right prefrontal sessions of active or sham tDCS on weekdays and then 1 session every fortnight until week 6.</AbstractText><AbstractText Label="Main Outcomes and Measures">Change in HDRS-17 scores at week 6.</AbstractText><AbstractText Label="Results">Fifty-nine patients (40 [68%] women), with a mean (SD) age of 45.9 (12) years participated; 36 (61%) with bipolar I and 23 (39%) with bipolar II disorder were randomized and 52 finished the trial. In the intention-to-treat analysis, patients in the active tDCS condition showed significantly superior improvement compared with those receiving sham (βint = -1.68; number needed to treat, 5.8; 95% CI, 3.3-25.8; P = .01). Cumulative response rates were higher in the active vs sham groups (67.6% vs 30.4%; number needed to treat, 2.69; 95% CI, 1.84-4.99; P = .01), but not remission rates (37.4% vs 19.1%; number needed to treat, 5.46; 95% CI, 3.38-14.2; P = .18). Adverse events, including treatment-emergent affective switches, were similar between groups, except for localized skin redness that was higher in the active group (54% vs 19%; P = .01).</AbstractText><AbstractText Label="Conclusions and Relevance">In this trial, tDCS was an effective, safe, and tolerable add-on intervention for this small bipolar depression sample. Further trials should examine tDCS efficacy in a larger sample.</AbstractText><AbstractText Label="Trial Registration">clinicaltrials.gov Identifier: NCT02152878.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sampaio-Junior</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Center for Clinical and Epidemiological Research &amp; Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neuroscience and National Institute of Biomarkers in Psychiatry, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortella</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Center for Clinical and Epidemiological Research &amp; Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neuroscience and National Institute of Biomarkers in Psychiatry, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borrione</LastName><ForeName>Lucas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Clinical and Epidemiological Research &amp; Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moffa</LastName><ForeName>Adriano H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Center for Clinical and Epidemiological Research &amp; Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado-Vieira</LastName><ForeName>Rodrigo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroscience and National Institute of Biomarkers in Psychiatry, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Experimental Therapeutics and Molecular Pathophysiology Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cretaz</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Research Program, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandes da Silva</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Center for Clinical and Epidemiological Research &amp; Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fraguas</LastName><ForeName>Renério</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Clinical and Epidemiological Research &amp; Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aparício</LastName><ForeName>Luana V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Center for Clinical and Epidemiological Research &amp; Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Izio</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafer</LastName><ForeName>Beny</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Research Program, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goerigk</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychological Methodology and Assessment, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Hochschule Fresenius, University of Applied Sciences, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Benseñor</LastName><ForeName>Isabela Martins</ForeName><Initials>IM</Initials><AffiliationInfo><Affiliation>Center for Clinical and Epidemiological Research &amp; Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lotufo</LastName><ForeName>Paulo Andrade</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Center for Clinical and Epidemiological Research &amp; Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gattaz</LastName><ForeName>Wagner F</ForeName><Initials>WF</Initials><AffiliationInfo><Affiliation>Laboratory of Neuroscience and National Institute of Biomarkers in Psychiatry, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunoni</LastName><ForeName>André Russowsky</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Center for Clinical and Epidemiological Research &amp; Interdisciplinary Center for Applied Neuromodulation, University Hospital, University of São Paulo, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service of Interdisciplinary Neuromodulation, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neuroscience and National Institute of Biomarkers in Psychiatry, Department and Institute of Psychiatry, University of São Paulo Medical School, São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Ludwig-Maximilians-University, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02152878</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Front Hum Neurosci. 2018 Dec 03;12:480</RefSource><PMID Version="1">30574077</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061214" MajorTopicYN="N">Patient Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017397" MajorTopicYN="N">Prefrontal Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065908" MajorTopicYN="N">Transcranial Direct Current Stimulation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29282470</ArticleId><ArticleId IdType="pii">2666768</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2017.4040</ArticleId><ArticleId IdType="pmc">PMC5838572</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Psychiatry. 2013 Nov;170(11):1249-62</Citation><ArticleIdList><ArticleId IdType="pubmed">24030475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Feb;15(1):1-44</Citation><ArticleIdList><ArticleId IdType="pubmed">23237061</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromodulation. 2014 Dec;17(8):737-42; discussion 742</Citation><ArticleIdList><ArticleId IdType="pubmed">24725075</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2013 Feb;15(1):61-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23190379</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2017 Aug 1;78:123-131</Citation><ArticleIdList><ArticleId IdType="pubmed">28552295</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Oct 15;48(8):830-43</Citation><ArticleIdList><ArticleId IdType="pubmed">11063978</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2012 Jan;37(1):102-16</Citation><ArticleIdList><ArticleId IdType="pubmed">21976043</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2016 Aug;18(5):440-50</Citation><ArticleIdList><ArticleId IdType="pubmed">27566286</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2001;62 Suppl 16:5-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11480882</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2015 Jan;172(1):41-51</Citation><ArticleIdList><ArticleId IdType="pubmed">25219389</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2014 Mar;31(3):196-206</Citation><ArticleIdList><ArticleId IdType="pubmed">24610817</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Methods Psychiatr Res. 2014 Dec;23(4):469-73</Citation><ArticleIdList><ArticleId IdType="pubmed">24038349</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1999 Dec 4;319(7223):1492-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10582940</ArticleId></ArticleIdList></Reference><Reference><Citation>Neural Plast. 2015;2015:684025</Citation><ArticleIdList><ArticleId IdType="pubmed">25878904</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2014 Dec;130(6):452-69</Citation><ArticleIdList><ArticleId IdType="pubmed">25283309</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2008 Feb 19;148(4):295-309</Citation><ArticleIdList><ArticleId IdType="pubmed">18283207</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2018 Feb;85:81-92</Citation><ArticleIdList><ArticleId IdType="pubmed">28688701</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Stimul. 2016 Sep-Oct;9(5):671-81</Citation><ArticleIdList><ArticleId IdType="pubmed">27261431</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2015 Jun;72(6):603-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25785575</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2006 Jun 1;59(11):990-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16368078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2002 Feb 9;359(9305):515-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11853818</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuromodulation. 2015 Jun;18(4):261-5</Citation><ArticleIdList><ArticleId IdType="pubmed">25209456</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychopharmacology. 2017 Dec;42(13):2593-2601</Citation><ArticleIdList><ArticleId IdType="pubmed">28145409</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2007 Jan;58(1):85-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17215417</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2012 Sep;42(9):1791-800</Citation><ArticleIdList><ArticleId IdType="pubmed">22236735</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Apr;70(4):383-91</Citation><ArticleIdList><ArticleId IdType="pubmed">23389323</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Stimul. 2012 Jul;5(3):242-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21962978</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2016 Jun;208(6):522-31</Citation><ArticleIdList><ArticleId IdType="pubmed">27056623</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2013 Nov 27;310(20):2191-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2007 Feb 06;7:7</Citation><ArticleIdList><ArticleId IdType="pubmed">17284321</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2013 Aug;28(6):356-61</Citation><ArticleIdList><ArticleId IdType="pubmed">23182847</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Stimul. 2015 May-Jun;8(3):590-602</Citation><ArticleIdList><ArticleId IdType="pubmed">25862601</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2015 Jun;14(2):119-36</Citation><ArticleIdList><ArticleId IdType="pubmed">26043321</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 2010 Jun;30(3):306-11</Citation><ArticleIdList><ArticleId IdType="pubmed">20473068</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):170-175</Citation><ArticleIdList><ArticleId IdType="pubmed">27815324</ArticleId></ArticleIdList></Reference><Reference><Citation>Int Rev Psychiatry. 2017 Apr;29(2):146-167</Citation><ArticleIdList><ArticleId IdType="pubmed">28523976</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2012 Jan;200(1):52-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22215866</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2016 Feb;15(1):85-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26833619</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015 Dec;45(16):3411-32</Citation><ArticleIdList><ArticleId IdType="pubmed">26349810</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2007 Apr 26;356(17):1711-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17392295</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):96-101</Citation><ArticleIdList><ArticleId IdType="pubmed">20854868</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2011 Sep;14(8):1133-45</Citation><ArticleIdList><ArticleId IdType="pubmed">21320389</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2017 Feb 1;74(2):143-152</Citation><ArticleIdList><ArticleId IdType="pubmed">28030740</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2017 Jun 29;376(26):2523-2533</Citation><ArticleIdList><ArticleId IdType="pubmed">28657871</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Stimul. 2017 Mar - Apr;10 (2):260-262</Citation><ArticleIdList><ArticleId IdType="pubmed">27916405</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32305265</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2021</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-7862</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><PubDate><Year>2020</Year><Month>05</Month></PubDate></JournalIssue><Title>European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology</Title><ISOAbbreviation>Eur Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>The black sheep of the family- whole-exome sequencing in family of lithium response discordant bipolar monozygotic twins.</ArticleTitle><Pagination><MedlinePgn>19-27</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0924-977X(20)30072-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.euroneuro.2020.03.009</ELocationID><Abstract><AbstractText>Twin studies are among the most promising strategies for studying heritable disorders, including bipolar disorder (BD). The aim of the present study was to identify distinguishing genes between monozygotic (MZ) twins with different BD phenotype and compare them to their non-affected siblings. Whole-exome sequencing (WES) can identify rare and structural variants that could detect the polygenetic burden of complex disorders. WES was performed on a family composed of two MZ twins with BD, their unaffected brother and unaffected parents. The twins have a discordant response to lithium and distinct course of illness. Following WES, six genes of particular interest emerged: Neurofibromin type 1 (NF1), Biorientation of chromosomes in cell division 1 (BOD1), Golgi-associated gamma adaptin ear-containing ARF binding protein 3 (GGA3), Disrupted in schizophrenia 1 (DISC1), Neuromedin U receptor 2 (NMUR2), and Huntingtin interacting protein 1-related (HIP1R). Interestingly, many of these influence glutamatergic pathways and thus the findings may have therapeutical implications. These results may provide important insights to unveil genetic underpinnings of BD and the response to lithium.</AbstractText><CopyrightInformation>Copyright © 2020. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Asaf</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Psychiatry, Sheba Medical Center, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagin</LastName><ForeName>Michal</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatry, Sheba Medical Center, Ramat Gan, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shugol</LastName><ForeName>Miraz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatry, Sheba Medical Center, Ramat Gan, Israel; Mayaney Yehoshua Hospital, Bnei Brak, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shomron</LastName><ForeName>Noam</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pillar</LastName><ForeName>Nir</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel; Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fañanás</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Evolutionary Biology, Ecology and Environmental Sciences, Faculty of Biology, University of Barcelona, CIBERSAM, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical and NeuroMotor Science, University of Bologna, Bologna, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Popovic</LastName><ForeName>Dina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Psychiatry, Sheba Medical Center, Ramat Gan, Israel; Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain. Electronic address: popovic.dina@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Eur Neuropsychopharmacol</MedlineTA><NlmUniqueID>9111390</NlmUniqueID><ISSNLinking>0924-977X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014430" MajorTopicYN="N">Twins, Monozygotic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073359" MajorTopicYN="N">Whole Exome Sequencing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Bipolar Disorder</Keyword><Keyword MajorTopicYN="Y">Lithium</Keyword><Keyword MajorTopicYN="Y">Whole exome sequencing</Keyword><Keyword MajorTopicYN="Y">genetics</Keyword></KeywordList><CoiStatement>Competing interest Prof. Vieta has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Galenica, Janssen, Lundbeck, Novartis, Otsuka, Sage, Sanofi-Aventis, and Takeda. Prof. Serretti is or has been consultant/speaker for: Abbott, Abbvie, Angelini, Astra Zeneca, Clinical Data, Boheringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Innovapharma, Italfarmaco, Janssen, Lundbeck, Naurex, Pfizer, Polifarma, Sanofi, Servier. Dr. Popovic has served as a speaker and/or medical writer or has participated in advisory boards for Bristol-Myers Squibb, Merck Sharp &amp; Dohme, Janssen-Cilag, Ferrer, and Forum Pharmaceuticals.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>10</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32305265</ArticleId><ArticleId IdType="pii">S0924-977X(20)30072-9</ArticleId><ArticleId IdType="doi">10.1016/j.euroneuro.2020.03.009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22329478</PMID><DateCompleted><Year>2012</Year><Month>06</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2012</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Olfactory acuity is associated with mood and function in a pilot study of stable bipolar disorder patients.</ArticleTitle><Pagination><MedlinePgn>109-17</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2012.00986.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Olfactory dysfunction is described in several neuropsychiatric disorders but there is little research on olfactory processing in bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We assessed odor detection threshold (sensitivity) and smell identification test scores, along with symptoms, cognition, and social function in 20 DSM-IV bipolar disorder patients and 44 control subjects.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The patient and control groups had similar demographic measures, intelligence, and mean olfaction scores, but significantly differed in social domains, including adjustment, function, and anxiety. Odor detection sensitivity showed significantly opposite correlations for the depressive and manic mood domains in bipolar disorder (r to z = 2.83, p = 0.005). Depressive symptoms were related to increased sensitivity (the ability to detect odors at a lower concentration) and mania symptoms were related to decreased sensitivity for odor detection. Increased sensitivity for odor detection also predicted significantly better employment (r = -0.642, p = 0.024), whereas less sensitivity was associated with social avoidance (r = 0.702, p =0.024) and social fear (r = 0.610, p = 0.046).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Diminished odor detection sensitivity predicted mania and social avoidance, whereas more sensitive odor detection predicted more depressive symptoms but better employment functioning in bipolar disorder patients. Odor acuity may be an illness state marker of mood syndromes in bipolar disorder. Alternatively, differences in odor acuity may identify heterogeneous subgroups within the bipolar spectrum. Longitudinal assessments in a large, sex-stratified sample are needed to understand the implications of odor sensitivity in patients with bipolar disorder.</AbstractText><CopyrightInformation>© 2012 John Wiley and Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hardy</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, New York University (NYU) School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosedale</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Messinger</LastName><ForeName>Julie W</ForeName><Initials>JW</Initials></Author><Author ValidYN="Y"><LastName>Kleinhaus</LastName><ForeName>Karine</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Aujero</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Silva</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Raymond R</ForeName><Initials>RR</Initials></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Harkavy-Friedman</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Dolores</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH066428</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 MH001699-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH066428-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>2 K24 MH01699</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH066428-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 MH001699</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="Y">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="N">Olfaction Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012684" MajorTopicYN="Y">Sensory Thresholds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="Y">Smell</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="Y">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="Y">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22329478</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2012.00986.x</ArticleId><ArticleId IdType="pmc">PMC3281516</ArticleId><ArticleId IdType="mid">NIHMS348115</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 2006 Feb;90(2-3):187-91</Citation><ArticleIdList><ArticleId IdType="pubmed">16376994</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1999 Jan;29(1):199-212</Citation><ArticleIdList><ArticleId IdType="pubmed">10077308</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Spectr. 2002 Jan;7(1):43-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15254448</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Dec;127(1-3):50-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20557947</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Nov;51(11):849-59; discussion 863-4</Citation><ArticleIdList><ArticleId IdType="pubmed">7944874</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1987;13(2):261-76</Citation><ArticleIdList><ArticleId IdType="pubmed">3616518</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Apr 30;176(2-3):190-6</Citation><ArticleIdList><ArticleId IdType="pubmed">20207422</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Apr;114(1-3):1-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18819715</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 1994 Summer;6(3):273-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7950351</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2008 Dec;10(6):505-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18980734</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Behav. 1984 Mar;32(3):489-502</Citation><ArticleIdList><ArticleId IdType="pubmed">6463130</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2010 Oct;25(6):328-33</Citation><ArticleIdList><ArticleId IdType="pubmed">20444581</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Jun;60(6):578-84</Citation><ArticleIdList><ArticleId IdType="pubmed">12796221</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2009 Feb;166(2):226-33</Citation><ArticleIdList><ArticleId IdType="pubmed">19074977</ArticleId></ArticleIdList></Reference><Reference><Citation>J Gerontol. 1993 Jan;48(1):M26-32</Citation><ArticleIdList><ArticleId IdType="pubmed">8418141</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2004 Apr;254(2):61-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15146334</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2008 Jul;8(7):1101-13</Citation><ArticleIdList><ArticleId IdType="pubmed">18590480</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Mar 1;67(5):414-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19931855</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurosci. 2008 Nov 12;28(46):11785-91</Citation><ArticleIdList><ArticleId IdType="pubmed">19005040</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2001 Sep-Oct;35(5):271-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11591429</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 1997;30(5):263-74</Citation><ArticleIdList><ArticleId IdType="pubmed">9353855</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1990 Dec;157:853-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2289094</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Mar 1;67(5):422-31</Citation><ArticleIdList><ArticleId IdType="pubmed">20159144</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1987 Dec;22(12):1481-5</Citation><ArticleIdList><ArticleId IdType="pubmed">3676376</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol (New York). 2009 Jun 1;16(2):188-201</Citation><ArticleIdList><ArticleId IdType="pubmed">20360999</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2009 Aug 1;33(5):827-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19345708</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):183-96</Citation><ArticleIdList><ArticleId IdType="pubmed">17391360</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2006 Feb;163(2):217-24</Citation><ArticleIdList><ArticleId IdType="pubmed">16449474</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Manag Care. 2007 Nov;13(7 Suppl):S164-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18041877</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Jul;87(1):101-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15894380</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2005 Dec 15;80(2-3):283-93</Citation><ArticleIdList><ArticleId IdType="pubmed">16125904</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2009 Jan;9(1):109-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19102673</ArticleId></ArticleIdList></Reference><Reference><Citation>J Anxiety Disord. 2006;20(8):1148-57</Citation><ArticleIdList><ArticleId IdType="pubmed">16630705</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 2006 Jul;31(4):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">16862244</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1994 May 15;35(10):798-802</Citation><ArticleIdList><ArticleId IdType="pubmed">8043710</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Dec;160(12):2099-107</Citation><ArticleIdList><ArticleId IdType="pubmed">14638578</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1988 Jan 15;23(2):123-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3334881</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2008 Aug;62(4):450-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18778443</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Nov;35(6):1117-31</Citation><ArticleIdList><ArticleId IdType="pubmed">19793796</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Dec;59(12):1119-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12470128</ArticleId></ArticleIdList></Reference><Reference><Citation>Isr Med Assoc J. 2009 Apr;11(4):238-43</Citation><ArticleIdList><ArticleId IdType="pubmed">19603599</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroscience. 2010 Aug 11;169(1):415-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20472036</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1999 Jun 1;45(11):1419-25</Citation><ArticleIdList><ArticleId IdType="pubmed">10356623</ArticleId></ArticleIdList></Reference><Reference><Citation>Radiology. 2010 Apr;255(1):23-41</Citation><ArticleIdList><ArticleId IdType="pubmed">20308442</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropharmacology. 2010 May;58(6):884-93</Citation><ArticleIdList><ArticleId IdType="pubmed">20060007</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2012 Mar;135(1-3):144-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22177347</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Neurol. 2009 Feb;29(1):74-81</Citation><ArticleIdList><ArticleId IdType="pubmed">19214935</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Feb;12(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20148862</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2007 Dec;9(6):512-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18221633</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopathology. 2010;43(1):1-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19893338</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Nov;56(1):27-35</Citation><ArticleIdList><ArticleId IdType="pubmed">10626777</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Dec;189:515-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17139035</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Oct;8(5 Pt 2):558-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17042829</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2008 Sep;32(7):1315-25</Citation><ArticleIdList><ArticleId IdType="pubmed">18555528</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19689509</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 May;49(5):371-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1586272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Sep;102(1-3):101-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17291590</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26746321</PMID><DateCompleted><Year>2016</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0013-7006</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>4 Suppl 1</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>L'Encephale</Title><ISOAbbreviation>Encephale</ISOAbbreviation></Journal><ArticleTitle>[Circadian markers and genes in bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>S38-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S0013-7006(15)30005-1</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0013-7006(15)30005-1</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Bipolar disorder is a severe and complex multifactorial disease, characterized by alternance of acute episodes of depression and mania/hypomania, interspaced by euthymic periods. The etiological determinants of bipolar disorder yet, are still poorly understood. For the last 30 years, chronobiology is an important field of investigation to better understand the pathophysiology of bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a review using Medline, ISI Database, EMBase, PsyInfo up to January 2015, using the following keywords combinations: "mood disorder", "bipolar disorder", "depression", "unipolar disorder", "major depressive disorder", "affective disorder", for psychiatric conditions; and "circadian rhythms", "circadian markers", "circadian gene", "clock gene", "melatonin" for circadian rhythms. The search critera was presence of word in any field of the article.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Quantitative and qualitative circadian abnormalities are associated with bipolar disorders both during acute episodes and euthymic periods, suggesting that these altered circadian rhythms may represent biological trait markers of the disorder. These circadian dysfunctions were assessed by various validated tools including polysomnography, actigraphy, sleep diaries, chronotype assessments and blood melatonin/cortisol measures. Other altered endogenous circadian activities have also been reported in bipolar patients, such as hormones secretion, core body temperature or fibroblasts activity. Moreover, these markers were also altered in healthy relatives of bipolar patients, suggesting a degree of heritability. Several genetic association studies have also showed associations between multiple circadian genes and bipolar disorder, such as CLOCK, ARTNL1, GSK3β, PER3, NPAS2, NR1D1, TIMELESS, RORA, RORB, and CSNK1ε. Thus, these circadian gene variants may contribute to the genetic susceptibility of the disease. Furthermore, the study of the clock system may help to better understand some phenotypic aspects like the mechanisms of pharmacological treatments used in bipolar disorder, in particular lithium carbonate.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Several clinical, physiological and genetic data suggest that circadian rhythms dysregulations are involved in the pathophysiology of bipolar disorder. The circadian model has led to the development of new therapeutic strategies such as chronotherapeutics or Inter Personal Social and Rhythms Therapies. Further studies are needed in this promising research field to keep exploring the relationship between these circadian markers, genes and the clinical aspects of the disease.</AbstractText><CopyrightInformation>Copyright © 2015 L’Encéphale. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yeim</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S1144, Paris, F-75013, France; AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris Cedex 10, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boudebesse</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Pôle de Psychiatrie, Hôpital Henri Mondor -Albert Chenevier, Créteil, 94000, France; Inserm, U955, Créteil, 94000, France; Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etain</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pôle de Psychiatrie, Hôpital Henri Mondor -Albert Chenevier, Créteil, 94000, France; Inserm, U955, Créteil, 94000, France; Fondation Fondamental, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belliviera</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Inserm, U1144, Paris, F-75006, France; Université Paris Descartes, UMR-S1144, Paris, F-75006, France; Université Paris Diderot, Sorbonne Paris Cité, UMR-S1144, Paris, F-75013, France; AP-HP, GH Saint-Louis - Lariboisière - F. Widal, Pôle de Psychiatrie et de Médecine Addictologique, 75475 Paris Cedex 10, France; Fondation Fondamental, Créteil, France. Electronic address: frank.bellivier@inserm.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Biomarqueurs et gènes circadiens dans le trouble bipolaire.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Encephale</MedlineTA><NlmUniqueID>7505643</NlmUniqueID><ISSNLinking>0013-7006</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D021081" MajorTopicYN="N">Chronobiology Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005786" MajorTopicYN="N">Gene Expression Regulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="N">Melatonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Biomarqueurs</Keyword><Keyword MajorTopicYN="N">Bipolar disorders</Keyword><Keyword MajorTopicYN="N">Chronotype</Keyword><Keyword MajorTopicYN="N">Circadian genes</Keyword><Keyword MajorTopicYN="N">Circadian rhythms</Keyword><Keyword MajorTopicYN="N">Gènes circadiens</Keyword><Keyword MajorTopicYN="N">Rythmes circadiens</Keyword><Keyword MajorTopicYN="N">Trouble bipolaire</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>1</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26746321</ArticleId><ArticleId IdType="pii">S0013-7006(15)30005-1</ArticleId><ArticleId IdType="doi">10.1016/S0013-7006(15)30005-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7553547</PMID><DateCompleted><Year>1995</Year><Month>10</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0706-7437</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>5</Issue><PubDate><Year>1995</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Canadian journal of psychiatry. Revue canadienne de psychiatrie</Title><ISOAbbreviation>Can J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A comparison of comorbid patterns in treatment-resistant unipolar and bipolar depression.</ArticleTitle><Pagination><MedlinePgn>270-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To examine the occurrence of concomitant psychiatric disorders in patients with treatment-resistant unipolar and bipolar depression.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Forty-nine patients participated as subjects. Twenty-four (49%) had unipolar depression and 25 (51%) had bipolar depression using DSM-III-R criteria. Structured clinical interviews were conducted with all patients. Chart reviews and interviews with family members were also carried out. Information relating to both current and lifetime diagnoses was obtained.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the entire sample, 75.5% were found to have at least one other Axis I diagnosis and 46.9% had at least two additional Axis I diagnoses. The unipolar group had significantly more current comorbid diagnoses. When type of diagnoses was examined, unipolar patients had significantly more anxiety diagnoses at the time of the index episode, and over their entire lifetime. Bipolar patients had significantly more lifetime substance abuse diagnoses.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Axis I comorbidity appears to be differentially associated with treatment resistance in unipolar and bipolar depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Mood Disorders Unit, London Psychiatric Hospital, Ontario.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazmanian</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Persad</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kueneman</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Can J Psychiatry</MedlineTA><NlmUniqueID>7904187</NlmUniqueID><ISSNLinking>0706-7437</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7553547</ArticleId><ArticleId IdType="doi">10.1177/070674379504000509</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7068543</PMID><DateCompleted><Year>1982</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>4</Issue><PubDate><Year>1982</Year><Month>Apr</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Relapse in patients with shifting RDC diagnoses treated with lithium alone.</ArticleTitle><Pagination><MedlinePgn>134-6</MedlinePgn></Pagination><Abstract><AbstractText>After a research diagnostic interview with 60 chronic outpatients clinically diagnosed as schizophrenic, the authors identified four patients who by retrospective history had had affective episodes at one time in their life and schizophrenic episodes at another. Lithium was substituted for antipsychotic medications and the patients were followed for 13 months. Two patients relapsed on lithium alone, one relapsed on no medications and one did well on lithium alone. The phenomenology observed in the three relapsing cases included: 1) RDC mania; 2) rapid onset with confusion; 3) sexually regressive behavior; and 4) improvement with reinitiation of antipsychotic medication. Caution is advised in the use of lithium alone for patients fitting this diagnostic description.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Glazer</LastName><ForeName>W M</ForeName><Initials>WM</Initials></Author><Author ValidYN="Y"><LastName>Sheard</LastName><ForeName>M H</ForeName><Initials>MH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1982</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1982</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1982</Year><Month>4</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7068543</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29345040</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>05</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Assessing and addressing cognitive impairment in bipolar disorder: the International Society for Bipolar Disorders Targeting Cognition Task Force recommendations for clinicians.</ArticleTitle><Pagination><MedlinePgn>184-194</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12595</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Cognition is a new treatment target to aid functional recovery and enhance quality of life for patients with bipolar disorder. The International Society for Bipolar Disorders (ISBD) Targeting Cognition Task Force aimed to develop consensus-based clinical recommendations on whether, when and how to assess and address cognitive impairment.</AbstractText><AbstractText Label="METHODS">The task force, consisting of 19 international experts from nine countries, discussed the challenges and recommendations in a face-to-face meeting, telephone conference call and email exchanges. Consensus-based recommendations were achieved through these exchanges with no need for formal consensus methods.</AbstractText><AbstractText Label="RESULTS">The identified questions were: (I) Should cognitive screening assessments be routinely conducted in clinical settings? (II) What are the most feasible screening tools? (III) What are the implications if cognitive impairment is detected? (IV) What are the treatment perspectives? Key recommendations are that clinicians: (I) formally screen cognition in partially or fully remitted patients whenever possible, (II) use brief, easy-to-administer tools such as the Screen for Cognitive Impairment in Psychiatry and Cognitive Complaints in Bipolar Disorder Rating Assessment, and (III) evaluate the impact of medication and comorbidity, refer patients for comprehensive neuropsychological evaluation when clinically indicated, and encourage patients to build cognitive reserve. Regarding question (IV), there is limited evidence for current evidence-based treatments but intense research efforts are underway to identify new pharmacological and/or psychological cognition treatments.</AbstractText><AbstractText Label="CONCLUSIONS">This task force paper provides the first consensus-based recommendations for clinicians on whether, when, and how to assess and address cognition, which may aid patients' functional recovery and improve their quality of life.</AbstractText><CopyrightInformation>© 2018 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miskowiak</LastName><ForeName>K W</ForeName><Initials>KW</Initials><Identifier Source="ORCID">0000-0003-2572-1384</Identifier><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Deparment of Psychology, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burdick</LastName><ForeName>K E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez-Aran</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnin</LastName><ForeName>C M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowie</LastName><ForeName>C R</ForeName><Initials>CR</Initials><Identifier Source="ORCID">0000-0002-1983-8861</Identifier><AffiliationInfo><Affiliation>Department of Psychology, Queen's University, Kingston, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carvalho</LastName><ForeName>A F</ForeName><Initials>AF</Initials><Identifier Source="ORCID">0000-0001-5593-2778</Identifier><AffiliationInfo><Affiliation>Department of Clinical Medicine and Translational Psychiatry Research Group, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallagher</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Neuroscience, Newcastle University, Newcastle-upon-Tyne, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafer</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Research Program, Departamento de Psiquiatria, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>López-Jaramillo</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Research Group in Psychiatry, Department of Psychiatry, Universidad de Antioquia, Medellín, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sumiyoshi</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Clinical Epidemiology, Translational Medical Center, National Center of Neurology and Psychiatry, Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>R S</ForeName><Initials>RS</Initials><Identifier Source="ORCID">0000-0003-4733-2523</Identifier><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit Brain and Cognition Discovery Foundation, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaffer</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>R J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Purdon</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Alberta, Edmonton, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Torres</LastName><ForeName>I J</ForeName><Initials>IJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yatham</LastName><ForeName>L N</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>A H</ForeName><Initials>AH</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>L V</ForeName><Initials>LV</Initials><Identifier Source="ORCID">0000-0001-9377-9436</Identifier><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Centre (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0548-0053</Identifier><AffiliationInfo><Affiliation>Clinical Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058245" MajorTopicYN="N">Cognitive Reserve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">cognitive impairment</Keyword><Keyword MajorTopicYN="Y">neuropsychological</Keyword><Keyword MajorTopicYN="Y">recommendations</Keyword><Keyword MajorTopicYN="Y">screening</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>09</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>1</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29345040</ArticleId><ArticleId IdType="doi">10.1111/bdi.12595</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23686158</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-736X</ISSN><JournalIssue CitedMedium="Internet"><Volume>201</Volume><Issue>6</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Social cognition and clinical insight in schizophrenia and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>445-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NMD.0b013e31829480c8</ELocationID><Abstract><AbstractText>The association between clinical insight and social cognition assessed with an emotion perception task was investigated in schizophrenia (n = 29) and bipolar I disorder (n = 19). Persons with schizophrenia had reduced auditory emotion perception compared with individuals with bipolar I disorder, but levels of visual emotion perception and clinical insight were comparable. In the schizophrenia group, clinical insight was moderately associated with auditory and visual emotion perception (r = 0.36-0.44) and negative symptoms (r = -0.33). Better insight was associated with better social cognition and fewer negative symptoms. In the bipolar I disorder group, clinical insight showed small associations with social cognition (largest r = -0.28) and moderate to large associations with positive, negative, manic, and depressive symptoms. Poorer insight was associated with higher symptom load. Social cognition seems to be of importance for clinical insight in schizophrenia, whereas symptoms are important in bipolar I disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vaskinn</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>KG Jebsen Centre for Psychosis Research, Oslo University Hospital, Oslo, Norway. anja.vaskinn@medisin.uio.no</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sundet</LastName><ForeName>Kjetil</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Ueland</LastName><ForeName>Torill</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Agartz</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Melle</LastName><ForeName>Ingrid</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Andreassen</LastName><ForeName>Ole A</ForeName><Initials>OA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001307" MajorTopicYN="N">Auditory Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D032882" MajorTopicYN="Y">Comprehension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056348" MajorTopicYN="N">Emotional Intelligence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011581" MajorTopicYN="N">Psychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012938" MajorTopicYN="Y">Social Perception</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23686158</ArticleId><ArticleId IdType="doi">10.1097/NMD.0b013e31829480c8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32636474</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5578</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>01</Month></PubDate></JournalIssue><Title>Molecular psychiatry</Title><ISOAbbreviation>Mol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Advances toward precision medicine for bipolar disorder: mechanisms &amp; molecules.</ArticleTitle><Pagination><MedlinePgn>168-185</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41380-020-0831-4</ELocationID><Abstract><AbstractText>Given its chronicity, contribution to disability and morbidity, and prevalence of more than 2%, the effective treatment, and prevention of bipolar disorder represents an area of significant unmet medical need. While more than half a century has passed since the introduction of lithium into widespread use at the birth of modern psychopharmacology, that medication remains a mainstay for the acute treatment and prevention of recurrent mania/hypomania and depression that characterize bipolar disorder. However, the continued limited understanding of how lithium modulates affective behavior and lack of validated cellular and animal models have resulted in obstacles to discovering more effective mood stabilizers with fewer adverse side effects. In particular, while there has been progress in developing new pharmacotherapy for mania, developing effective treatments for acute bipolar depression remain inadequate. Recent large-scale human genetic studies have confirmed the complex, polygenic nature of the risk architecture of bipolar disorder, and its overlap with other major neuropsychiatric disorders. Such discoveries have begun to shed light on the pathophysiology of bipolar disorder. Coupled with broader advances in human neurobiology, neuropharmacology, noninvasive neuromodulation, and clinical trial design, we can envision novel therapeutic strategies informed by defined molecular mechanisms and neural circuits and targeted to the root cause of the pathophysiology. Here, we review recent advances toward the goal of better treatments for bipolar disorder, and we outline major challenges for the field of translational neuroscience that necessitate continued focus on fundamental research and discovery.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haggarty</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Chemical Neurobiology Laboratory, Center for Genomic Medicine, Massachusetts General Hospital, Departments of Psychiatry &amp; Neurology, Harvard Medical School, 185 Cambridge Street, Boston, MA, USA. shaggarty@mgh.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karmacharya</LastName><ForeName>Rakesh</ForeName><Initials>R</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-0565-5482</Identifier><AffiliationInfo><Affiliation>Center for Genomic Medicine, Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School Boston, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Schizophrenia and Bipolar Disorder Program, McLean Hospital, Belmont, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perlis</LastName><ForeName>Roy H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Center for Quantitative Health, Center for Genomic Medicine and Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH120227</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AT009144</GrantID><Acronym>AT</Acronym><Agency>NCCIH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH113858</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Psychiatry</MedlineTA><NlmUniqueID>9607835</NlmUniqueID><ISSNLinking>1359-4184</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>01</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>06</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>04</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32636474</ArticleId><ArticleId IdType="doi">10.1038/s41380-020-0831-4</ArticleId><ArticleId IdType="pii">10.1038/s41380-020-0831-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust. 1949;2:349–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">18142718</ArticleId></ArticleIdList></Reference><Reference><Citation>https://enacademic.com/dic.nsf/enwiki/9778 Accessed 1 July 2020.</Citation></Reference><Reference><Citation>Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543–52.</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId><ArticleId IdType="pmcid">1931566</ArticleId></ArticleIdList></Reference><Reference><Citation>Schioldann J. History of the introduction of lithium into medicine and psychiatry: birth of modern psychopharmacology. Adelaide: Academic Press; 1949.</Citation></Reference><Reference><Citation>Parker G, McCraw S, Hadzi-Pavlovic D, Fletcher K. Costs of the principal mood disorders: a study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. J Affect Disord. 2013;149:46–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">23141630</ArticleId></ArticleIdList></Reference><Reference><Citation>Judd LL, Akiskal HS, Schettler PJ, Coryell W, Endicott J, Maser JD, et al. A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Arch Gen Psychiatry. 2003;60:261–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12622659</ArticleId></ArticleIdList></Reference><Reference><Citation>Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002;59:530–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohen M, Hennen J, Zarate CM Jr, Baldessarini RJ, Strakowski SM, Stoll AL, et al. Two-year syndromal and functional recovery in 219 cases of first-episode major affective disorder with psychotic features. Am J Psychiatry. 2000;157:220–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10671390</ArticleId></ArticleIdList></Reference><Reference><Citation>Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–50.</Citation></Reference><Reference><Citation>Keck PE, Perlis RH, Otto MW, Carpenter D, Ross R, Docherty JP. Expert Consensus Guideline Series: Treatment of Bipolar Disorder 2004. Postgrad Med. 2004:1–120.</Citation></Reference><Reference><Citation>Hirschfeld RA, Bowden CL, Gitlin MJ, Keck PE, Perlis RH, Suppes T et al. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(Suppl 4):1–11.</Citation></Reference><Reference><Citation>Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR, et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870–86.</Citation><ArticleIdList><ArticleId IdType="pubmed">16013903</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">17392295</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemeroff CB, Evans DL, Gyulai L, Sachs GS, Bowden CL, Gergel IP, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry. 2001;158:906–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">11384898</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord. 2008;10:323–33.</Citation><ArticleIdList><ArticleId IdType="pubmed">18271912</ArticleId></ArticleIdList></Reference><Reference><Citation>Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079–88.</Citation><ArticleIdList><ArticleId IdType="pubmed">14609883</ArticleId></ArticleIdList></Reference><Reference><Citation>Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17110817</ArticleId></ArticleIdList></Reference><Reference><Citation>Vieta E, Calabrese JR, Goikolea JM, Raines S, Macfadden W. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2007;9:413–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">17547587</ArticleId></ArticleIdList></Reference><Reference><Citation>Weisler RH, Calabrese JR, Thase ME, Arvekvist R, Stening G, Paulsson B, et al. Efficacy of quetiapine monotherapy for the treatment of depressive episodes in bipolar I disorder: a post hoc analysis of combined results from 2 double-blind, randomized, placebo-controlled studies. J Clin Psychiatry. 2008;69:769–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">18452345</ArticleId></ArticleIdList></Reference><Reference><Citation>Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19:1–93.</Citation><ArticleIdList><ArticleId IdType="pubmed">15998156</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherk H, Pajonk FG, Leucht S. Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials. Arch Gen Psychiatry. 2007;64:442–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">17404121</ArticleId></ArticleIdList></Reference><Reference><Citation>Cosgrove VE, Kelsoe JR, Suppes T. Toward a valid animal model of bipolar disorder: how the research domain criteria help bridge the clinical-basic science divide. Biol Psychiatry. 2016;79:62–70.</Citation><ArticleIdList><ArticleId IdType="pubmed">26531027</ArticleId></ArticleIdList></Reference><Reference><Citation>Scolnick EM. The path to new therapies for schizophrenia and bipolar illness. FASEB J. 2017;31:1254–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28360375</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HM, DeLong CJ, Bame M, Rajapakse I, Herron TJ, McInnis MG, et al. Transcripts involved in calcium signaling and telencephalic neuronal fate are altered in induced pluripotent stem cells from bipolar disorder patients. Transl Psychiatry. 2014;4:e375.</Citation><ArticleIdList><ArticleId IdType="pubmed">25116795</ArticleId><ArticleId IdType="pmcid">3966040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JL, Shamah SM, Sun AX, Waldman ID, Haggarty SJ, Perlis RH. Label-free, live optical imaging of reprogrammed bipolar disorder patient-derived cells reveals a functional correlate of lithium responsiveness. Transl Psychiatry. 2014;4:e428.</Citation><ArticleIdList><ArticleId IdType="pubmed">25158003</ArticleId><ArticleId IdType="pmcid">4150245</ArticleId></ArticleIdList></Reference><Reference><Citation>Madison JM, Zhou F, Nigam A, Hussain A, Barker DD, Nehme R, et al. Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities. Mol Psychiatry. 2015;20:703–17.</Citation><ArticleIdList><ArticleId IdType="pubmed">25733313</ArticleId><ArticleId IdType="pmcid">4440839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bavamian S, Mellios N, Lalonde J, Fass DM, Wang J, Sheridan SD, et al. Dysregulation of miR-34a links neuronal development to genetic risk factors for bipolar disorder. Mol Psychiatry. 2015;20:573–84.</Citation><ArticleIdList><ArticleId IdType="pubmed">25623948</ArticleId><ArticleId IdType="pmcid">4414679</ArticleId></ArticleIdList></Reference><Reference><Citation>Mertens J, Wang QW, Kim Y, Yu DX, Pham S, Yang B, et al. Differential responses to lithium in hyperexcitable neurons from patients with bipolar disorder. Nature. 2015;527:95–99.</Citation><ArticleIdList><ArticleId IdType="pubmed">26524527</ArticleId><ArticleId IdType="pmcid">4742055</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KH, Liu J, Sells Galvin RJ, Dage JL, Egeland JA, Smith RC, et al. Transcriptomic analysis of induced pluripotent stem cells derived from patients with bipolar disorder from an old order amish pedigree. PLoS ONE. 2015;10:e0142693.</Citation><ArticleIdList><ArticleId IdType="pubmed">26554713</ArticleId><ArticleId IdType="pmcid">4640865</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobe BTD, Crain AM, Winquist AM, Calabrese B, Makihara H, Zhao WN, et al. Probing the lithium-response pathway in hiPSCs implicates the phosphoregulatory set-point for a cytoskeletal modulator in bipolar pathogenesis. Proc Natl Acad Sci USA. 2017;114:E4462–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">28500272</ArticleId></ArticleIdList></Reference><Reference><Citation>Vizlin-Hodzic D, Zhai Q, Illes S, Sodersten K, Truve K, Parris TZ, et al. Early onset of inflammation during ontogeny of bipolar disorder: the NLRP2 inflammasome gene distinctly differentiates between patients and healthy controls in the transition between iPS cell and neural stem cell stages. Transl Psychiatry. 2017;7:e1010.</Citation><ArticleIdList><ArticleId IdType="pubmed">28117838</ArticleId><ArticleId IdType="pmcid">5545741</ArticleId></ArticleIdList></Reference><Reference><Citation>Stern S, Santos R, Marchetto MC, Mendes APD, Rouleau GA, Biesmans S, et al. Neurons derived from patients with bipolar disorder divide into intrinsically different sub-populations of neurons, predicting the patients’ responsiveness to lithium. Mol Psychiatry. 2018;23:1453–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">28242870</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggarty SJ, Silva MC, Cross A, Brandon NJ, Perlis RH. Advancing drug discovery for neuropsychiatric disorders using patient-specific stem cell models. Mol Cell Neurosci. 2016;73:104–15.</Citation><ArticleIdList><ArticleId IdType="pubmed">26826498</ArticleId><ArticleId IdType="pmcid">5292010</ArticleId></ArticleIdList></Reference><Reference><Citation>Nehme R, Zuccaro E, Ghosh SD, Li C, Sherwood JL, Pietilainen O, et al. Combining NGN2 programming with developmental patterning generates human excitatory neurons with NMDAR-mediated synaptic transmission. Cell Rep. 2018;23:2509–23.</Citation><ArticleIdList><ArticleId IdType="pubmed">29791859</ArticleId><ArticleId IdType="pmcid">6003669</ArticleId></ArticleIdList></Reference><Reference><Citation>Marton RM, Pasca SP. Organoid and assembloid technologies for investigating cellular crosstalk in human brain development and disease. Trends Cell Biol. 2019;30:133–43.</Citation><ArticleIdList><ArticleId IdType="pubmed">31879153</ArticleId></ArticleIdList></Reference><Reference><Citation>Velasco S, Kedaigle AJ, Simmons SK, Nash A, Rocha M, Quadrato G, et al. Individual brain organoids reproducibly form cell diversity of the human cerebral cortex. Nature. 2019;570:523–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31168097</ArticleId><ArticleId IdType="pmcid">6906116</ArticleId></ArticleIdList></Reference><Reference><Citation>NIMH Repository &amp; Genomics Resource ( https://www.nimhgenetics.org ). 2020.</Citation></Reference><Reference><Citation>Insel TR. The NIMH research domain criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014;171:395–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">24687194</ArticleId></ArticleIdList></Reference><Reference><Citation>McCoy TH Jr, Castro VM, Hart KL, Pellegrini AM, Yu S, Cai T, et al. Genome-wide association study of dimensional psychopathology using electronic health records. Biol Psychiatry. 2018;83:1005–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">29496196</ArticleId><ArticleId IdType="pmcid">5972060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lago SG, Tomasik J, van Rees GF, Steeb H, Cox DA, Rustogi N, et al. Drug discovery for psychiatric disorders using high-content single-cell screening of signaling network responses ex vivo. Sci Adv. 2019;5:eaau9093.</Citation><ArticleIdList><ArticleId IdType="pubmed">31086815</ArticleId><ArticleId IdType="pmcid">6506238</ArticleId></ArticleIdList></Reference><Reference><Citation>Perlis RH. Translating biomarkers to clinical practice. Mol Psychiatry. 2011;16:1076–87.</Citation><ArticleIdList><ArticleId IdType="pubmed">21709685</ArticleId><ArticleId IdType="pmcid">3752672</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueckert EH, Barker D, Ruderfer D, Bergen SE, O’Dushlaine C, Luce CJ, et al. Cis-acting regulation of brain-specific ANK3 gene expression by a genetic variant associated with bipolar disorder. Mol Psychiatry. 2013;18:922–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">22850628</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes T, Hansson L, Sonderby IE, Athanasiu L, Zuber V, Tesli M, et al. A loss-of-function variant in a minor isoform of ANK3 protects against bipolar disorder and schizophrenia. Biol Psychiatry. 2016;80:323–30.</Citation><ArticleIdList><ArticleId IdType="pubmed">26682468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes T, Sonderby IE, Polushina T, Hansson L, Holmgren A, Athanasiu L, et al. Elevated expression of a minor isoform of ANK3 is a risk factor for bipolar disorder. Transl Psychiatry. 2018;8:210.</Citation><ArticleIdList><ArticleId IdType="pubmed">30297702</ArticleId><ArticleId IdType="pmcid">6175894</ArticleId></ArticleIdList></Reference><Reference><Citation>Leussis MP, Berry-Scott EM, Saito M, Jhuang H, de Haan G, Alkan O, et al. The ANK3 bipolar disorder gene regulates psychiatric-related behaviors that are modulated by lithium and stress. Biol Psychiatry. 2013;73:683–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">23237312</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottschalk MG, Leussis MP, Ruland T, Gjeluci K, Petryshen TL, Bahn S. Lithium reverses behavioral and axonal transport-related changes associated with ANK3 bipolar disorder gene disruption. Eur Neuropsychopharmacol. 2017;27:274–88.</Citation><ArticleIdList><ArticleId IdType="pubmed">28109561</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu S, Cordner ZA, Xiong J, Chiu CT, Artola A, Zuo Y, et al. Genetic disruption of ankyrin-G in adult mouse forebrain causes cortical synapse alteration and behavior reminiscent of bipolar disorder. Proc Natl Acad Sci USA. 2017;114:10479–84.</Citation><ArticleIdList><ArticleId IdType="pubmed">28894008</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Werf IM, Van Dam D, Missault S, Yalcin B, De Deyn PP, Vandeweyer G, et al. Behavioural characterization of AnkyrinG deficient mice, a model for ANK3 related disorders. Behav Brain Res. 2017;328:218–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">28411148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez AY, Wang X, Xu M, Maheshwari A, Curry D, Lam S, et al. Ankyrin-G isoform imbalance and interneuronopathy link epilepsy and bipolar disorder. Mol Psychiatry. 2017;22:1464–72.</Citation><ArticleIdList><ArticleId IdType="pubmed">27956739</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson AD, Caballero-Floran RN, Rodriguez Diaz JC, Hull JM, Yuan Y, Li J et al. Ankyrin-G regulates forebrain connectivity and network synchronization via interaction with GABARAP. Mol Psychiatry. 2018. https://doi.org/10.1038/s41380-018-0308-x .</Citation></Reference><Reference><Citation>Garza JC, Qi X, Gjeluci K, Leussis MP, Basu H, Reis SA, et al. Disruption of the psychiatric risk gene Ankyrin 3 enhances microtubule dynamics through GSK3/CRMP2 signaling. Transl Psychiatry. 2018;8:135.</Citation><ArticleIdList><ArticleId IdType="pubmed">30046097</ArticleId><ArticleId IdType="pmcid">6060177</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis LD, Soanes KH. A larval zebrafish model of bipolar disorder as a screening platform for neuro-therapeutics. Behav Brain Res. 2012;233:450–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">22677277</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin X, Duan X, Jacobs C, Ullmann J, Chan CY, Chen S, et al. High-throughput brain activity mapping and machine learning as a foundation for systems neuropharmacology. Nat Commun. 2018;9:5142.</Citation><ArticleIdList><ArticleId IdType="pubmed">30510233</ArticleId><ArticleId IdType="pmcid">6277389</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA. 1996;93:8455–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8710892</ArticleId></ArticleIdList></Reference><Reference><Citation>Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr Biol. 1996;6:1664–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8994831</ArticleId></ArticleIdList></Reference><Reference><Citation>Freland L, Beaulieu JM. Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci. 2012;5:14.</Citation><ArticleIdList><ArticleId IdType="pubmed">22363263</ArticleId><ArticleId IdType="pmcid">3282483</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryves WJ, Dajani R, Pearl L, Harwood AJ. Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem Biophys Res Commun. 2002;290:967–72.</Citation><ArticleIdList><ArticleId IdType="pubmed">11798168</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland C, Leighton IA, Cohen P. Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem J. 1993;296:15–19.</Citation><ArticleIdList><ArticleId IdType="pubmed">8250835</ArticleId><ArticleId IdType="pmcid">1137648</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci USA. 1999;96:8745–50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10411946</ArticleId></ArticleIdList></Reference><Reference><Citation>De Sarno P, Li X, Jope RS. Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology. 2002;43:1158–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">12504922</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem. 2003;278:33067–77.</Citation><ArticleIdList><ArticleId IdType="pubmed">12796505</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Friedman AB, Zhu W, Wang L, Boswell S, May RS, et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biol Psychiatry. 2007;61:216–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">16806104</ArticleId></ArticleIdList></Reference><Reference><Citation>Polter A, Beurel E, Yang S, Garner R, Song L, Miller CA, et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology. 2010;35:1761–74.</Citation><ArticleIdList><ArticleId IdType="pubmed">20357757</ArticleId><ArticleId IdType="pmcid">2891528</ArticleId></ArticleIdList></Reference><Reference><Citation>Haggarty SJ, Singh K, Perlis RH, Karmacharya R. Wnt signaling in mood &amp; psychotic disorders. In: Wnt signaling in development and disease: molecular mechanisms and biological functions. Vol. 29. USA: Wiley; 2014. pp. 379–392.</Citation></Reference><Reference><Citation>Haggarty SJ, Singh K, Perlis RH, Karmacharya R. Neuropsychiatric disease-associated genetic variation in the Wnt pathway. In: Wnt signaling in development and disease: molecular mechanisms and biological functions. vol. 30. USA: Wiley; 2014. pp. 393–410.</Citation></Reference><Reference><Citation>Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, et al. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci USA. 2004;101:5099–104.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044694</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology. 2004;29:32–38.</Citation><ArticleIdList><ArticleId IdType="pubmed">12942141</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Brien WT, Harper AD, Jove F, Woodgett JR, Maretto S, Piccolo S, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci. 2004;24:6791–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15282284</ArticleId><ArticleId IdType="pmcid">5328671</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TD, Manji HK. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology. 2005;30:1223–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">15827567</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TD, Einat H, O’Donnell KC, Picchini AM, Schloesser RJ, Manji HK. Beta-catenin overexpression in the mouse brain phenocopies lithium-sensitive behaviors. Neuropsychopharmacology. 2007;32:2173–83.</Citation><ArticleIdList><ArticleId IdType="pubmed">17299510</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, et al. A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell. 2008;132:125–36.</Citation><ArticleIdList><ArticleId IdType="pubmed">18191226</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan JQ, Lewis MC, Ketterman JK, Clore EL, Riley M, Richards KR, et al. AKT kinase activity is required for lithium to modulate mood-related behaviors in mice. Neuropsychopharmacology. 2011;36:1397–11.</Citation><ArticleIdList><ArticleId IdType="pubmed">21389981</ArticleId><ArticleId IdType="pmcid">3096809</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris TJ, Peifer M. Decisions, decisions: beta-catenin chooses between adhesion and transcription. Trends Cell Biol. 2005;15:234–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">15866026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist. 2002;8:497–511.</Citation><ArticleIdList><ArticleId IdType="pubmed">12374432</ArticleId></ArticleIdList></Reference><Reference><Citation>Wexler EM, Geschwind DH, Palmer TD. Lithium regulates adult hippocampal progenitor development through canonical Wnt pathway activation. Mol Psychiatry. 2008;13:285–92.</Citation><ArticleIdList><ArticleId IdType="pubmed">17968353</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WN, Cheng C, Theriault KM, Sheridan SD, Tsai LH, Haggarty SJ. A high-throughput screen for Wnt/beta-catenin signaling pathway modulators in human iPSC-derived neural progenitors. J Biomol Screen. 2012;17:1252–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">22923789</ArticleId><ArticleId IdType="pmcid">3903585</ArticleId></ArticleIdList></Reference><Reference><Citation>Maguschak KA, Ressler KJ. Beta-catenin is required for memory consolidation. Nat Neurosci. 2008;11:1319–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">18820693</ArticleId><ArticleId IdType="pmcid">2597638</ArticleId></ArticleIdList></Reference><Reference><Citation>Toledo EM, Colombres M, Inestrosa NC. Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol. 2008;86:281–96.</Citation><ArticleIdList><ArticleId IdType="pubmed">18786602</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen G, Rajkowska G, Du F, Seraji-Bozorgzad N, Manji HK. Enhancement of hippocampal neurogenesis by lithium. J Neurochem. 2000;75:1729–34.</Citation><ArticleIdList><ArticleId IdType="pubmed">10987856</ArticleId></ArticleIdList></Reference><Reference><Citation>Choe Y, Pleasure SJ. Wnt signaling regulates intermediate precursor production in the postnatal dentate gyrus by regulating CXCR4 expression. Dev Neurosci. 2012;34:502–14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23257686</ArticleId></ArticleIdList></Reference><Reference><Citation>Snitow ME, Zanni G, Ciesielski B, Burgess-Jones P, Eisch AJ, O’Brien WT, et al. Adult hippocampal neurogenesis is not necessary for the response to lithium in the forced swim test. Neurosci Lett. 2019;704:67–72.</Citation><ArticleIdList><ArticleId IdType="pubmed">30940476</ArticleId><ArticleId IdType="pmcid">6594907</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Y, Ge X, Frank CL, Madison JM, Koehler AN, Doud MK, et al. Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling. Cell. 2009;136:1017–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">19303846</ArticleId><ArticleId IdType="pmcid">2704382</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipina TV, Kaidanovich-Beilin O, Patel S, Wang M, Clapcote SJ, Liu F, et al. Genetic and pharmacological evidence for schizophrenia-related Disc1 interaction with GSK-3. Synapse. 2011;65:234–48.</Citation><ArticleIdList><ArticleId IdType="pubmed">20687111</ArticleId><ArticleId IdType="pmcid">4485461</ArticleId></ArticleIdList></Reference><Reference><Citation>Hennig KM, Fass DM, Zhao WN, Sheridan SD, Fu T, Erdin S, et al. WNT/beta-catenin pathway and epigenetic mechanisms regulate the Pitt-Hopkins syndrome and schizophrenia risk gene TCF4. Mol Neuropsychiatry. 2017;3:53–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">28879201</ArticleId><ArticleId IdType="pmcid">5582445</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuechler A, Willemsen MH, Albrecht B, Bacino CA, Bartholomew DW, van Bokhoven H, et al. De novo mutations in beta-catenin (CTNNB1) appear to be a frequent cause of intellectual disability: expanding the mutational and clinical spectrum. Hum Genet. 2015;134:97–109.</Citation><ArticleIdList><ArticleId IdType="pubmed">25326669</ArticleId></ArticleIdList></Reference><Reference><Citation>Krumm N, O’Roak BJ, Shendure J, Eichler EE. A de novo convergence of autism genetics and molecular neuroscience. Trends Neurosci. 2014;37:95–105.</Citation><ArticleIdList><ArticleId IdType="pubmed">24387789</ArticleId></ArticleIdList></Reference><Reference><Citation>Beaulieu JM, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122:261–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">16051150</ArticleId></ArticleIdList></Reference><Reference><Citation>O’Brien WT, Huang J, Buccafusca R, Garskof J, Valvezan AJ, Berry GT, et al. Glycogen synthase kinase-3 is essential for beta-arrestin-2 complex formation and lithium-sensitive behaviors in mice. J Clin Invest. 2011;121:3756–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">21821916</ArticleId><ArticleId IdType="pmcid">3163947</ArticleId></ArticleIdList></Reference><Reference><Citation>Urs NM, Snyder JC, Jacobsen JP, Peterson SM, Caron MG. Deletion of GSK3beta in D2R-expressing neurons reveals distinct roles for beta-arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci USA. 2012;109:20732–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23188793</ArticleId></ArticleIdList></Reference><Reference><Citation>Latapy C, Rioux V, Guitton MJ, Beaulieu JM. Selective deletion of forebrain glycogen synthase kinase 3beta reveals a central role in serotonin-sensitive anxiety and social behaviour. Philos Trans R Soc Lond B Biol Sci. 2012;367:2460–74.</Citation><ArticleIdList><ArticleId IdType="pubmed">22826345</ArticleId><ArticleId IdType="pmcid">3405679</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W, Won SY, Yoon BJ. CRMP2 mediates GSK3beta actions in the striatum on regulating neuronal structure and mania-like behavior. J Affect Disord. 2019;245:1079–88.</Citation><ArticleIdList><ArticleId IdType="pubmed">30699850</ArticleId></ArticleIdList></Reference><Reference><Citation>Masri B, Salahpour A, Didriksen M, Ghisi V, Beaulieu JM, Gainetdinov RR, et al. Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics. Proc Natl Acad Sci USA. 2008;105:13656–61.</Citation><ArticleIdList><ArticleId IdType="pubmed">18768802</ArticleId></ArticleIdList></Reference><Reference><Citation>Khlghatyan J, Evstratova A, Chamberland S, Marakhovskaia A, Bahremand A, Toth K, et al. Mental Illnesses-Associated Fxr1 and Its Negative Regulator Gsk3beta Are Modulators of Anxiety and Glutamatergic Neurotransmission. Front Mol Neurosci. 2018;11:119.</Citation><ArticleIdList><ArticleId IdType="pubmed">29706865</ArticleId><ArticleId IdType="pmcid">5906571</ArticleId></ArticleIdList></Reference><Reference><Citation>Del’Guidice T, Latapy C, Rampino A, Khlghatyan J, Lemasson M, Gelao B, et al. FXR1P is a GSK3beta substrate regulating mood and emotion processing. Proc Natl Acad Sci USA. 2015;112:E4610–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26240334</ArticleId></ArticleIdList></Reference><Reference><Citation>Li YC, Panikker P, Xing B, Yang SS, Alexandropoulos C, McEachern EP, et al. Deletion of glycogen synthase kinase-3beta in D2 receptor-positive neurons ameliorates cognitive impairment via nmda receptor-dependent synaptic plasticity. Biol Psychiatry. 2020;87:745–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">31892408</ArticleId></ArticleIdList></Reference><Reference><Citation>Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734–41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11473107</ArticleId></ArticleIdList></Reference><Reference><Citation>Fass DM, Shah R, Ghosh B, Hennig K, Norton S, Zhao WN, et al. Effect of inhibiting histone deacetylase with short-chain carboxylic acids and their hydroxamic acid analogs on vertebrate development and neuronal chromatin. ACS Med Chem Lett. 2010;2:39–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">21874153</ArticleId><ArticleId IdType="pmcid">3161516</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder FA, Lin CL, Crusio WE, Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry. 2007;62:55–64.</Citation><ArticleIdList><ArticleId IdType="pubmed">16945350</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamawaki Y, Fuchikami M, Morinobu S, Segawa M, Matsumoto T, Yamawaki S. Antidepressant-like effect of sodium butyrate (HDAC inhibitor) and its molecular mechanism of action in the rat hippocampus. World J Biol Psychiatry. 2012;13:458–67.</Citation><ArticleIdList><ArticleId IdType="pubmed">21812623</ArticleId></ArticleIdList></Reference><Reference><Citation>Arent CO, Valvassori SS, Fries GR, Stertz L, Ferreira CL, Lopes-Borges J, et al. Neuroanatomical profile of antimaniac effects of histone deacetylases inhibitors. Mol Neurobiol. 2011;43:207–14.</Citation><ArticleIdList><ArticleId IdType="pubmed">21424678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim WY, Kim S, Kim JH. Chronic microinjection of valproic acid into the nucleus accumbens attenuates amphetamine-induced locomotor activity. Neurosci Lett. 2008;432:54–57.</Citation><ArticleIdList><ArticleId IdType="pubmed">18164815</ArticleId></ArticleIdList></Reference><Reference><Citation>Covington HE III, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O, et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci. 2009;29:11451–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19759294</ArticleId><ArticleId IdType="pmcid">2775805</ArticleId></ArticleIdList></Reference><Reference><Citation>Covington HE III, Vialou VF, LaPlant Q, Ohnishi YN, Nestler EJ. Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci Lett. 2011;493:122–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">21335060</ArticleId><ArticleId IdType="pmcid">3074929</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder FA, Lewis MC, Fass DM, Wagner FF, Zhang YL, Hennig KM, et al. A selective HDAC 1/2 inhibitor modulates chromatin and gene expression in brain and alters mouse behavior in two mood-related tests. PLoS ONE. 2013;8:e71323.</Citation><ArticleIdList><ArticleId IdType="pubmed">23967191</ArticleId><ArticleId IdType="pmcid">3743770</ArticleId></ArticleIdList></Reference><Reference><Citation>Covington HE III, Maze I, Vialou V, Nestler EJ. Antidepressant action of HDAC inhibition in the prefrontal cortex. Neuroscience. 2015;298:329–35.</Citation><ArticleIdList><ArticleId IdType="pubmed">25907440</ArticleId><ArticleId IdType="pmcid">4441835</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan JS, Haggarty SJ, Giacometti E, Dannenberg JH, Joseph N, Gao J, et al. HDAC2 negatively regulates memory formation and synaptic plasticity. Nature. 2009;459:55–60.</Citation><ArticleIdList><ArticleId IdType="pubmed">19424149</ArticleId><ArticleId IdType="pmcid">3498958</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner FF, Zhang YL, Fass DM, Joseph N, Gale JP, Weiwer M, et al. Kinetically selective inhibitors of histone deacetylase 2 (HDAC2) as cognition enhancers. Chem Sci. 2015;6:804–15.</Citation><ArticleIdList><ArticleId IdType="pubmed">25642316</ArticleId></ArticleIdList></Reference><Reference><Citation>An WF, Germain AR, Bishop JA, Nag PP, Metkar S, Ketterman J, et al. Discovery of Potent and Highly Selective Inhibitors of GSK3b. Bethesda (MD): Probe Reports from the NIH Molecular Libraries Program; 2010.</Citation></Reference><Reference><Citation>Georgievska B, Sandin J, Doherty J, Mortberg A, Neelissen J, Andersson A, et al. AZD1080, a novel GSK3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. J Neurochem. 2013;125:446–56.</Citation><ArticleIdList><ArticleId IdType="pubmed">23410232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner FF, Benajiba L, Campbell AJ, Weiwer M, Sacher JR, Gale JP et al. Exploiting an Asp-Glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018;10:eaam8460.</Citation><ArticleIdList><ArticleId IdType="pubmed">29515000</ArticleId><ArticleId IdType="pmcid">6553635</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagner FF, Bishop JA, Gale JP, Shi X, Walk M, Ketterman J, et al. Inhibitors of glycogen synthase kinase 3 with exquisite kinome-wide selectivity and their functional effects. ACS Chem Biol. 2016;11:1952–63.</Citation><ArticleIdList><ArticleId IdType="pubmed">27128528</ArticleId></ArticleIdList></Reference><Reference><Citation>Griebel G, Stemmelin J, Lopez-Grancha M, Boulay D, Boquet G, Slowinski F, et al. The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents. Sci Rep. 2019;9:18045.</Citation><ArticleIdList><ArticleId IdType="pubmed">31792284</ArticleId><ArticleId IdType="pmcid">6888874</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard-Gauthier V, Mossine AV, Knight A, Patnaik D, Zhao WN, Cheng C, et al. Structural basis for achieving GSK-3beta inhibition with high potency, selectivity, and brain exposure for positron emission tomography imaging and drug discovery. J Med Chem. 2019;62:9600–17.</Citation><ArticleIdList><ArticleId IdType="pubmed">31535859</ArticleId><ArticleId IdType="pmcid">6883410</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhat RV, Andersson U, Andersson S, Knerr L, Bauer U, Sundgren-Andersson AK. The conundrum of gsk3 inhibitors: is it the dawn of a new beginning? J Alzheimers Dis. 2018;64:S547–54.</Citation><ArticleIdList><ArticleId IdType="pubmed">29758944</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WN. Discovery of suppressors of CRMP2 phosphorylation reveals compounds that mimic the behavioral effects of lithium on amphetamine-induced hyperlocomotion. Transl Psychiatry. 2020;10:76.</Citation><ArticleIdList><ArticleId IdType="pubmed">32094324</ArticleId><ArticleId IdType="pmcid">7039883</ArticleId></ArticleIdList></Reference><Reference><Citation>Soutar MP, Kim WY, Williamson R, Peggie M, Hastie CJ, McLauchlan H, et al. Evidence that glycogen synthase kinase-3 isoforms have distinct substrate preference in the brain. J Neurochem. 2010;115:974–83.</Citation><ArticleIdList><ArticleId IdType="pubmed">20831597</ArticleId></ArticleIdList></Reference><Reference><Citation>Caberlotto L, Carboni L, Zanderigo F, Andreetta F, Andreoli M, Gentile G, et al. Differential effects of glycogen synthase kinase 3 (GSK3) inhibition by lithium or selective inhibitors in the central nervous system. Naunyn Schmiedebergs Arch Pharm. 2013;386:893–903.</Citation></Reference><Reference><Citation>Bocchetta A, Bernardi F, Burrai C, Pedditzi M, Del Zompo M. A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives. Acta Psychiatr Scand. 1993;88:434–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">8310852</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng W, Xiang YQ, Li XB, Ungvari GS, Chiu HF, Sun F, et al. Adjunctive huperzine A for cognitive deficits in schizophrenia: a systematic review and meta-analysis. Hum Psychopharmacol. 2016;31:286–95.</Citation><ArticleIdList><ArticleId IdType="pubmed">27302211</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratia M, Gimenez-Llort L, Camps P, Munoz-Torrero D, Perez B, Clos MV, et al. Huprine X and huperzine A improve cognition and regulate some neurochemical processes related with Alzheimer’s disease in triple transgenic mice (3xTg-AD). Neurodegener Dis. 2013;11:129–40.</Citation><ArticleIdList><ArticleId IdType="pubmed">22626981</ArticleId></ArticleIdList></Reference><Reference><Citation>Berridge MJ, Downes CP, Hanley MR. Neural and developmental actions of lithium: a unifying hypothesis. Cell. 1989;59:411–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">2553271</ArticleId></ArticleIdList></Reference><Reference><Citation>Atack JR, Broughton HB, Pollack SJ. Inositol monophosphatase–a putative target for Li+ in the treatment of bipolar disorder. Trends Neurosci. 1995;18:343–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7482796</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N, Halliday AC, Thomas JM, Kuznetsova OV, Baldwin R, Woon EC, et al. A safe lithium mimetic for bipolar disorder. Nat Commun. 2013;4:1332.</Citation><ArticleIdList><ArticleId IdType="pubmed">23299882</ArticleId><ArticleId IdType="pmcid">3605789</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkus C, Ferland JN, Adams WK, Churchill GC, Cowen PJ, Bannerman DM, et al. The putative lithium-mimetic ebselen reduces impulsivity in rodent models. J Psychopharmacol. 2018;32:1018–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">29986609</ArticleId></ArticleIdList></Reference><Reference><Citation>Tondo L, Baldessarini RJ. Antisuicidal effects in mood disorders: are they unique to lithium? Pharmacopsychiatry. 2018;51:177–88.</Citation><ArticleIdList><ArticleId IdType="pubmed">29672801</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh N, Sharpley AL, Emir UE, Masaki C, Herzallah MM, Gluck MA, et al. Effect of the putative lithium mimetic ebselen on brain myo-inositol, sleep, and emotional processing in humans. Neuropsychopharmacology. 2016;41:1768–78.</Citation><ArticleIdList><ArticleId IdType="pubmed">26593266</ArticleId></ArticleIdList></Reference><Reference><Citation>Masaki C, Sharpley AL, Cooper CM, Godlewska BR, Singh N, Vasudevan SR, et al. Effects of the potential lithium-mimetic, ebselen, on impulsivity and emotional processing. Psychopharmacol (Berl). 2016;233:2655–61.</Citation></Reference><Reference><Citation>Craddock N, Sklar P. Genetics of bipolar disorder. Lancet. 2013;381:1654–62.</Citation><ArticleIdList><ArticleId IdType="pubmed">23663951</ArticleId></ArticleIdList></Reference><Reference><Citation>Stahl EA, Breen G, Forstner AJ, McQuillin A, Ripke S, Trubetskoy V, et al. Genome-wide association study identifies 30 loci associated with bipolar disorder. Nat Genet. 2019;51:793–803.</Citation><ArticleIdList><ArticleId IdType="pubmed">31043756</ArticleId><ArticleId IdType="pmcid">6956732</ArticleId></ArticleIdList></Reference><Reference><Citation>Cross-Disorder Group of the Psychiatric Genomics Consortium. Electronic address pmhe, Cross-Disorder Group of the Psychiatric Genomics C. Genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. Cell. 2019;179:1469–82. e1411.</Citation></Reference><Reference><Citation>Hoffman GE, Bendl J, Voloudakis G, Montgomery KS, Sloofman L, Wang YC, et al. CommonMind Consortium provides transcriptomic and epigenomic data for schizophrenia and bipolar disorder. Sci Data. 2019;6:180.</Citation><ArticleIdList><ArticleId IdType="pubmed">31551426</ArticleId><ArticleId IdType="pmcid">6760149</ArticleId></ArticleIdList></Reference><Reference><Citation>Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Disco. 2013;12:581–94.</Citation></Reference><Reference><Citation>Cipriani A, Saunders K, Attenburrow MJ, Stefaniak J, Panchal P, Stockton S, et al. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development. Mol Psychiatry. 2016;21:1324–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">27240535</ArticleId><ArticleId IdType="pmcid">5030455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabir ZD, Martinez-Rivera A, Rajadhyaksha AM. From gene to behavior: L-type calcium channel mechanisms underlying neuropsychiatric symptoms. Neurotherapeutics. 2017;14:588–613.</Citation><ArticleIdList><ArticleId IdType="pubmed">28497380</ArticleId><ArticleId IdType="pmcid">5509628</ArticleId></ArticleIdList></Reference><Reference><Citation>Brunet G, Cerlich B, Robert P, Dumas S, Souetre E, Darcourt G. Open trial of a calcium antagonist, nimodipine, in acute mania. Clin Neuropharmacol. 1990;13:224–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">2192795</ArticleId></ArticleIdList></Reference><Reference><Citation>Grunze H, Walden J, Wolf R, Berger M. Combined treatment with lithium and nimodipine in a bipolar I manic syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:419–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">8771598</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazzaglia PJ, Post RM, Ketter TA, George MS, Marangell LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res. 1993;49:257–72.</Citation><ArticleIdList><ArticleId IdType="pubmed">8177920</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazzaglia PJ, Post RM, Ketter TA, Callahan AM, Marangell LB, Frye MA, et al. Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J Clin Psychopharmacol. 1998;18:404–13.</Citation><ArticleIdList><ArticleId IdType="pubmed">9790159</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostacher MJ, Iosifescu DV, Hay A, Blumenthal SR, Sklar P, Perlis RH. Pilot investigation of isradipine in the treatment of bipolar depression motivated by genome-wide association. Bipolar Disord. 2014;16:199–203.</Citation><ArticleIdList><ArticleId IdType="pubmed">24372835</ArticleId></ArticleIdList></Reference><Reference><Citation>Atkinson LZ, Colbourne L, Smith A, Harmer CH, Nobre AC, Rendell J, et al. The oxford study of calcium channel antagonism, cognition, mood instability and sleep (OxCaMS): study protocol for a randomised controlled, experimental medicine study. Trials. 2019;20:120.</Citation><ArticleIdList><ArticleId IdType="pubmed">30755265</ArticleId><ArticleId IdType="pmcid">6373140</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006;9:519–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">16501568</ArticleId></ArticleIdList></Reference><Reference><Citation>Renthal W, Maze I, Krishnan V, Covington HE III, Xiao G, Kumar A, et al. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron. 2007;56:517–29.</Citation><ArticleIdList><ArticleId IdType="pubmed">17988634</ArticleId></ArticleIdList></Reference><Reference><Citation>Wey HY, Gilbert TM, Zurcher NR, She A, Bhanot A, Taillon BD, et al. Insights into neuroepigenetics through human histone deacetylase PET imaging. Sci Transl Med. 2016;8:351ra106.</Citation><ArticleIdList><ArticleId IdType="pubmed">27510902</ArticleId><ArticleId IdType="pmcid">5784409</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert TM, Zurcher NR, Wu CJ, Bhanot A, Hightower BG, Kim M, et al. PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia. J Clin Invest. 2019;129:364–72.</Citation><ArticleIdList><ArticleId IdType="pubmed">30530989</ArticleId></ArticleIdList></Reference><Reference><Citation>Arjmand S, Behzadi M, Kohlmeier KA, Mazhari S, Sabahi A, Shabani M. Bipolar disorder and the endocannabinoid system. Acta Neuropsychiatr. 2019;31:193–201.</Citation><ArticleIdList><ArticleId IdType="pubmed">31159897</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrhart J, Obregon D, Mori T, Hou H, Sun N, Bai Y, et al. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation. 2005;2:29.</Citation><ArticleIdList><ArticleId IdType="pubmed">16343349</ArticleId><ArticleId IdType="pmcid">1352348</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Vaccarino A, Macqueen G, et al. A randomized, double-blind, controlled trial evaluating the effect of intranasal insulin on neurocognitive function in euthymic patients with bipolar disorder. Bipolar Disord. 2012;14:697–706.</Citation><ArticleIdList><ArticleId IdType="pubmed">23107220</ArticleId></ArticleIdList></Reference><Reference><Citation>Loebel A, Xu J, Hsu J, Cucchiaro J, Pikalov A. The development of lurasidone for bipolar depression. Ann N Y Acad Sci. 2015;1358:95–104.</Citation><ArticleIdList><ArticleId IdType="pubmed">26771990</ArticleId></ArticleIdList></Reference><Reference><Citation>DelBello MP, Goldman R, Phillips D, Deng L, Cucchiaro J, Loebel A. Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2017;56:1015–25.</Citation><ArticleIdList><ArticleId IdType="pubmed">29173735</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharm. 2007;572:160–70.</Citation></Reference><Reference><Citation>Yatham LN, Mackala S, Basivireddy J, Ahn S, Walji N, Hu C, et al. Lurasidone versus treatment as usual for cognitive impairment in euthymic patients with bipolar I disorder: a randomised, open-label, pilot study. Lancet Psychiatry. 2017;4:208–17.</Citation><ArticleIdList><ArticleId IdType="pubmed">28185899</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey PD, Ogasa M, Cucchiaro J, Loebel A, Keefe RS. Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. Schizophr Res. 2011;127:188–94.</Citation><ArticleIdList><ArticleId IdType="pubmed">21277745</ArticleId></ArticleIdList></Reference><Reference><Citation>Enomoto T, Ishibashi T, Tokuda K, Ishiyama T, Toma S, Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res. 2008;186:197–207.</Citation><ArticleIdList><ArticleId IdType="pubmed">17881065</ArticleId></ArticleIdList></Reference><Reference><Citation>Horisawa T, Ishibashi T, Nishikawa H, Enomoto T, Toma S, Ishiyama T, et al. The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone. Behav Brain Res. 2011;220:83–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">21277905</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Rheenen TE, Lewandowski KE, Bauer IE, Kapczinski F, Miskowiak K, Burdick KE et al. Current understandings of the trajectory and emerging correlates of cognitive impairment in bipolar disorder: An overview of evidence. Bipolar Disord. 2019;22:13–27.</Citation><ArticleIdList><ArticleId IdType="pubmed">31408230</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuomo I, Piacentino D, Kotzalidis GD, Lionetto L, De Filippis S. Lacosamide in bipolar disorder: A 30-day comparison to a retrospective control group treated with other antiepileptics. Psychiatry Clin Neurosci. 2018;72:864–75.</Citation><ArticleIdList><ArticleId IdType="pubmed">30251375</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson SM, Khanna R. Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide. Mol Neurobiol. 2015;51:599–609.</Citation><ArticleIdList><ArticleId IdType="pubmed">24944082</ArticleId></ArticleIdList></Reference><Reference><Citation>Fava M. The possible antianxiety and mood-stabilizing effects of rufinamide. Psychother Psychosom. 2010;79:194–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">20234151</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza M, Marano G, Janiri L. Retigabine-ezogabine: a new treatment option for bipolar disorder? Bipolar Disord. 2019;21:283–4.</Citation><ArticleIdList><ArticleId IdType="pubmed">30811779</ArticleId></ArticleIdList></Reference><Reference><Citation>Amann B, Sterr A, Vieta E, Stampfer R, Walden J, Grunze H. An exploratory open trial on safety and efficacy of the anticonvulsant retigabine in acute manic patients. J Clin Psychopharmacol. 2006;26:534–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16974202</ArticleId></ArticleIdList></Reference><Reference><Citation>Dencker D, Dias R, Pedersen ML, Husum H. Effect of the new antiepileptic drug retigabine in a rodent model of mania. Epilepsy Behav. 2008;12:49–53.</Citation><ArticleIdList><ArticleId IdType="pubmed">18086455</ArticleId></ArticleIdList></Reference><Reference><Citation>Dencker D, Husum H. Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Behav Brain Res. 2010;207:78–83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19815032</ArticleId></ArticleIdList></Reference><Reference><Citation>Kristensen LV, Sandager-Nielsen K, Hansen HH. K(v) 7 (KCNQ) channel openers normalize central 2-deoxyglucose uptake in a mouse model of mania and increase prefrontal cortical and hippocampal serine-9 phosphorylation levels of GSK3beta. J Neurochem. 2012;121:373–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">22356228</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedic N, Jones PG, Hopkins SC, Lew R, Shao L, Campbell JE, et al. SEP-363856, a novel psychotropic agent with a unique, non-D2 receptor mechanism of action. J Pharm Exp Ther. 2019;371:1–14.</Citation></Reference><Reference><Citation>Harmeier A, Obermueller S, Meyer CA, Revel FG, Buchy D, Chaboz S, et al. Trace amine-associated receptor 1 activation silences GSK3beta signaling of TAAR1 and D2R heteromers. Eur Neuropsychopharmacol. 2015;25:2049–61.</Citation><ArticleIdList><ArticleId IdType="pubmed">26372541</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmacharya R, Lynn SK, Demarco S, Ortiz A, Wang X, Lundy MY, et al. Behavioral effects of clozapine: involvement of trace amine pathways in C. elegans and M. musculus. Brain Res. 2011;1393:91–99.</Citation><ArticleIdList><ArticleId IdType="pubmed">21529784</ArticleId><ArticleId IdType="pmcid">3107707</ArticleId></ArticleIdList></Reference><Reference><Citation>McNamara RK, Welge JA. Meta-analysis of erythrocyte polyunsaturated fatty acid biostatus in bipolar disorder. Bipolar Disord. 2016;18:300–6.</Citation><ArticleIdList><ArticleId IdType="pubmed">27087497</ArticleId><ArticleId IdType="pmcid">4882238</ArticleId></ArticleIdList></Reference><Reference><Citation>Saunders EF, Ramsden CE, Sherazy MS, Gelenberg AJ, Davis JM, Rapoport SI. Omega-3 and omega-6 polyunsaturated fatty acids in bipolar disorder: a review of biomarker and treatment studies. J Clin Psychiatry. 2016;77:e1301–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">27631140</ArticleId></ArticleIdList></Reference><Reference><Citation>Grayson DS, Kroenke CD, Neuringer M, Fair DA. Dietary omega-3 fatty acids modulate large-scale systems organization in the rhesus macaque brain. J Neurosci. 2014;34:2065–74.</Citation><ArticleIdList><ArticleId IdType="pubmed">24501348</ArticleId><ArticleId IdType="pmcid">3913863</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao WN, Hylton NK, Wang J, Chindavong PS, Alural B, Kurtser I, et al. Activation of WNT and CREB signaling pathways in human neuronal cells in response to the Omega-3 fatty acid docosahexaenoic acid (DHA). Mol Cell Neurosci. 2019;99:103386.</Citation><ArticleIdList><ArticleId IdType="pubmed">31202891</ArticleId><ArticleId IdType="pmcid">7001743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N. Engl J Med. 2019;380:11–22.</Citation><ArticleIdList><ArticleId IdType="pubmed">30415628</ArticleId></ArticleIdList></Reference><Reference><Citation>Nierenberg AA, Ghaznavi SA, Sande Mathias I, Ellard KK, Janos JA, Sylvia LG. Peroxisome proliferator-activated receptor gamma coactivator-1 alpha as a novel target for bipolar disorder and other neuropsychiatric disorders. Biol Psychiatry. 2018;83:761–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">29502862</ArticleId></ArticleIdList></Reference><Reference><Citation>Kemp DE, Schinagle M, Gao K, Conroy C, Ganocy SJ, Ismail-Beigi F, et al. PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs. 2014;28:571–81.</Citation><ArticleIdList><ArticleId IdType="pubmed">24715548</ArticleId><ArticleId IdType="pmcid">4113193</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, Salimi S, et al. Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety. 2015;32:167–73.</Citation><ArticleIdList><ArticleId IdType="pubmed">25620378</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutt D. Psychedelic drugs-a new era inpsychiatry? Dialogues Clin Neurosci. 2019;21:139–47.</Citation><ArticleIdList><ArticleId IdType="pubmed">31636488</ArticleId><ArticleId IdType="pmcid">6787540</ArticleId></ArticleIdList></Reference><Reference><Citation>Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7:13187.</Citation><ArticleIdList><ArticleId IdType="pubmed">29030624</ArticleId><ArticleId IdType="pmcid">5640601</ArticleId></ArticleIdList></Reference><Reference><Citation>Carhart-Harris RL, Bolstridge M, Day CMJ, Rucker J, Watts R, Erritzoe DE, et al. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacol (Berl). 2018;235:399–408.</Citation></Reference><Reference><Citation>Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbaek DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44:1328–34.</Citation><ArticleIdList><ArticleId IdType="pubmed">30685771</ArticleId><ArticleId IdType="pmcid">6785028</ArticleId></ArticleIdList></Reference><Reference><Citation>Chouinard G, Young SN, Annable L. A controlled clinical trial of L-tryptophan in acute mania. Biol Psychiatry. 1985;20:546–57.</Citation><ArticleIdList><ArticleId IdType="pubmed">3886024</ArticleId></ArticleIdList></Reference><Reference><Citation>Lindseth G, Helland B, Caspers J. The effects of dietary tryptophan on affective disorders. Arch Psychiatr Nurs. 2015;29:102–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25858202</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritter PS, Marx C, Bauer M, Leopold K, Pfennig A. The role of disturbed sleep in the early recognition of bipolar disorder: a systematic review. Bipolar Disord. 2011;13:227–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">21676126</ArticleId></ArticleIdList></Reference><Reference><Citation>Plante DT, Winkelman JW. Sleep disturbance in bipolar disorder: therapeutic implications. Am J Psychiatry. 2008;165:830–43.</Citation><ArticleIdList><ArticleId IdType="pubmed">18483132</ArticleId><ArticleId IdType="pmcid">18483132</ArticleId></ArticleIdList></Reference><Reference><Citation>Seleem MA, Merranko JA, Goldstein TR, Goldstein BI, Axelson DA, Brent DA, et al. The longitudinal course of sleep timing and circadian preferences in adults with bipolar disorder. Bipolar Disord. 2015;17:392–402.</Citation><ArticleIdList><ArticleId IdType="pubmed">25524085</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinan MK, Scott J, Lagerberg TV, Melle I, Andreassen OA, Vaaler AE, et al. Sleep problems in bipolar disorders: more than just insomnia. Acta Psychiatr Scand. 2016;133:368–77.</Citation><ArticleIdList><ArticleId IdType="pubmed">26590799</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber J, Harvey AG, Wang PW, Brooks JO III, Thase ME, Sachs GS, et al. Sleep functioning in relation to mood, function, and quality of life at entry to the systematic treatment enhancement program for bipolar disorder (STEP-BD). J Affect Disord. 2009;114:41–49.</Citation><ArticleIdList><ArticleId IdType="pubmed">18707765</ArticleId></ArticleIdList></Reference><Reference><Citation>Wirz-Justice A, Benedetti F. Perspectives in affective disorders: Clocks and sleep. Eur J Neurosci. 2019;51:346–65.</Citation><ArticleIdList><ArticleId IdType="pubmed">30702783</ArticleId></ArticleIdList></Reference><Reference><Citation>Gold AK, Kinrys G. Treating circadian rhythm disruption in bipolar disorder. Curr Psychiatry Rep. 2019;21:14.</Citation><ArticleIdList><ArticleId IdType="pubmed">30826893</ArticleId><ArticleId IdType="pmcid">6812517</ArticleId></ArticleIdList></Reference><Reference><Citation>Maruani J, Geoffroy PA. Bright light as a personalized precision treatment of mood disorders. Front Psychiatry. 2019;10:85.</Citation><ArticleIdList><ArticleId IdType="pubmed">30881318</ArticleId><ArticleId IdType="pmcid">6405415</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine bipolar study G. Agomelatine adjunctive therapy for acute bipolar depression: preliminary open data. Bipolar Disord. 2007;9:628–35.</Citation><ArticleIdList><ArticleId IdType="pubmed">17845278</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornaro M, McCarthy MJ, De Berardis D, De Pasquale C, Tabaton M, Martino M, et al. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: a preliminary open label study. Neuropsychiatr Dis Treat. 2013;9:243–51.</Citation><ArticleIdList><ArticleId IdType="pubmed">23430979</ArticleId><ArticleId IdType="pmcid">3575211</ArticleId></ArticleIdList></Reference><Reference><Citation>Yatham LN, Vieta E, Goodwin GM, Bourin M, de Bodinat C, Laredo J, et al. Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: randomised double-blind placebo-controlled trial. Br J Psychiatry. 2016;208:78–86.</Citation><ArticleIdList><ArticleId IdType="pubmed">25999335</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahableshwarkar AR, Calabrese JR, Macek TA, Budur K, Adefuye A, Dong X, et al. Efficacy and safety of sublingual ramelteon as an adjunctive therapy in the maintenance treatment of bipolar I disorder in adults: A phase 3, randomized controlled trial. J Affect Disord. 2017;221:275–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">28662460</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou TH, Dang WM, Ma YT, Hu CQ, Wang N, Zhang GY, et al. Clinical efficacy, onset time and safety of bright light therapy in acute bipolar depression as an adjunctive therapy: a randomized controlled trial. J Affect Disord. 2018;227:90–96.</Citation><ArticleIdList><ArticleId IdType="pubmed">29053981</ArticleId></ArticleIdList></Reference><Reference><Citation>Sit DK, McGowan J, Wiltrout C, Diler RS, Dills JJ, Luther J, et al. Adjunctive bright light therapy for bipolar depression: a randomized double-blind placebo-controlled trial. Am J Psychiatry. 2018;175:131–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">28969438</ArticleId></ArticleIdList></Reference><Reference><Citation>Phelps J. A powerful non-pharmacologic treatment for mania – virtually. Bipolar Disord. 2016;18:379–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">27218661</ArticleId></ArticleIdList></Reference><Reference><Citation>Do MTH. Melanopsin and the intrinsically photosensitive retinal ganglion cells: biophysics to behavior. Neuron. 2019;104:205–26.</Citation><ArticleIdList><ArticleId IdType="pubmed">31647894</ArticleId><ArticleId IdType="pmcid">6944442</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KY, Rios LC, Le H, Perez AJ, Phan S, Bushong EA, et al. Synaptic specializations of melanopsin-retinal ganglion cells in multiple brain regions revealed by genetic label for light and electron microscopy. Cell Rep. 2019;29:628–44 e626.</Citation><ArticleIdList><ArticleId IdType="pubmed">31618632</ArticleId><ArticleId IdType="pmcid">7045601</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP. Light suppresses melatonin secretion in humans. Science. 1980;210:1267–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7434030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones KA, Hatori M, Mure LS, Bramley JR, Artymyshyn R, Hong SP, et al. Small-molecule antagonists of melanopsin-mediated phototransduction. Nat Chem Biol. 2013;9:630–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23974117</ArticleId><ArticleId IdType="pmcid">3839535</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen TE, Skrede S, Fasmer OB, Hamre B, Gronli J, Lund A. Blocking blue light during mania - markedly increased regularity of sleep and rapid improvement of symptoms: a case report. Bipolar Disord. 2014;16:894–8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25264124</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen TE, Skrede S, Fasmer OB, Schoeyen H, Leskauskaite I, Bjorke-Bertheussen J, et al. Blue-blocking glasses as additive treatment for mania: a randomized placebo-controlled trial. Bipolar Disord. 2016;18:221–32.</Citation><ArticleIdList><ArticleId IdType="pubmed">27226262</ArticleId><ArticleId IdType="pmcid">5089565</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24217867</PMID><DateCompleted><Year>2014</Year><Month>06</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2044-8341</ISSN><JournalIssue CitedMedium="Internet"><Volume>86</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Psychology and psychotherapy</Title><ISOAbbreviation>Psychol Psychother</ISOAbbreviation></Journal><ArticleTitle>High and happy? Exploring the experience of positive states of mind in people who have been given a diagnosis of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>431-46</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.2044-8341.2012.02064.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To approach the experience of 'happiness' and 'mania' for people who have been given a diagnosis of 'bipolar disorder' and to explore how they might differentiate or associate between these experiences.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">A qualitative design was used in which four participants who had been given a diagnosis of 'bipolar disorder' were interviewed individually regarding their experiences and ideas about 'mania' and 'happiness'.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Transcriptions from the interviews were analysed using the iterative process of interpretative phenomenological analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four superordinate themes were identified. Two highlighted the conceptual fluidity and similarities between their ideas about and experiences of 'happiness' and 'mania'. Two emphasized the differences between these notions for the participants, which reflected the destruction, disruption, and chaos of 'mania' in contrast to the importance of self-acceptance, peacefulness, and social connection for 'happiness'.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There may be benefit in maintaining an active dialogue or 'poly-vocality' about the meanings of 'happiness' in clinical work with people who experience 'positive states' of mind, which are personally problematic. This can be supported by drawing on ideas and narratives about 'happiness' from the field of positive psychology.</AbstractText><CopyrightInformation>© 2012 The British Psychological Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Russell</LastName><ForeName>Leo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Psychology Service, Somerset Partnership NHS Foundation Trust, UKDepartment of Clinical Psychology, University of Plymouth, Devon, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Duncan</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>04</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Psychol Psychother</MedlineTA><NlmUniqueID>101135751</NlmUniqueID><ISSNLinking>1476-0835</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="Y">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006240" MajorTopicYN="Y">Happiness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007398" MajorTopicYN="N">Interpersonal Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011582" MajorTopicYN="N">Psychological Theory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011584" MajorTopicYN="Y">Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="Y">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>11</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24217867</ArticleId><ArticleId IdType="doi">10.1111/j.2044-8341.2012.02064.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23691813</PMID><DateCompleted><Year>2013</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2013</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-2658</ISSN><JournalIssue CitedMedium="Print"><Volume>115</Volume><Issue>3</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Seishin shinkeigaku zasshi = Psychiatria et neurologia Japonica</Title><ISOAbbreviation>Seishin Shinkeigaku Zasshi</ISOAbbreviation></Journal><ArticleTitle>[The clinical meaning and academic significance of "endogenous depression" as an ideal type].</ArticleTitle><Pagination><MedlinePgn>267-76</MedlinePgn></Pagination><Abstract><AbstractText>The assumption that a core group of depressive disorders is due to a discontinuous change in the function of the brain system, suggests that the symptoms of the core group of depressive disorders should be discerned from those of non-core depression. Core depression is thought to correspond to depression of an endogenous nature, which has recently been disregarded in diagnosing mood disorders. However, in diagnosing endogenous depression, we can identify its characteristic symptoms by referring to a traditional symptomatology. Therefore, the idea of Verstehen (Jaspers, K) becomes essential, but has been neglected in academic journals in English-speaking countries. The depressive mood in endogenous depression may be an inhibition of various kinds of emotion, which can never be experienced within a normal emotional state. Thus, it is thought to be 'unverstaendlich' (incomprehensible) in nature. The "anhedonia hypothesis" of depression from DSM-IV permits the inclusion of the non-core group of depression into major depressive disorder, because patients with the endogenous type suffer not only from a loss of pleasure but also from a loss of sadness. A new type of depression that has recently been debated in Japan is diagnosed as major depressive disorder in DSM-IV, but many suspected cases are thought to be due to a psychogenic state or neurotic condition, because their symptoms are thought to be 'verstaendlich' (comprehensible). Endogenous depression can manifest as manic-depressive disorder in almost all cases, but psychiatric practitioners have taken the necessary precautions against the risk of a shift to a manic state even when treating pure depression which seemingly appears to have no manic component. According to recent studies on bipolar disorder, pure mania is not empirically found. Thus, the manic pole may not exist, and we may be able to think of endogenous depression as manic-depressive disorder based on its genetic entity. Additionally, from the viewpoint of its symptomatology there is one pole of depression modified by manic tendencies based on various intensities. The current study presents the hypothesis that there is one entity for disease, manic-depression, but whether the disorder manifests itself as uni- or bipolar disorder depends upon the regulation of manic manifestations by a meticulous, obsessive-compulsive personality which has been considered to be the premorbid personality for unipolar depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Matsunami</LastName><ForeName>Katsufumi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Seiwa Hospital, Institute of Neuropsychiatry.</Affiliation></AffiliationInfo></Author></AuthorList><Language>jpn</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Seishin Shinkeigaku Zasshi</MedlineTA><NlmUniqueID>9801787</NlmUniqueID><ISSNLinking>0033-2658</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23691813</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16318823</PMID><DateCompleted><Year>2006</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1523-3812</ISSN><JournalIssue CitedMedium="Print"><Volume>7</Volume><Issue>6</Issue><PubDate><Year>2005</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Current psychiatry reports</Title><ISOAbbreviation>Curr Psychiatry Rep</ISOAbbreviation></Journal><ArticleTitle>Evidence-based research on the efficacy of psychologic interventions in bipolar disorders: a critical review.</ArticleTitle><Pagination><MedlinePgn>449-55</MedlinePgn></Pagination><Abstract><AbstractText>Although pharmacotherapy is the mainstay of treatment strategies for bipolar disorder, research over the last 5 years suggests that combining psychologic interventions with drug treatment increases overall effectiveness, mostly by further protecting from relapse or recurrence. We aimed at critically examining the relevance and effectiveness of psychosocial approaches to bipolar illness by doing a systematic review of the current literature. Currently, most studies show that patients receiving psychologic treatments have significantly fewer relapses, reduced hospitalization rates, and increased treatment adherence. Psychoeducation, family-focused psychoeducation, and cognitive-behavioral therapy seem to be the most efficacious interventions in the prophylaxis from recurrences in medicated bipolar patients. Recent studies have shown that psychologic approaches do not have the same "weight" in all bipolar patients. Pharmacologic treatment and psychologic interventions are complementary and share many goals, such as avoiding recurrences and improving clinical outcome. A wise combination of these two approaches may help bipolar patients to achieve a better symptomatic and functional recovery. Further research should focus on determining the therapeutic value of each ingredient of the tested psychologic interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Clinical Institute of Neuroscience, Hospital Clinic de Barcelona, Villarroel 170, Barcelona 08036, Barcelona, Spain. EVIETA@clinic.ub.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacchiarotti</LastName><ForeName>Isabella</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sánchez-Moreno</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Di Marzo</LastName><ForeName>Sylvia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>Francesc</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Psychiatry Rep</MedlineTA><NlmUniqueID>100888960</NlmUniqueID><ISSNLinking>1523-3812</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005196" MajorTopicYN="N">Family Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>50</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>2</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>12</Month><Day>2</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16318823</ArticleId><ArticleId IdType="doi">10.1007/s11920-005-0066-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2002 Dec;4(6):386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12519098</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2005 Aug;20(5-6):359-64</Citation><ArticleIdList><ArticleId IdType="pubmed">16112848</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Apr;60(4):402-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12695318</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Aug;5(4):265-78</Citation><ArticleIdList><ArticleId IdType="pubmed">12895204</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1995 Nov;167(5):581-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8564312</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Aug;6(4):294-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15225146</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychopharmacol. 2003 Jun;17 (2):149-73; discussion 147</Citation><ArticleIdList><ArticleId IdType="pubmed">12870562</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):262-70</Citation><ArticleIdList><ArticleId IdType="pubmed">14754775</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 May;64(5):506-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12755652</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Apr;65(4):571-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15119923</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Feb;60(2):145-52</Citation><ArticleIdList><ArticleId IdType="pubmed">12578431</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Aug;61(8):549-55</Citation><ArticleIdList><ArticleId IdType="pubmed">10982196</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 2000 Mar-Apr;26(2):76-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10858920</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2005 Jun;28(2):371-84</Citation><ArticleIdList><ArticleId IdType="pubmed">15826737</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Sep;62(9):996-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">16143731</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1999 Nov;108(4):579-87</Citation><ArticleIdList><ArticleId IdType="pubmed">10609422</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1991 Feb;158:197-200</Citation><ArticleIdList><ArticleId IdType="pubmed">1707323</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Feb;157(2):220-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10671390</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2005;74(2):113-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15741761</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Sep;60(9):904-12</Citation><ArticleIdList><ArticleId IdType="pubmed">12963672</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Dec;6(6):487-97</Citation><ArticleIdList><ArticleId IdType="pubmed">15541064</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Feb;5(1):14-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12656933</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Feb;162(2):324-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15677598</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 May;74(3):209-17</Citation><ArticleIdList><ArticleId IdType="pubmed">12738039</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2003 Jun;71(3):482-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12795572</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1984 Oct;52(5):873-8</Citation><ArticleIdList><ArticleId IdType="pubmed">6501672</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Feb;64(2):182-91</Citation><ArticleIdList><ArticleId IdType="pubmed">12633127</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1988 Jun;24(2):191-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3134056</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Oct;3(5):253-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11903208</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Dec;6(6):498-503</Citation><ArticleIdList><ArticleId IdType="pubmed">15541065</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2001 Feb;3(1):11-22</Citation><ArticleIdList><ArticleId IdType="pubmed">11256459</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1999 Jan 16;318(7177):149-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9888904</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):593-604</Citation><ArticleIdList><ArticleId IdType="pubmed">11018230</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2000 Sep 15;48(6):582-92</Citation><ArticleIdList><ArticleId IdType="pubmed">11018229</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Sep;64(9):1101-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14628987</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Feb;61(2):134-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10732661</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2004 Sep-Oct;73(5):312-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15292629</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1991 Feb;158:200-4</Citation><ArticleIdList><ArticleId IdType="pubmed">2012911</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2001 Apr;31(3):459-67</Citation><ArticleIdList><ArticleId IdType="pubmed">11305854</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Jun;6(3):224-32</Citation><ArticleIdList><ArticleId IdType="pubmed">15117401</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2002 Mar;105(3):164-72</Citation><ArticleIdList><ArticleId IdType="pubmed">11939969</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2005;66 Suppl 1:24-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15693749</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 1998;67(1):3-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9491434</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychother Psychosom. 2002 Jan-Feb;71(1):2-10</Citation><ArticleIdList><ArticleId IdType="pubmed">11740163</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2668995</PMID><DateCompleted><Year>1989</Year><Month>09</Month><Day>19</Day></DateCompleted><DateRevised><Year>2005</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0702-8466</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>2</Issue><PubDate><Year>1989</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatric journal of the University of Ottawa : Revue de psychiatrie de l'Universite d'Ottawa</Title><ISOAbbreviation>Psychiatr J Univ Ott</ISOAbbreviation></Journal><ArticleTitle>Psychodynamic psychotherapy for the depressive syndrome.</ArticleTitle><Pagination><MedlinePgn>397-402; discussion 409-12</MedlinePgn></Pagination><Abstract><AbstractText>Historical approaches of psychotherapy for depression are contrasted with current psychotherapeutic strategies. Now more strategies are focused, structured, time-limited, observable, testable, researchable and data based. The following depressive syndromes are reviewed in terms of the literature that demonstrates the effectiveness of psychotherapy: major depressive disorder, bipolar depressive disorder, depression associated with medical illness such as cancer, myocardial infarction and stroke, resistant depression post-traumatic stress disorder, grief reactions and depression during adolescence, mid-life and the geriatric period of the life cycle. A conceptual model favoring tripartite focus of intervention is recommended. Psychodynamic psychotherapy for depression must consider intrapsychic, interpersonal and family dynamics as well as social supports. A model for each population needs to be studied and developed further. Recommendations for current research are suggested. In the individual modification of psychotherapeutic approaches we must consider the varying maturity of ego defenses and the ego strength of the individual patient. Forty well-designed studies that demonstrate the effectiveness of psychotherapy in the depressive syndromes are quoted in this paper.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cameron</LastName><ForeName>P M</ForeName><Initials>PM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>Psychiatr J Univ Ott</MedlineTA><NlmUniqueID>7703518</NlmUniqueID><ISSNLinking>0702-8466</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000275" MajorTopicYN="N">Adjustment Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011575" MajorTopicYN="N">Psychoanalytic Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>46</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2668995</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28437055</PMID><DateCompleted><Year>2017</Year><Month>06</Month><Day>15</Day></DateCompleted><DateRevised><Year>2017</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2159-3000</ISSN><JournalIssue CitedMedium="Print"><Volume>455</Volume><PubDate><Year>2017</Year><Month>Apr</Month></PubDate></JournalIssue><Title>FP essentials</Title><ISOAbbreviation>FP Essent</ISOAbbreviation></Journal><ArticleTitle>Psychotic and Bipolar Disorders: Foreword.</ArticleTitle><Pagination><MedlinePgn>2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rew</LastName><ForeName>Karl T</ForeName><Initials>KT</Initials><AffiliationInfo><Affiliation>University of Michigan Health System, 24 Frank Lloyd Wright Drive Lobby H SPC 5795, Ann Arbor, MI 48109-5795, karlr@med.umich.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D054711">Introductory Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>FP Essent</MedlineTA><NlmUniqueID>101578821</NlmUniqueID><ISSNLinking>2159-3000</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="N">Dementia</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005194" MajorTopicYN="Y">Family Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28437055</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10910805</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>157</Volume><Issue>8</Issue><PubDate><Year>2000</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Quetiapine for treatment-resistant mania.</ArticleTitle><Pagination><MedlinePgn>1341</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dunayevich</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>S M</ForeName><Initials>SM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>29</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>7</Month><Day>27</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10910805</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.157.8.1341</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5143407</PMID><DateCompleted><Year>1972</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0048-2285</ISSN><JournalIssue CitedMedium="Print"><Volume>39</Volume><Issue>1</Issue><PubDate><MedlineDate>1971 Jan-Mar</MedlineDate></PubDate></JournalIssue><Title>L'Ospedale psichiatrico</Title><ISOAbbreviation>Osp Psichiatr</ISOAbbreviation></Journal><ArticleTitle>[Prefrontal leukotomy (by the Mariotti method) (à propos of 2 personal cases). Anatomo-physiological and psychopathogenetic deductions].</ArticleTitle><Pagination><MedlinePgn>100-41</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fina</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>ita</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>La leucotomia prefrontale (con il metodo Mariotti) (a proposito di due casi personali). Deduzioni anatomo-fisiologiche e psicopatogenetiche.</VernacularTitle></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Osp Psichiatr</MedlineTA><NlmUniqueID>0312304</NlmUniqueID><ISSNLinking>0048-2285</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008722" MajorTopicYN="N">Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="N">Paranoid Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011612" MajorTopicYN="Y">Psychosurgery</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1971</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1971</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1971</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5143407</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1876627</PMID><DateCompleted><Year>1991</Year><Month>09</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>2</Issue><PubDate><Year>1991</Year><Month>May</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Disengagement of attention in schizophrenia.</ArticleTitle><Pagination><MedlinePgn>139-46</MedlinePgn></Pagination><Abstract><AbstractText>We compared covert shift of visual attention in patients with schizophrenia or bipolar disorder, both in states of remission, to normal controls to examine the persistence of lateralized attentional deficits into nonpsychotic states. Although patients were slower in all conditions than normals, there was no difference in pattern of attentional shift among the groups. This suggests that the left-hemisphere deficit in shift of covert attention in schizophrenia may be limited to periods of florid illness.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strauss</LastName><ForeName>M E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Psychology, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Novakovic</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Tien</LastName><ForeName>A Y</ForeName><Initials>AY</Initials></Author><Author ValidYN="Y"><LastName>Bylsma</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Pearlson</LastName><ForeName>G D</ForeName><Initials>GD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-43326</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1876627</ArticleId><ArticleId IdType="pii">0165-1781(91)90071-V</ArticleId><ArticleId IdType="doi">10.1016/0165-1781(91)90071-v</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30208971</PMID><DateCompleted><Year>2019</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>01</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>Effect of action-based cognitive remediation on cognition and neural activity in bipolar disorder: study protocol for a randomized controlled trial.</ArticleTitle><Pagination><MedlinePgn>487</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-018-2860-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive impairment is present in bipolar disorder (BD) during the acute and remitted phases and hampers functional recovery. However, there is currently no clinically available treatment with direct and lasting effects on cognitive impairment in BD. We will examine the effect of a novel form of cognitive remediation, action-based cognitive remediation (ABCR), on cognitive impairment in patients with BD, and explore the neural substrates of potential treatment efficacy on cognition.</AbstractText><AbstractText Label="METHODS/DESIGN" NlmCategory="METHODS">The trial has a randomized, controlled, parallel-group design. In total, 58 patients with BD in full or partial remission aged 18-55 years with objective cognitive impairment will be recruited. Participants are randomized to 10 weeks of ABCR or a control group. Assessments encompassing neuropsychological testing and mood ratings, and questionnaires on subjective cognitive complaints, psychosocial functioning, and quality of life are carried out at baseline, after 2 weeks of treatment, after the end of treatment, and at a six-month-follow-up after treatment completion. Functional magnetic resonance imaging scans are performed at baseline and 2 weeks into treatment. The primary outcome is a cognitive composite score spanning verbal memory, attention, and executive function. Two complete data sets for 52 patients will provide a power of 80% to detect a clinically relevant between-group difference on the primary outcome. Behavioral data will be analyzed using mixed models in SPSS while MRI data will be analyzed with the FMRIB Expert Analysis Tool (FEAT). Early treatment-related changes in neural activity from baseline to week 2 will be investigated for the dorsal prefrontal cortex and hippocampus as the regions of interest and with an exploratory whole-brain analysis.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The results will provide insight into whether ABCR has beneficial effects on cognition and functioning in remitted patients with BD. The results will also provide insight into early changes in neural activity associated with improvement of cognition, which can aid future treatment development.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">Clinicaltrials.gov , NCT03295305 . Registered on 26 September 2017.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ott</LastName><ForeName>Caroline V</ForeName><Initials>CV</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinberg</LastName><ForeName>Maj</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowie</LastName><ForeName>Christopher R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Psychology Department, Queen's University, Kingston, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christensen</LastName><ForeName>Ellen Margrethe</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knudsen</LastName><ForeName>Gitte M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Neurobiology Research Unit and Center for Experimental Medicine Neuropharmacology, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessing</LastName><ForeName>Lars V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miskowiak</LastName><ForeName>Kamilla W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Centre Copenhagen, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. kamilla.woznica.miskowiak@regionh.dk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, University of Copenhagen, Copenhagen, Denmark. kamilla.woznica.miskowiak@regionh.dk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03295305</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R215-2015-4121</GrantID><Agency>Lundbeckfonden</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Trials. 2019 Apr 8;20(1):201</RefSource><PMID Version="1">30961672</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001288" MajorTopicYN="N">Attention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058256" MajorTopicYN="Y">Brain Waves</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="Y">Cognition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072466" MajorTopicYN="N">Cognitive Remediation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003718" MajorTopicYN="N" Type="Geographic">Denmark</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="N">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008568" MajorTopicYN="N">Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarker</Keyword><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Cognition</Keyword><Keyword MajorTopicYN="N">Cognitive impairment</Keyword><Keyword MajorTopicYN="N">Cognitive remediation</Keyword><Keyword MajorTopicYN="N">Functional magnetic resonance imaging</Keyword><Keyword MajorTopicYN="N">Pro-cognitive effect</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>08</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30208971</ArticleId><ArticleId IdType="doi">10.1186/s13063-018-2860-8</ArticleId><ArticleId IdType="pii">10.1186/s13063-018-2860-8</ArticleId><ArticleId IdType="pmc">PMC6134776</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2003 Apr;60(4):402-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12695318</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2001;27(2):235-45</Citation><ArticleIdList><ArticleId IdType="pubmed">11354591</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 5;150(2):456-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23684514</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2016 Jun;46(8):1679-91</Citation><ArticleIdList><ArticleId IdType="pubmed">26996196</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2012 Jan;26(1):90-5</Citation><ArticleIdList><ArticleId IdType="pubmed">21839826</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Nov 15;187:10-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26301477</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2015 Dec 1;188:149-59</Citation><ArticleIdList><ArticleId IdType="pubmed">26363613</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2014 Oct;44(14):3083-96</Citation><ArticleIdList><ArticleId IdType="pubmed">25065409</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuro Endocrinol Lett. 2011;32(4):540-4</Citation><ArticleIdList><ArticleId IdType="pubmed">21876502</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2016 Oct;26(10):1541-61</Citation><ArticleIdList><ArticleId IdType="pubmed">27593623</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Aug 30;228(3):386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">26160203</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2017 May;19(3):214-224</Citation><ArticleIdList><ArticleId IdType="pubmed">28544426</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2016 Sep;134(3):249-59</Citation><ArticleIdList><ArticleId IdType="pubmed">27259062</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9845158</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2015 Sep 30;229(1-2):565-71</Citation><ArticleIdList><ArticleId IdType="pubmed">26073281</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 May;16(3):217-29</Citation><ArticleIdList><ArticleId IdType="pubmed">24219657</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Dec;6(6):550-64</Citation><ArticleIdList><ArticleId IdType="pubmed">15541071</ArticleId></ArticleIdList></Reference><Reference><Citation>Qual Life Res. 1999 May;8(3):209-24</Citation><ArticleIdList><ArticleId IdType="pubmed">10472152</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Rehabil J. 2017 Mar;40(1):53-60</Citation><ArticleIdList><ArticleId IdType="pubmed">27100095</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Nov 15;205:165-181</Citation><ArticleIdList><ArticleId IdType="pubmed">27449549</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2016 Aug;26(8):1264-73</Citation><ArticleIdList><ArticleId IdType="pubmed">27349944</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2013;68(2):63-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23881005</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2002 May;180:461-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11983645</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Pharmacol. 2014 Feb;14:54-61</Citation><ArticleIdList><ArticleId IdType="pubmed">24565013</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Dec;164(12):1791-802</Citation><ArticleIdList><ArticleId IdType="pubmed">18056233</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Dec;17 Suppl 2:41-55</Citation><ArticleIdList><ArticleId IdType="pubmed">26688289</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Jun 12;10(6):e0127955</Citation><ArticleIdList><ArticleId IdType="pubmed">26070195</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2016 Nov 15;205:378-386</Citation><ArticleIdList><ArticleId IdType="pubmed">27573491</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Aug 15;150(1):29-36</Citation><ArticleIdList><ArticleId IdType="pubmed">23497792</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2017 Dec;19(8):614-626</Citation><ArticleIdList><ArticleId IdType="pubmed">28895274</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2017 Nov/Dec;78(9):e1242-e1249</Citation><ArticleIdList><ArticleId IdType="pubmed">29045770</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2015 Nov;41(6):1276-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25800249</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Bipolar Disord. 2017 Dec;5(1):8</Citation><ArticleIdList><ArticleId IdType="pubmed">28168631</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Jun;47(6):589-93</Citation><ArticleIdList><ArticleId IdType="pubmed">2190539</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2012 Jan;19(1):155-62</Citation><ArticleIdList><ArticleId IdType="pubmed">22175760</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pract Epidemiol Ment Health. 2007 Jun 07;3:5</Citation><ArticleIdList><ArticleId IdType="pubmed">17555558</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Dec 15;142(1-3):13-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22840620</ArticleId></ArticleIdList></Reference><Reference><Citation>Trials. 2011 Feb 09;12:35</Citation><ArticleIdList><ArticleId IdType="pubmed">21306612</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ Open. 2017 Jun 23;7(6):e015462</Citation><ArticleIdList><ArticleId IdType="pubmed">28645967</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17551352</PMID><DateCompleted><Year>2007</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2010</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0951-7367</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>4</Issue><PubDate><Year>2007</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Current opinion in psychiatry</Title><ISOAbbreviation>Curr Opin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Schizoaffective disorder merges schizophrenia and bipolar disorders as one disease--there is no schizoaffective disorder.</ArticleTitle><Pagination><MedlinePgn>365-79</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">Schizoaffective disorder was named as a compromise diagnosis in 1933, and remains popular as judged by its place in the International Classification of Diseases and the Diagnostic and Statistical Manual of Mental Disorders, its frequent use in clinical practice, and its extensive discussion in the literature. Some, however, have questioned the validity of schizoaffective disorder as separate from psychotic mood disorder. We examined the literature to assess the rationale for the continuation of schizoaffective disorder as a legitimate diagnostic category.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">The diagnosis of schizoaffective disorder depends on the disease specificity of the diagnostic criteria for schizophrenia; however, the psychotic symptoms for schizophrenia, traditionally held as specific, can be accounted for by psychotic bipolar. Further, the interrater reliability for diagnosing schizoaffective disorder is very low. A recent and expanding body of comparative evidence from a wide range of clinical and basic science studies, especially genetic, reveals multiple similarities between schizoaffective disorder, schizophrenia and psychotic bipolar.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Schizoaffective disorder unifies schizophrenia and bipolar, blurring the zones of rarity between them and suggesting that schizoaffective disorder is not a separate, 'bona-fide' disease. Patients diagnosed with schizoaffective disorder likely suffer from a psychotic mood disorder. The diagnosis of schizoaffective disorder, which can result in substandard treatment, should be eliminated from the diagnostic nomenclature.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lake</LastName><ForeName>Charles Ray</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine, Kansas City, Kansas 66160, USA. clake@kumc.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurwitz</LastName><ForeName>Nathaniel</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Psychiatry</MedlineTA><NlmUniqueID>8809880</NlmUniqueID><ISSNLinking>0951-7367</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002869" MajorTopicYN="N">Chromosome Aberrations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008040" MajorTopicYN="N">Genetic Linkage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011582" MajorTopicYN="N">Psychological Theory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="Y">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>150</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>9</Month><Day>6</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>6</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17551352</ArticleId><ArticleId IdType="doi">10.1097/YCO.0b013e3281a305ab</ArticleId><ArticleId IdType="pii">00001504-200707000-00011</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25142103</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>15</Day></DateCompleted><DateRevised><Year>2014</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6238</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>10</Issue><PubDate><Year>2014</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JAMA psychiatry</Title><ISOAbbreviation>JAMA Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Reward processing in healthy offspring of parents with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1148-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamapsychiatry.2014.1031</ELocationID><Abstract><AbstractText Label="IMPORTANCE" NlmCategory="OBJECTIVE">Bipolar disorder (BD) is highly familial and characterized by deficits in reward processing. It is not known, however, whether these deficits precede illness onset or are a consequence of the disorder.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine whether anomalous neural processing of reward characterizes children at familial risk for BD in the absence of a personal history of a psychopathologic disorder.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS" NlmCategory="METHODS">This study compared neural activity and behaviors of children at high and low risk for mania while they anticipate and respond to reward and loss. The study was performed from September 15, 2009, through February 17, 2012, in a university functional magnetic resonance imaging facility and included 8- to 15-year-old children without disorders born to a parent with BD (n = 20 high-risk children) and demographically matched healthy comparison children (n = 25 low-risk children).</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES" NlmCategory="METHODS">Neural activity, as measured with functional magnetic resonance imaging, during anticipation and receipt of reward and loss during a monetary incentive delay task.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">While anticipating losses, high-risk children had less activation in the pregenual cingulate than did their low-risk counterparts (t19 = -2.44, P = .02). When receiving rewards, high-risk children had greater activation in the left lateral orbitofrontal cortex than did low-risk children (t43 = -3.04, P = .004). High-risk children also had weaker functional connectivity between the pregenual cingulate and the right ventrolateral prefrontal cortex while anticipating rewards than did low-risk children (t19 = -4.38, P &lt; .001) but had a stronger connectivity between these regions while anticipating losses (t24 = 2.76, P = .01). Finally, in high- but not low-risk children, novelty seeking was associated with increased striatal and amygdalar activation in the anticipation of losses, and impulsivity was associated with increased striatal and insula activation in the receipt of rewards.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE" NlmCategory="CONCLUSIONS">Aberrant prefrontal activations and connectivities during reward processing suggest mechanisms that underlie early vulnerabilities for developing dysfunctional regulation of goal pursuit and motivation in children at high risk for mania. Longitudinal studies are needed to examine whether these patterns of neural activation predict the onset of mania and other mood disorders in high-risk children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Manpreet K</ForeName><Initials>MK</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelley</LastName><ForeName>Ryan G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Howe</LastName><ForeName>Meghan E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiss</LastName><ForeName>Allan L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotlib</LastName><ForeName>Ian H</ForeName><Initials>IH</Initials><AffiliationInfo><Affiliation>Department of Psychology, Stanford University, Stanford, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Kiki D</ForeName><Initials>KD</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH085919</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Psychiatry</MedlineTA><NlmUniqueID>101589550</NlmUniqueID><ISSNLinking>2168-622X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059031" MajorTopicYN="N">Anticipation, Psychological</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016241" MajorTopicYN="N">Child of Impaired Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="N">Functional Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009434" MajorTopicYN="N">Neural Pathways</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="Y">Reward</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25142103</ArticleId><ArticleId IdType="pii">1897299</ArticleId><ArticleId IdType="doi">10.1001/jamapsychiatry.2014.1031</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19996269</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1545-7222</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Season>Fall</Season></PubDate></JournalIssue><Title>The Journal of neuropsychiatry and clinical neurosciences</Title><ISOAbbreviation>J Neuropsychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>New-onset vascular mania in a patient with chronic depression.</ArticleTitle><Pagination><MedlinePgn>480-2</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.neuropsych.21.4.480</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duggal</LastName><ForeName>Harpreet S</ForeName><Initials>HS</Initials></Author><Author ValidYN="Y"><LastName>Singh</LastName><ForeName>Ira</ForeName><Initials>I</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Neuropsychiatry Clin Neurosci</MedlineTA><NlmUniqueID>8911344</NlmUniqueID><ISSNLinking>0895-0172</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>33CM23913M</RegistryNumber><NameOfSubstance UI="D002220">Carbamazepine</NameOfSubstance></Chemical><Chemical><RegistryNumber>6UKA5VEJ6X</RegistryNumber><NameOfSubstance UI="C092292">ziprasidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002220" MajorTopicYN="N">Carbamazepine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015140" MajorTopicYN="N">Dementia, Vascular</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19996269</ArticleId><ArticleId IdType="pii">21/4/480</ArticleId><ArticleId IdType="doi">10.1176/jnp.2009.21.4.480</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21823964</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2012</Year><Month>01</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1940-3208</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>7</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Journal of American college health : J of ACH</Title><ISOAbbreviation>J Am Coll Health</ISOAbbreviation></Journal><ArticleTitle>Special considerations in the treatment of college students with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>666-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/07448481.2010.528100</ELocationID><Abstract><AbstractText>Bipolar disorder is a relatively common mental disorder that often has its onset during the college years. This means that students simultaneously face both the challenge of late adolescent development and the challenge of adapting to a major mental illness. As a further complication, the college environment is not well suited to the kinds of lifestyle changes that add stability to the lives of people with bipolar disorder. Treatment involves establishing an alliance, education about lifestyle changes, aiding adaptation to the illness, careful medication to minimize side effects, and loosening the affective constriction that can result from fear of relapse. Both the health care provider and student can use the culture of learning and self-discovery in the college setting to the treatment's benefit. As well, the provider can use the time-limited nature of college to lessen ambivalence about making long-term changes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lejeune</LastName><ForeName>Simon M W</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>MIT Medical Service, Cambridge, Massachusetts 02139, USA. simon-lejeune@hms.harvard.edu</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Coll Health</MedlineTA><NlmUniqueID>8214119</NlmUniqueID><ISSNLinking>0744-8481</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Am Coll Health. 2012;60(1):99</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D041923" MajorTopicYN="Y">Adolescent Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D037001" MajorTopicYN="N">Directive Counseling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="N">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013334" MajorTopicYN="N">Students</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014495" MajorTopicYN="Y">Universities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21823964</ArticleId><ArticleId IdType="doi">10.1080/07448481.2010.528100</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10671833</PMID><DateCompleted><Year>2000</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-3190</ISSN><JournalIssue CitedMedium="Print"><Volume>69</Volume><Issue>2</Issue><PubDate><MedlineDate>2000 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>Psychotherapy and psychosomatics</Title><ISOAbbreviation>Psychother Psychosom</ISOAbbreviation></Journal><ArticleTitle>A case report showing that subclinical hypothyroidism rather than hyperthyroidism stabilizes rapidly cycling bipolar illness.</ArticleTitle><Pagination><MedlinePgn>110-1</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bech</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychother Psychosom</MedlineTA><NlmUniqueID>0024046</NlmUniqueID><ISSNLinking>0033-3190</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006980" MajorTopicYN="N">Hyperthyroidism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007037" MajorTopicYN="N">Hypothyroidism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10671833</ArticleId><ArticleId IdType="pii">12375</ArticleId><ArticleId IdType="doi">10.1159/000012375</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27304258</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1809-452X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>1</Issue><PubDate><MedlineDate>2017 Jan-Mar</MedlineDate></PubDate></JournalIssue><Title>Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999)</Title><ISOAbbreviation>Braz J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Virginia Woolf, neuroprogression, and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>69-71</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1516-44462017000100069</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1590/1516-4446-2016-1962</ELocationID><Abstract><AbstractText>Family history and traumatic experiences are factors linked to bipolar disorder. It is known that the lifetime risk of bipolar disorder in relatives of a bipolar proband are 5-10% for first degree relatives and 40-70% for monozygotic co-twins. It is also known that patients with early childhood trauma present earlier onset of bipolar disorder, increased number of manic episodes, and more suicide attempts. We have recently reported that childhood trauma partly mediates the effect of family history on bipolar disorder diagnosis. In light of these findings from the scientific literature, we reviewed the work of British writer Virginia Woolf, who allegedly suffered from bipolar disorder. Her disorder was strongly related to her family background. Moreover, Virginia Woolf was sexually molested by her half siblings for nine years. Her bipolar disorder symptoms presented a pernicious course, associated with hospitalizations, suicidal behavioral, and functional impairment. The concept of neuroprogression has been used to explain the clinical deterioration that takes places in a subgroup of bipolar disorder patients. The examination of Virgina Woolf's biography and art can provide clinicians with important insights about the course of bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boeira</LastName><ForeName>Manuela V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Programa de Transtorno Bipolar, Laboratório de Psiquiatria Molecular, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Psiquiatria, Departamento de Psiquiatria, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berni</LastName><ForeName>Gabriela de Á</ForeName><Initials>GÁ</Initials><AffiliationInfo><Affiliation>Programa de Transtorno Bipolar, Laboratório de Psiquiatria Molecular, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Psiquiatria, Departamento de Psiquiatria, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passos</LastName><ForeName>Ives C</ForeName><Initials>IC</Initials><AffiliationInfo><Affiliation>Programa de Transtorno Bipolar, Laboratório de Psiquiatria Molecular, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Psiquiatria, Departamento de Psiquiatria, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kauer-Sant'Anna</LastName><ForeName>Márcia</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Programa de Transtorno Bipolar, Laboratório de Psiquiatria Molecular, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Psiquiatria, Departamento de Psiquiatria, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>Flávio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Programa de Transtorno Bipolar, Laboratório de Psiquiatria Molecular, Hospital de Clínicas de Porto Alegre (HCPA), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Programa de Pós-Graduação em Psiquiatria, Departamento de Psiquiatria, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D019215">Biography</PublicationType><PublicationType UI="D016456">Historical Article</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Braz J Psychiatry</MedlineTA><NlmUniqueID>100895975</NlmUniqueID><ISSNLinking>1516-4446</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D054523" MajorTopicYN="N">Adult Survivors of Child Abuse</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="N">history</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005197" MajorTopicYN="Y">Famous Persons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049672" MajorTopicYN="N">History, 19th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049673" MajorTopicYN="N">History, 20th Century</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008093" MajorTopicYN="N">Literature, Modern</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000266" MajorTopicYN="Y">history</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList><PersonalNameSubjectList><PersonalNameSubject><LastName>Woolf</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></PersonalNameSubject></PersonalNameSubjectList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>03</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27304258</ArticleId><ArticleId IdType="pii">S1516-44462016005007105</ArticleId><ArticleId IdType="doi">10.1590/1516-4446-2016-1962</ArticleId><ArticleId IdType="pmc">PMC7112729</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Psychiatr Res. 2016 Feb;73:102-107</Citation><ArticleIdList><ArticleId IdType="pubmed">26714201</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2013 Mar;202(3):172-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23457180</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2016 Aug;134(2):91-103</Citation><ArticleIdList><ArticleId IdType="pubmed">27097559</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2002 Nov;159(11):1841-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12411217</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Mar 1;1(2):186-194</Citation><ArticleIdList><ArticleId IdType="pubmed">27047994</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2016 Oct;134(4):281-6</Citation><ArticleIdList><ArticleId IdType="pubmed">26826334</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2013 May 11;381(9878):1654-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23663951</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2014 May;75(5):e450-6</Citation><ArticleIdList><ArticleId IdType="pubmed">24922497</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2001 Dec;179:550-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11731361</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2006 Apr 1;367(9516):1040-1042</Citation><ArticleIdList><ArticleId IdType="pubmed">16581389</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2487180</PMID><DateCompleted><Year>1991</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0920-9964</ISSN><JournalIssue CitedMedium="Print"><Volume>2</Volume><Issue>4-5</Issue><PubDate><MedlineDate>1989 Jul-Oct</MedlineDate></PubDate></JournalIssue><Title>Schizophrenia research</Title><ISOAbbreviation>Schizophr Res</ISOAbbreviation></Journal><ArticleTitle>Social competence in schizoaffective disorder, bipolar disorder, and negative and non-negative schizophrenia.</ArticleTitle><Pagination><MedlinePgn>391-401</MedlinePgn></Pagination><Abstract><AbstractText>Social skill and role functioning were assessed in matched groups of patients with DSM-III-R schizoaffective disorder, bipolar disorder, and schizophrenia. Schizophrenics were categorized as negative syndrome or non-negative on the basis of the SANS. The negative schizophrenics were significantly more impaired on almost every measure of social functioning. The other three groups were not consistently different from one another. The results suggest that when patients are comparable on dimensions such as duration and severity of illness, schizoaffectives do not occupy an intermediate position between schizophrenics without negative syndrome and bipolar patients. Rather, the three groups exhibit similar degrees of social disability. In contrast, negative syndrome schizophrenics were more impaired even when they were similar in chronicity and severity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bellack</LastName><ForeName>A S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Medical College of Pennsylvania/EPPI, Philadelphia 19129.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>R L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Mueser</LastName><ForeName>K T</ForeName><Initials>KT</Initials></Author><Author ValidYN="Y"><LastName>Wade</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 38636</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 39998</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Schizophr Res</MedlineTA><NlmUniqueID>8804207</NlmUniqueID><ISSNLinking>0920-9964</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="Y">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012919" MajorTopicYN="N">Social Behavior</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>7</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>7</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2487180</ArticleId><ArticleId IdType="pii">0920-9964(89)90032-7</ArticleId><ArticleId IdType="doi">10.1016/0920-9964(89)90032-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28590601</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2155-7780</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>The primary care companion for CNS disorders</Title><ISOAbbreviation>Prim Care Companion CNS Disord</ISOAbbreviation></Journal><ArticleTitle>Patient Characteristics Associated With Use of Lurasidone Versus Other Atypical Antipsychotics in Patients With Bipolar Disorder: Analysis From a Claims Database in the United States.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4088/PCC.16m02066</ELocationID><Abstract><AbstractText Label="Objective" NlmCategory="UNASSIGNED">To compare patient characteristics, medical comorbidities, health care utilization, and health care costs among patients with bipolar disorder who initiated lurasidone versus other atypical antipsychotics in usual clinical practice.</AbstractText><AbstractText Label="Methods" NlmCategory="UNASSIGNED">A retrospective analysis of administrative claims data was conducted using the US Optum Research Database (December 30, 2012, through February 27, 2014). Adult, commercially insured patients with bipolar disorder with an atypical antipsychotic prescription between June 28, 2013, and November 30, 2013, were included. The lurasidone cohort first included any patients with a lurasidone prescription; remaining patients were assigned to their first atypical antipsychotic (aripiprazole, olanzapine, quetiapine, risperidone, ziprasidone). Preindex patient characteristics comparisons to lurasidone were conducted with t tests (continuous variables) and χ² or Fisher exact tests (categorical variables).</AbstractText><AbstractText Label="Results" NlmCategory="UNASSIGNED">A total of 3,329 patients were included in this database analysis. A higher percentage of the lurasidone cohort (31.1%) had bipolar depression compared with the other cohorts (23.5%-28.0%). The lurasidone cohort had a statistically significantly higher percentage of patients with prior diabetes mellitus (13.3%) and lipid metabolism disorders (23.2%) than did the quetiapine cohort (8.4% and 16.3%, P &lt; .01). In addition, the lurasidone cohort had significantly more prior antipsychotic polypharmacy (23.0% vs 6.7%-12.9%, P &lt; .01) and atypical antipsychotic use (55.6% vs 11.8%-26.3%, P &lt; .01) than other cohorts. The lurasidone cohort had a statistically significantly higher mean number of prior all-cause and mental health office visits (P &lt; .001) and higher mean prior pharmacy costs than most cohorts (P &lt; .01).</AbstractText><AbstractText Label="Conclusions" NlmCategory="UNASSIGNED">Lurasidone-treated patients with bipolar disorder tended to have a more complex clinical profile, comorbidities, and prior treatment history compared to patients initiated with other atypical antipsychotics in this claims database study. This pattern of treatment may have reflected the overall clinical profile of lurasidone, the role perceived for lurasidone in the therapeutic armamentarium by practitioners, and the recent introduction of lurasidone into clinical practice during the study period.</AbstractText><CopyrightInformation>© Copyright 2017 Physicians Postgraduate Press, Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>Mauricio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>The University of New Mexico, Department of Psychiatry and Behavioral Sciences, Albuquerque, New Mexico, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ng-Mak</LastName><ForeName>Daisy</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>84 Waterford Dr, Marlborough, MA 01752. Daisy.Ng-Mak@Sunovion.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajagopalan</LastName><ForeName>Krithika</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halpern</LastName><ForeName>Rachel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Optum, Eden Prairie, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chuang</LastName><ForeName>Chien-Chia</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Vertex Pharmaceuticals Inc, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loebel</LastName><ForeName>Antony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sunovion Pharmaceuticals Inc, Fort Lee, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Prim Care Companion CNS Disord</MedlineTA><NlmUniqueID>101547532</NlmUniqueID><ISSNLinking>2155-7780</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>O0P4I5851I</RegistryNumber><NameOfSubstance UI="D000069056">Lurasidone Hydrochloride</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007348" MajorTopicYN="N">Insurance, Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069056" MajorTopicYN="N">Lurasidone Hydrochloride</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010342" MajorTopicYN="N">Patient Acceptance of Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>04</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28590601</ArticleId><ArticleId IdType="doi">10.4088/PCC.16m02066</ArticleId><ArticleId IdType="pii">16m02066</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12880937</PMID><DateCompleted><Year>2004</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>75</Volume><Issue>3</Issue><PubDate><Year>2003</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Spiritual beliefs in bipolar affective disorder: their relevance for illness management.</ArticleTitle><Pagination><MedlinePgn>247-57</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There has been growing interest in investigating religion as a relevant element in illness outcome. Having religious beliefs has been shown repeatedly to be associated with lessened rates of depression. Most of the limited published research has been restricted to elderly samples. Religious coping is thought to play a key role in religion's effects. Strangely, psychiatric research has neglected this area.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A questionnaire covering religious, spiritual and philosophical beliefs and religious practice was given to a sample of patients with bipolar affective disorder in remission.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Most patients often held strong religious or spiritual beliefs (78%) and practised their religion frequently (81.5%). Most saw a direct link between their beliefs and the management of their illness. Many used religious coping, and often religio-spiritual beliefs and practice put them in conflict with illness models (24%) and advice (19%) used by their medical advisors.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This was a cross-sectional design without a control group and thus it is not possible to determine causal associations from the data set.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Religio-spiritual ideas are of great salience to many patients with bipolar disorder and shape the ways in which they think about their illness. Many reported experiencing significant paradigm conflict in understanding and managing their illness between medical and their spiritual advisors. These data suggest that the whole area of religion and spirituality is directly relevant to people living with a chronic psychiatric illness and should be firmly on the discussion agenda of clinicians working with patients with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>Logan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, P.O. Box 913, Dunedin, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romans</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000534" MajorTopicYN="N">rehabilitation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003469" MajorTopicYN="Y">Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019468" MajorTopicYN="Y">Disease Management</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029181" MajorTopicYN="Y">Spirituality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>7</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>1</Month><Day>30</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>7</Month><Day>26</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12880937</ArticleId><ArticleId IdType="pii">S0165032702000551</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(02)00055-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3734766</PMID><DateCompleted><Year>1986</Year><Month>09</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-3018</ISSN><JournalIssue CitedMedium="Print"><Volume>174</Volume><Issue>8</Issue><PubDate><Year>1986</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>The consistency of thought disorder in mania and schizophrenia. II. An assessment at consecutive admissions.</ArticleTitle><Pagination><MedlinePgn>443-7</MedlinePgn></Pagination><Abstract><AbstractText>Manic (N = 8) and schizophrenic (N = 14) acute admissions were assessed 10 days after they arrived at the hospital. These assessments were conducted on two consecutive acute admissions for each patient. Interview-based clinical ratings were collected and examined for the stability of both positive and negative thought disorders. For schizophrenics, negative thought disorder, particularly poverty of speech, was relatively consistent across admissions. In the manic sample, much less consistency was observed. The results are evaluated in terms of the statements that they make regarding the validity of the thought disorder construct and for their implications regarding causal factors in communication disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Earle-Boyer</LastName><ForeName>E A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Levinson</LastName><ForeName>J C</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Grant</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Harvey</LastName><ForeName>P D</ForeName><Initials>PD</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 38431</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3734766</ArticleId><ArticleId IdType="doi">10.1097/00005053-198608000-00001</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29905660</PMID><DateCompleted><Year>2019</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-736X</ISSN><JournalIssue CitedMedium="Internet"><Volume>206</Volume><Issue>7</Issue><PubDate><Year>2018</Year><Month>07</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Resilience Predicts Social Functioning in Clinically Stable Patients With Bipolar Disorder.</ArticleTitle><Pagination><MedlinePgn>567-574</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NMD.0000000000000843</ELocationID><Abstract><AbstractText>The current study focused on the association between resilience and social functioning in patients with bipolar disorder (BD). Forty clinically stable patients with BD type I and BD type II, as well as 40 healthy controls, matched for age, sex, and educational background were enrolled. Clinical status was assessed by the Montgomery-Åsberg Depression Rating Scale and the Young Mania Rating Scale. Functioning was evaluated by the Mini International Classification of Functioning, Disability and Health rating of activities and participation in mental illnesses, and the Social and Occupational Functioning Scale. Resilience was measured by the Connor-Davidson Resilience scale. Patients demonstrated significantly lower resilience levels compared with healthy individuals. A stepwise regression analysis indicated that only resilience contributed significantly to social functioning's outcome. Because resilience may constitute a social functioning moderator in clinically stable patients with BD, a paradigm shift toward protective factors could lead to implementation of resilience-oriented interventions designed specifically for patients with BD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bozikas</LastName><ForeName>Vasilis P</ForeName><Initials>VP</Initials><AffiliationInfo><Affiliation>1st Department of Psychiatry, Aristotle University of Thessaloniki, General Hospital "Papageorgiou".</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parlapani</LastName><ForeName>Eleni</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1st Department of Psychiatry, Aristotle University of Thessaloniki, General Hospital "Papageorgiou".</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ntouros</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>1st Department of Psychiatry, Aristotle University of Thessaloniki, General Hospital "Papageorgiou".</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bargiota</LastName><ForeName>Stavroula I</ForeName><Initials>SI</Initials><AffiliationInfo><Affiliation>1st Department of Psychiatry, Aristotle University of Thessaloniki, General Hospital "Papageorgiou".</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Floros</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>2nd Department of Psychiatry, Aristotle University of Thessaloniki, Psychiatric Hospital of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nazlidou</LastName><ForeName>Elena I</ForeName><Initials>EI</Initials><AffiliationInfo><Affiliation>1st Department of Psychiatry, Aristotle University of Thessaloniki, General Hospital "Papageorgiou".</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garyfallos</LastName><ForeName>Georgios</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>2nd Department of Psychiatry, Aristotle University of Thessaloniki, Psychiatric Hospital of Thessaloniki, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055500" MajorTopicYN="Y">Resilience, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="Y">Social Adjustment</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29905660</ArticleId><ArticleId IdType="doi">10.1097/NMD.0000000000000843</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24837443</PMID><DateCompleted><Year>2016</Year><Month>01</Month><Day>07</Day></DateCompleted><DateRevised><Year>2015</Year><Month>04</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1465-3656</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Neurocase</Title><ISOAbbreviation>Neurocase</ISOAbbreviation></Journal><ArticleTitle>Unawareness of bipolar disorder: the role of the cingulate cortex.</ArticleTitle><Pagination><MedlinePgn>438-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/13554794.2014.917682</ELocationID><Abstract><AbstractText>Reduced awareness of illness is a well-known phenomenon that has been understudied in remitted patients with bipolar disorder. In particular, the relationship between reduced awareness and executive dysfunction is an intriguing question that has yet to be resolved. The aim of the current study is to analyze the link between reduced awareness, brain dysfunction, and concomitant cognitive-behavioral disturbances from a neurocognitive perspective. In previous studies, we demonstrated the role of the anterior cingulate cortex (ACC) in the unawareness of distinct pathologies that exhibit overlapping symptoms in the context of overlapping circuit-specific dysfunction. Given the clinical importance of the results obtained, the present study considers six aware and four unaware remitted bipolar disorder patients. Cingulate functionality was assessed with functional magnetic resonance imaging while patients performed a go/no-go task. Patients were also studied on an overall cognitive task battery and with behavioral assessment of mood changes in terms of apathy and disinhibited behavior. Unaware patients showed frontoparietal hypo-perfusion, with a significant reduction of task-sensitive activity in the bilateral superior and middle frontal gyrus, putamen, insular, and ACCs. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Palermo</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a Department of Psychology , University of Turin , Turin , Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cauda</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Duca</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gallino</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Geminiani</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Amanzio</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neurocase</MedlineTA><NlmUniqueID>9511374</NlmUniqueID><ISSNLinking>1355-4794</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="N">Awareness</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005193" MajorTopicYN="N">Family Planning Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007722" MajorTopicYN="N">Health Knowledge, Attitudes, Practice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anterior cingulate cortex</Keyword><Keyword MajorTopicYN="N">awareness deficit</Keyword><Keyword MajorTopicYN="N">fMRI</Keyword><Keyword MajorTopicYN="N">remitted bipolar disorder patients</Keyword><Keyword MajorTopicYN="N">response inhibition</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>1</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24837443</ArticleId><ArticleId IdType="doi">10.1080/13554794.2014.917682</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29533425</PMID><DateCompleted><Year>2018</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2567-6407</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><Issue>5</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>Nuklearmedizin. Nuclear medicine</Title><ISOAbbreviation>Nuklearmedizin</ISOAbbreviation></Journal><ArticleTitle>Different patterns of dopaminergic and serotonergic dysfunction in manic, depressive and euthymic phases of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>191-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3413/Nukmed-0893-17-04</ELocationID><Abstract><AbstractText>A variety of alterations in brain neurotransmitter systems has been proposed as the cause of bipolar disorder (BD). We conducted a PUBMED search, which provided a total of 45 in vivo investigations with PET and SPECT, in which binding to serotonin transporter (SERT), 5-HT<sub>1A</sub> receptor (R), 5-HT<sub>2A</sub>R, dopamine transporter (DAT), vesicular monoamine transporter (VMAT2), D<sub>1</sub>R, D<sub>2</sub>R, muscarinic M2R and nicotinic ß2-nAChR as well as dopamine synthesis and/or dopamine release were assessed in BD patients in the manic (6 studies, 39 patients, 77 controls), depressive (15 studies, 248 patients, 488 controls) or eu- thymic condition (18 studies, 265 patients, 293 controls) and in mixed collectives of BD patients (6 studies, 55 patients, 80 controls). The retrospective analysis revealed a complex pattern of dysregulations within and between neurotransmitter systems, which is causally linked to the acute and euthymic states of BD. While increased mesencephalic, limbic and parietotemporoccipital serotonin and increased frontal dopamine underlie mania, the depressive state is characterized by decreased frontal and limbic serotonin, increased frontal and limbic acetylcholine and increased frontal dopamine. Also in euthymia, no normalization of receptor and transporter densities was observed. Alterations of regulation states of bindings sites, however, act together to achieve a normalization of mesencephalic, limbic and cortical serotonin.</AbstractText><CopyrightInformation>Schattauer GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="N"><LastName>Nikolaus</LastName><ForeName>Susanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y" EqualContrib="N"><LastName>Müller</LastName><ForeName>Hans-Wilhelm</ForeName><Initials>HW</Initials></Author><Author ValidYN="Y" EqualContrib="N"><LastName>Hautzel</LastName><ForeName>Hubertus</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Verschiedene Muster dopaminerger und serotonerger Dysfunktion in manischen, depressiven und euthymischen Phasen der bipolaren Störungen.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2018</Year><Month>01</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nuklearmedizin</MedlineTA><NlmUniqueID>7609387</NlmUniqueID><ISSNLinking>0029-5566</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049268" MajorTopicYN="N">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="ger"><AbstractText>Verschiedenen Veränderungen in den Neurotransmittersystemen des Gehirns wird eine Rolle bei der bipolaren Störung (BD) zugeschrieben. Eine PUBMED-Recherche ergab insgesamt 45 in vivo Untersuchungen mit PET oder SPECT, in denen die Bindung an den Serotonintransporter (SERT), den 5-HT<sub>1A</sub>-Rezeptor (R), den 5-HT<sub>2A</sub>R, den Dopamintransporter (DAT), den vesikulären Monoamintransporter (VMAT2), den D<sub>1</sub>R, den D<sub>2</sub>R, den muskarini- schen M2R und den nikotinischen ß2-nAChR, die Dopaminsynthese und/oder die Dopaminfreisetzung in bipolaren Patienten im manischen (6 Studien, 39 Patienten, 77 Kontrollen), depressiven (15 Studien, 248 Patienten, 488 Kontrollen) oder euthymen Zustand (18 Studien, 265 Patienten, 293 Kontrollen) und in gemischen Kollektiven (6 Studien, 55 Patienten, 80 Kontrollen) untersucht wurden. Die retrospektive Analyse ergab ein komplexes Muster von Fehlregulationen innerhalb und zwischen den Neurotransmittersystemen, die in kausalem Zusammenhang mit den akuten und euthymen Zuständen stehen. Während der Manie erhöhte mesenzephale, limbische und parietotemporookzipitale Serotoninkonzentrationen sowie eine erhöhte frontale Dopaminkonzentration zu Grunde liegen, ist der depressive Zustand durch eine Erniedrigung der frontalen und limbischen Serotoninkonzentration, erhöhte frontale und limbische Azetylcholinkonzentrationen sowie eine erhöhte frontale Dopaminkonzentration gekennzeichnet. Auch im euthymen Zustand wurde keine Normalisierung der Rezeptor- und Transporterdichten gefunden. Veränderungen im Regulationszustand der Bindungsstellen wirken jedoch zusammen, um eine Normalisierung der mesenzephalen, limbischen und kortikalen Serotoninkonzentrationen zu erreichen.</AbstractText></OtherAbstract><CoiStatement>The authors declare that there are no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>11</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29533425</ArticleId><ArticleId IdType="doi">10.3413/Nukmed-0893-17-04</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24389147</PMID><DateCompleted><Year>2014</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1945-0508</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><PubDate><Year>2014</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Frontiers in bioscience (Elite edition)</Title><ISOAbbreviation>Front Biosci (Elite Ed)</ISOAbbreviation></Journal><ArticleTitle>Can the response to mood stabilizers be predicted in bipolar disorder?</ArticleTitle><Pagination><MedlinePgn>120-38</MedlinePgn></Pagination><Abstract><AbstractText>Bipolar disorder (BD) is a severe chronic multifactorial disease that requires maintenance therapy with mood stabilizers (MS). Even with medications, the rate of response among patients with BD is low and the risk of relapse is high. Therefore, in this context of the urgent need for reliable and reproducible predictors of individual responses to MS, pharmacogenetics research is expected to provide helpful progress. Most pharmacogenetic studies of MS have focused on the response to lithium with several good putative candidate genes but informative results are sparse. There have been few studies on valproate, lamotrigine or atypical antipsychotics. Overall, the results of pharmacogenomics studies have not provided sufficient data to change daily practices in BD significantly and further investigation is warranted to identify highly relevant genetic predictors of response their roles. Although progress still remains to be made, the clinical assessment of a subject including the identification of specific individual phenotypic and pharmacogenetic characteristics is likely to become a powerful instrument for the development of personalized therapies. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Geoffroy</LastName><ForeName>Pierre Alexis</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Pole de Psychiatrie, Centre Expert Bipolaire, Hopital Albert Chenevier, pavillon Hartman, 40, rue de Mesly, 94000 Creteil Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellivier</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>FondaMental Foundation, Creteil, 94000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leboyer</LastName><ForeName>Marion</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pole de Psychiatrie, Centre Expert Bipolaire, Hopital Albert Chenevier, pavillon Hartman, 40, rue de Mesly, 94000 Creteil Cedex, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etain</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Pole de Psychiatrie, Centre Expert Bipolaire, Hopital Albert Chenevier, pavillon Hartman, 40, rue de Mesly, 94000 Creteil Cedex, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>01</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Front Biosci (Elite Ed)</MedlineTA><NlmUniqueID>101485240</NlmUniqueID><ISSNLinking>1945-0494</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056925">Circadian Rhythm Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018377">Neurotransmitter Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4L6452S749</RegistryNumber><NameOfSubstance UI="D007294">Inositol</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056925" MajorTopicYN="N">Circadian Rhythm Signaling Peptides and Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="N">Genetic Association Studies</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007294" MajorTopicYN="N">Inositol</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018377" MajorTopicYN="N">Neurotransmitter Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010597" MajorTopicYN="N">Pharmacogenetics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24389147</ArticleId><ArticleId IdType="pii">E696</ArticleId><ArticleId IdType="doi">10.2741/e696</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">25277541</PMID><DateCompleted><Year>2015</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1614</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Australian and New Zealand journal of psychiatry</Title><ISOAbbreviation>Aust N Z J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Childhood adversity in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>975-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/0004867414553954</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Watson</LastName><ForeName>Stuart</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Wolfson Research Unit, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, United Kingdom stuart.watson@ncl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Porter</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine, University of Otago, Christchurch, New Zealand.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>10</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Aust N Z J Psychiatry</MedlineTA><NlmUniqueID>0111052</NlmUniqueID><ISSNLinking>0004-8674</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Aust N Z J Psychiatry. 2014 Nov;48(11):1017-24</RefSource><PMID Version="1">25122448</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D063868" MajorTopicYN="Y">Patient Outcome Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013315" MajorTopicYN="N">Stress, Psychological</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014754" MajorTopicYN="N">Violence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25277541</ArticleId><ArticleId IdType="pii">0004867414553954</ArticleId><ArticleId IdType="doi">10.1177/0004867414553954</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15780683</PMID><DateCompleted><Year>2005</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2009</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>85</Volume><Issue>1-2</Issue><PubDate><Year>2005</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Affective temperaments as measured by TEMPS-A in patients with bipolar I disorder and their first-degree relatives: a controlled study.</ArticleTitle><Pagination><MedlinePgn>127-33</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The aims of this study were to identify the dominant affective temperamental characteristics of patients with bipolar disorder (BP) and their clinically well first-degree relatives and to compare the prevalence rates of these temperaments with those in healthy control subjects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred bipolar I probands and their 219 unaffected first-degree relatives were enrolled in the study. The control group consisted of healthy subjects without any personal or family history of bipolar disorder, matched with the age and gender of the probands and first-degree relatives. To identify the dominant affective temperaments, the Turkish version of TEMPS-A scale was used.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At least one dominant temperament was found in 26% of the proband group, in 21.9% of the relative group, and 6.0% and 10.0% of the control groups, respectively. The most noteworthy finding was that both the probands and their relatives had significantly higher frequency of hyperthymic temperament than the controls.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Temperament had not been assessed premorbidly in the probands with bipolar disorder.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The study supports the familial, possibly genetic, basis for the hyperthymic temperament in the genesis of bipolar I dosorder. That the cyclothymic temperament was not similarly represented, may be due to the higher specificity of the cyclothymic temperament to the bipolar II sybtype (which we did not study). More research is needed on the relevance of cyclothymic and other temperaments to the genetics of bipolar disorders selected by rigorous subtyping along the clinical spectrum of bipolarity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kesebir</LastName><ForeName>Sermin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Affective Disorder Unit, Department of Psychiatry, Tip Fakultesi, Ege University, Bornova, Izmir 35100, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vahip</LastName><ForeName>Simavi</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Akdeniz</LastName><ForeName>Fisun</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Yüncü</LastName><ForeName>Zeki</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Alkan</LastName><ForeName>Müge</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop</ForeName><Initials>H</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003431" MajorTopicYN="Y">Cross-Cultural Comparison</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003527" MajorTopicYN="N">Cyclothymic Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007802" MajorTopicYN="Y">Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="Y">Temperament</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014421" MajorTopicYN="N" Type="Geographic">Turkey</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2003</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>9</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>3</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15780683</ArticleId><ArticleId IdType="pii">S0165032703003227</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2003.10.013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25403956</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2014</Year><Month>Nov</Month><Day>18</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Exploring psychosis and bipolar disorder in women: a critical review of the qualitative literature.</ArticleTitle><Pagination><MedlinePgn>281</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12888-014-0281-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The experiences of women with severe mental illness warrant particular consideration to identify the strategies they use to facilitate recovery. This review systematically examined women's experiences of psychosis and bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Following an extensive database search, 13 studies met inclusion criteria. Noblit and Hare's metasynthesis approach was used to synthesise these qualitative studies exploring the experiences of 250 women, of which 78 (31.2%) were also mothers.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twelve sub-ordinate themes were identified and categorised into three overarching themes: 1) women's beliefs about illness, 2) perceived consequences of illness, and 3) strategies used to cope with illness. Contextual factors and spiritual beliefs were found to be important in these women's illness appraisals. Women incorporated diagnosis-related information into illness models if it was concordant with their existing beliefs.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Women reported negative illness consequences relating to stigma, loss of self-determination and changes to relationships. They employed various strategies in order to cope with illness. Barriers to strategy use and clinical recommendations are presented.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wittkowski</LastName><ForeName>Anja</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of Manchester, School of Psychological Sciences, Zochonis Building, Brunswick Street, Manchester, UK. Anja.wittkowski@manchester.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGrath</LastName><ForeName>Laura K</ForeName><Initials>LK</Initials></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="N">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009035" MajorTopicYN="N">Mothers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D036301" MajorTopicYN="N">Qualitative Research</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057545" MajorTopicYN="Y">Social Stigma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014930" MajorTopicYN="Y">Women</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>09</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>11</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25403956</ArticleId><ArticleId IdType="pii">s12888-014-0281-0</ArticleId><ArticleId IdType="doi">10.1186/s12888-014-0281-0</ArticleId><ArticleId IdType="pmc">PMC4237757</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>PLoS One. 2012;7(3):e31660</Citation><ArticleIdList><ArticleId IdType="pubmed">22457710</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2000 Jul;177:4-7</Citation><ArticleIdList><ArticleId IdType="pubmed">10945080</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Dec;62(12):1322-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16330720</ArticleId></ArticleIdList></Reference><Reference><Citation>Midwifery. 2013 Jun;29(6):682-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22882968</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Sci Med. 1996 Sep;43(5):707-20</Citation><ArticleIdList><ArticleId IdType="pubmed">8870135</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2003 Sep;26(3):595-620</Citation><ArticleIdList><ArticleId IdType="pubmed">14563100</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Orthopsychiatry. 2006 Oct;76(4):461-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17209714</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2005 Aug;112(2):110-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15992392</ArticleId></ArticleIdList></Reference><Reference><Citation>Hosp Community Psychiatry. 1994 Oct;45(10):1015-20</Citation><ArticleIdList><ArticleId IdType="pubmed">7829038</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Sci Med. 2006 Oct;63(7):1900-11</Citation><ArticleIdList><ArticleId IdType="pubmed">16777306</ArticleId></ArticleIdList></Reference><Reference><Citation>Transcult Psychiatry. 2005 Dec;42(4):630-56</Citation><ArticleIdList><ArticleId IdType="pubmed">16570521</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Psychother. 2003 Dec;76(Pt 4):411-31</Citation><ArticleIdList><ArticleId IdType="pubmed">14670189</ArticleId></ArticleIdList></Reference><Reference><Citation>J Ment Health Adm. 1994 Fall;21(4):338-46</Citation><ArticleIdList><ArticleId IdType="pubmed">10138008</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2004 Sep;49(9):625-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15503735</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1996 Jul 24-31;276(4):293-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8656541</ArticleId></ArticleIdList></Reference><Reference><Citation>Issues Ment Health Nurs. 2008 May;29(5):437-53</Citation><ArticleIdList><ArticleId IdType="pubmed">18437605</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Nurs Stud. 2007 Mar;44(3):467-78</Citation><ArticleIdList><ArticleId IdType="pubmed">17049353</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Fam Physician. 2007 Jun 15;75(12):1821-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17619525</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Serv Res Policy. 2002 Oct;7(4):209-15</Citation><ArticleIdList><ArticleId IdType="pubmed">12425780</ArticleId></ArticleIdList></Reference><Reference><Citation>Patient Educ Couns. 2007 Jun;66(3):361-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17331691</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2000;401:3-38</Citation><ArticleIdList><ArticleId IdType="pubmed">10887978</ArticleId></ArticleIdList></Reference><Reference><Citation>Soc Psychiatry Psychiatr Epidemiol. 2004 Jun;39(6):472-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15205732</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Jan;165(1):15-20</Citation><ArticleIdList><ArticleId IdType="pubmed">18086748</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2008 Jul;196(7):522-30</Citation><ArticleIdList><ArticleId IdType="pubmed">18626292</ArticleId></ArticleIdList></Reference><Reference><Citation>Issues Ment Health Nurs. 2011;32(5):279-90</Citation><ArticleIdList><ArticleId IdType="pubmed">21574842</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Technol Assess Health Care. 2010 Jul;26(3):334-40</Citation><ArticleIdList><ArticleId IdType="pubmed">20584364</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 May;186:364-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15863738</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Rehabil J. 2003 Fall;27(2):122-30</Citation><ArticleIdList><ArticleId IdType="pubmed">14653545</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Aug;75(3):247-57</Citation><ArticleIdList><ArticleId IdType="pubmed">12880937</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1999 Oct;50(10):1357-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10506308</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1984;10(2):300-12</Citation><ArticleIdList><ArticleId IdType="pubmed">6729414</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Rehabil J. 2003 Winter;26(3):290-302</Citation><ArticleIdList><ArticleId IdType="pubmed">12653450</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2009 Apr;194(4):319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">19336782</ArticleId></ArticleIdList></Reference><Reference><Citation>Midwifery. 2006 Jun;22(2):108-19</Citation><ArticleIdList><ArticleId IdType="pubmed">16243416</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Cogn Psychother. 2012 Jul;40(4):425-37</Citation><ArticleIdList><ArticleId IdType="pubmed">22414657</ArticleId></ArticleIdList></Reference><Reference><Citation>Womens Health Issues. 2011 Jul-Aug;21(4):286-92</Citation><ArticleIdList><ArticleId IdType="pubmed">21330152</ArticleId></ArticleIdList></Reference><Reference><Citation>J Adv Nurs. 2001 Oct;36(1):143-50</Citation><ArticleIdList><ArticleId IdType="pubmed">11555058</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatr Rehabil. 2011 Apr;14(2):137-153</Citation><ArticleIdList><ArticleId IdType="pubmed">22180730</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2008 Feb;196(2):95-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18277216</ArticleId></ArticleIdList></Reference><Reference><Citation>New Dir Ment Health Serv. 2000 Winter;(88):73-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11242786</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>